Muscarinic receptor antagonists

ABSTRACT

Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent applicationSer. No. 09/325,725, filed on Jun. 4, 1999 which claims the benefit ofU.S. Patent Application Ser. No. 60/088,466, filed Jun. 8, 1998; U.S.Patent Application Ser. No. 60/092,938, filed Jul. 15, 1998; and U.S.Patent Application Ser. No. 60/120,287, filed Feb. 16, 1999; thedisclosures of which are incorporated herein by reference in theirentirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to novel multibinding compounds (agents) that aremuscarinic receptor antagonists, pharmaceutical compositions comprisingsuch compounds, and methods of preparing these compounds. Accordingly,the multibinding compounds and pharmaceutical compositions of thisinvention are useful in the treatment and prevention of diseasesmediated by these receptors such as chronic obstructive pulmonarydisease, chronic bronchitis, irritable bowel syndrome, urinaryincontinence, and the like.

REFERENCES

The following publications are cited in this application as superscriptnumbers:

-   ¹ Bonner, T. I. et al., Science (Washington D.C.) 1987, 237,    527-532.-   ² Goyal, R. K., J. Med., 1989, 321, 1022.-   ³ Hulme, E. C., et al., Annu. Rev. Pharmacol. Toxicol. 1990, 30,    633.-   ⁴ Eglen, R. M. and Hegde, S. S., Drug News Perspect. 1997, 10(8),    462-469.-   ⁵ Fisher, A., Invest. Drugs, 1997, 6(10), 1395-1411.-   ⁶ Martel, A. M., et al., Drugs Future, 1997, 22(2), 135-137.-   ⁷ Graul, A. and Castaner, J., Drugs Future, 1996, 21(11), 1105-1108.-   ⁸ Graul, A., et al., Drugs Future, 1997, 22(7), 733-737.

All of the above publications are herein incorporated by reference intheir entirety to the same extent as if each individual publication wasspecifically and individually indicated to be incorporated by referencein its entirety.

2. State of the Art

A receptor is a biological structure with one or more binding domainsthat reversibly complexes with one or more ligands, where thatcomplexation has biological consequences. Receptors can exist entirelyoutside the cell (extracellular receptors), within the cell membrane(but presenting sections of the receptor to the extracellular milieu andcytosol), or entirely within the cell (intracellular receptors). Theymay also function independently of a cell (e.g., clot formation).Receptors within the cell membrane allow a cell to communicate with thespace outside of its boundaries (i.e., signaling) as well as to functionin the transport of molecules and ions into and out of the cell.

A ligand is a binding partner for a specific receptor or family ofreceptors. A ligand may be the endogenous ligand for the receptor oralternatively may be a synthetic ligand for the receptor such as a drug,a drug candidate or a pharmacological tool.

The super family of seven transmembrane proteins (7-TMs), also calledG-protein coupled receptors (GPCRs), represents one of the mostsignificant classes of membrane bound receptors that communicate changesthat occur outside of the cell's boundaries to its interior, triggeringa cellular response when appropriate. The G-proteins, when activated,affect a wide range of downstream effector systems both positively andnegatively (e.g., ion channels, protein kinase cascades, transcription,transmigration of adhesion proteins, and the like).

Muscarinic receptors are members of the G-protein coupled receptors thatare composed of a family of five receptor sub-types (M₁, M₂, M₃, M₄ andM₅) and are activated by the neurotransmitter acetylcholine¹. Thesereceptors are widely distributed on multiple organs and tissues and arecritical to the maintenance of central and peripheral cholinergicneurotransmission. The regional distribution of these receptor subtypesin the brain and other organs has been documented¹⁻⁴. For example, thesmooth muscle is composed largely of M₂ and M₃ receptors, cardiac muscleis composed largely of M₂ receptors, and salivary glands are largelycomposed of M₃ receptors.

It has been established that the muscarinic receptors are involved indiseases such as chronic obstructive pulmonary disease⁵⁻⁶, asthma,irritable bowel syndrome⁷, urinary incontinence⁷⁻⁸, rhinitis, spasmodiccolitis, chronic cystitis, and alzheimer's disease, senile dementia,glaucoma, schizophrenia, gastroesophogeal reflux disease, cardiacarrhythmia, and hyper salvation syndromes. Currently, a number ofcompounds having muscarinic receptor antagonistic activities are beingused to treat these diseases. For example, oxybutynin is being used forthe treatment of urinary urge incontinence and dicyclomine for thetreatment of irritable bowel syndrome. However, these drugs have limitedutility as they produce side effects such as dry mouth, blurred vision,and mydriasis. Therefore, there is a need for muscarinic receptorantagonists that will help in the treatment of the above diseaseswithout the adverse side effects.

The multibinding compounds of the present invention fulfill this need.

SUMMARY OF THE INVENTION

This invention is directed to novel multibinding compounds (agents) thatare muscarinic receptor antagonists and are therefore useful in thetreatment and prevention of diseases such as chronic obstructivepulmonary disease, chronic bronchitis, irritable bowel syndrome, urinaryincontinence, and the like.

Accordingly, in one of its composition aspects, this invention providesa multibinding compound comprising of from 2 to 10 ligands covalentlyattached to one or more linkers, wherein each of said ligands comprises,independently of each other, a muscarinic receptor antagonist or anallosteric modulator of a muscarinic receptor, and pharmaceuticallyacceptable salts thereof provided that at least one of said ligands is amuscarinic receptor antagonist and further provided that when themultibinding compound comprises 2 or 3 ligands, then only one of theligands is11-acetyl-5,11-dihydro-6H-pyrido[2,3b][1,4]benzodiazepin-6-one,N-methylquinuclidine, or a compound of formula:

wherein:

n^(a) is 0 or 1;

R^(c) is hydrogen or alkyl;

R^(d) is hydrogen; and

R^(e) is —CO₂CR^(f) (phenyl)₂ wherein R^(f) is hydrogen or hydroxy.

In a second aspect, this invention provides a multibinding compound ofFormula (I):

(L)_(p)(X)_(q)  (I)

wherein:

each L is, independently of each other, a muscarinic receptor antagonistor an allosteric modulator of a muscarinic receptor;

each X is independently a linker;

p is an integer of from 2 to 10; and

q is an integer of from 1 to 20, and pharmaceutically acceptable saltsthereof, provided that at least one of said ligands is a muscarinicreceptor antagonist, and further provided that when the multibindingcompound comprises of 2 or 3 ligands, then only one of the ligands is11-acetyl-5,11-dihydro-6H-pyrido[2,3][1,4]benzodiazepin-6-one,N-methylquinuclidine, or a compound of formula:

wherein:

n^(a) is 0 or 1;

R^(c) is hydrogen or alkyl;

R^(d) is hydrogen; and

R^(e) is —CO₂CR^(f) (phenyl)₂ wherein R^(f) is hydrogen or hydroxy.

Preferably, q is less than p in the multibinding compounds of thisinvention.

Preferably, each ligand, L, that is a muscarinic receptor antagonist inthe multibinding compound of Formula (I) is independently selected fromthe group consisting of:

(1) a compound of formula (a):

wherein:

A is an aryl or a heteroaryl ring;

B″ is —CH₂—, —O— or —NR^(a)— where R^(a) is hydrogen, alkyl, orsubstituted alkyl;

R¹ is hydrogen or alkyl;

R² is selected from a group consisting of formula (I), (ii), (iii), or“Het”:

wherein:

----- is an optional double bond;

n₁ is an integer of from 1 to 4;

n₂ is an integer of from 1 to 3;

V is —CH—, —O—, —S(O)n₃- (where n₃ is an integer of from 0 to 2), or—NR⁴— (wherein R⁴ is hydrogen, alkyl, substituted-alkyl, aryl, orheteroaryl);

“Het” is a heteroaryl ring which optionally attaches the ligand to alinker;

R³ is hydrogen, alkyl, amino, substituted amino, —OR^(a) (where R^(a) ishydrogen, alkyl, or acyl), or a covalent bond attaching the ligand to alinker;

R⁵ is hydrogen, alkyl, amino, substituted amino, —OR^(b) (where R^(b) ishydrogen or alkyl), aryl, aralkyl, heteroaralkyl, or a covalent bondattaching the ligand to a linker;

R⁶, R⁷, and R⁸ are, independently of each other, hydrogen, halo,hydroxy, alkoxy, haloalkoxy, carboxy, alkoxycarbonyl, alkyl optionallysubstituted with one, two or three substituents selected from halo,hydroxy, carboxy, alkoxycarbonyl, alkylthio, alkylsulfonyl, amino,substituted amino, or a covalent bond attaching the ligand to a linker;

K is a bond or an alkylene group;

K″ is a bond, —C(O)—, —S(O)_(n4)— (where n₄ is an integer of from 0 to2), or an alkylene group optionally substituted with a hydroxyl group;and

B is a heterocycloamino group which optionally attaches the ligand to alinker;

provided that at least one of the R⁵, R⁶, R⁷, R⁸, “Het”, or theheterocycloamino group attaches the ligand to a linker;

(2) a compound of formula (b):

wherein:

C is an aryl or heteroaryl ring which optionally attaches the ligand toa linker;

R⁹ is hydrogen, hydroxy, cyano, aminocarbonyl which optionally links theligand to a linker, alkyl optionally substituted with one, two or threesubstituents selected from halo, hydroxy, carboxy, alkoxycarbonyl,alkylthio, alkylsulfonyl, amino, substituted amino, or a covalent bondattaching the ligand to a linker;

R¹⁰ is hydrogen, aryl, heteroaryl, cycloalkyl, alkyl optionallysubstituted with one, two or three substituents selected from halo,hydroxy, carboxy, alkoxycarbonyl, alkylthio, alkylsulfonyl, amino,substituted amino, or a covalent bond attaching the ligand to a linker;

Q is a single bond, —O—, —COCH₂—, —C(O)NH—, —NHC(O)O—, —NHC(O)NH—, or—C(O)O—;

Q″ is selected from the group consisting of:

(i) monoaalkylaminoalkyl, monoalkylaminoalkenyl, monoalkylaminoalkynylwherein the amino group optionally links the ligand to a linker;

(ii) carboxy which optionally links the ligand to a linker;

(iii) a group of formula (Iv):

where:

E is hydrogen, a covalent bond attaching the ligand to a linker, or—CH₂—W—R¹¹ wherein W is a single bond or alkylene wherein one of thecarbon atoms may optionally be replaced by —O—, —S—, or —NR^(g)—(whereinR^(g) is hydrogen or alkyl); and

R¹¹ is a group of formula (v), (vi), or “Het”:

wherein:

--- is an optional bond;

T and U are, independently of each other, —O— or —CH₂—;

n₅ is an integer of from 1 to 3; and

“Het” is heteroaryl; and

(iv) a group of formula (vii), (viii) or (ix):

wherein:

n₆ is 0 or 1;

M⁻ is a counterion;

R¹² is a covalent bond attaching the ligand to a linker;

R¹³ is alkyl, alkenyl, cycloalkyl, or a covalent bond attaching theligand to a linker;

R¹⁴ is hydrogen, alkyl, or a covalent bond attaching the ligand to alinker;

R⁵¹ is hydrogen or alkyl; and

J is:

provided that at least one of the C, R⁹, R¹⁰, and Q″ attaches the ligandto a linker;

(3) a compound of formula (c):

wherein:

G′ is pyrrolidine, piperidine, or

wherein said G′ groups optionally attach the ligand to a linker;

n₇ is an 0 or 1, provided that when the nitrogen atom of the quinclidinering attaches the ligand to the linker then n₇ is 0;

n⁸ is 1 or 2;

g is an integer of from 0 to 3;

each R¹⁵ is, independently of each other, hydrogen, halogen, nitro,cyano, hydroxy, alkoxy, carboxy, alkoxycarbonyl, acyl, thio, alkylthio,alkylsulfonyl, alkylsulfinyl, sulfonamido, alkylsulfonamido, carbarnoyl,thiocarbamoyl, mono or dialkylcarbamoyl, amino, mono- or dialkylamino,methylenedioxy, ethylenedioxy, alkyl optionally substituted with one,two or three substituents selected from halo, hydroxy, carboxy,alkoxycarbonyl, alkylthio, alkylsulfonyl, amino, or substituted amino,or a covalent bond attaching the ligand to a linker;

G is aryl, heteroaryl, heterocyclyl, or cycloalkyl which optionallyattach the ligand to a linker; and

G″ is a single bond or an alkylene group provided that at least one ofthe R¹⁵, G, G′, and G″ attaches the ligand to a linker;

(4) a compound of formula (d):

wherein:

n⁹ is 1 or 2;

n₁₀ is 0 or 1 provided that n₉+n₁₀ is 1 or 2;

P is an aryl or heteroaryl ring which optionally attaches the ligand toa linker;

P″ is a single bond or an alkylene group;

S is a heterocycloamino ring which optionally attaches the ligand to alinker provided that at least one of the P and S attaches the ligand toa linker;

(5) a compound of formula (e):

wherein:

n₁₄ is 0, 1, or 2;

n₅₂ is 0 or 1;

R¹⁶ is hydrogen, alkyl, or a covalent bond attaching the ligand to alinker;

R¹⁷, R¹⁸, and R¹⁹ are, independently of each other, hydrogen, alkyl,alkoxy, hydroxy, carbamoyl, sulfanoyl, halo, or a covalent bondattaching the ligand to a linker;

R²⁰ and R²¹ are, independently of each other, hydrogen, alkyl or acovalent bond attaching the ligand to a linker; or R²⁰ and R²¹ togetherwith the nitrogen atom to which they are attached form aheterocycloamino ring which optionally attaches the ligand to a linkerprovided that at least one of the R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, and R²¹attaches the ligand to a linker; or

(6) a compound of formula (f):

wherein:

R²² is hydrogen or halo;

R²³ is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, orheterocyclylalkyl;

R²⁴ is hydroxy, halo, or a covalent bond attaching the ligand to alinker;

R²⁵ and R²⁶ are, independently of each other, hydrogen, alkyl, aralkyl,or a covalent bond attaching the ligand to a linker, or R²⁵ and R²⁶together with the nitrogen atom to which they are attached form aheterocycloamino group which optionally attaches the ligand to a linkerprovided that at least one of the R²⁴, R²⁵, and R²⁶ attaches the ligandto a linker; and

each ligand, L, that is an allosteric modulator of a muscarinic receptorin the multibinding compound of Formula (I) is independently selectedfrom a group consisting of:

(7) a compound of formula (g):

wherein:

D″ is alkylene;

D is —NR³¹R³², —N⁺(R³³R³⁴R³⁵) or —OR³² where R³¹, R³³, and R³⁴ are,independently of each other, hydrogen, alkyl, or aralkyl; and R³² andR³⁵ represent a covalent bond attaching the ligand to a linker;

R²⁷ is hydrogen, halo, nitro, cyano, hydroxy, alkoxy, carboxy,alkoxycarbonyl, acyl, thio, alkylthio, alkylsulfonyl, alkylsulfinyl,sulfonamido, alkylsulfonamido, carbamoyl, thiocarbamoyl, mono ordialkylcarbamoyl, amino, mono- or dialkylamino, aryl, aryloxy, arylthio,heteroaryl, heteraryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy,aralkyl, heteroaralkyl, or alkyl optionally substituted with one, two orthree substituents selected from halo, hydroxy, carboxy, alkoxycarbonyl,alkylthio, alkylsulfonyl, amino, or substituted amino;

R²⁸ is hydrogen, halo, nitro, cyano, hydroxy, alkoxy, carboxy,alkoxycarbonyl, acyl, thio, alkylthio, alkylsulfonyl, alkylsulfinyl,sulfonamido, alkylsulfonamido, carbamoyl, thiocarbamoyl, mono ordialkylcarbamoyl, amino, mono- or dialkylamino, or alkyl optionallysubstituted with one, two, or three substituents selected from halo,hydroxy, carboxy, alkoxycarbonyl, alkylthio, alkylsulfonyl, amino, orsubstituted amino;

R²⁹ and R³⁰ are, independently of each other, hydrogen, alkyl,haloalkyl, halo, nitro, cyano, hydroxy, alkoxy, alkoxycarbonyl, acyl,thio, alkylthio, amino, mono- or dialkylamino; or

one of R²⁷, R²⁸, R²⁹, or R³⁰ together with the adjacent group forms amethylenedioxy or ethylenedioxy group;

(8) a compound of formula (h):

wherein:

n₁₁ is an integer of from 1 to 7;

n₁₂ is 0 to 7;

F is —NR⁴⁰—, —O—, —S—, or —CHR⁴¹— (wherein R⁴⁰ and R⁴¹ are,independently of each other, hydrogen, alkyl, or substituted alkyl);

F″ is a covalent bond, —OR⁴³, —NR⁴²R⁴³ or —N⁺R⁴³R⁴⁴R⁴⁵ wherein R⁴² ishydrogen or alkyl, R⁴⁴ and R⁴⁵ are alkyl, and R⁴³ is a covalent bondattaching the ligand to a linker;

R³⁶ is hydrogen, alkyl, halo, nitro, cyano, hydroxy, alkoxy, carboxy,alkoxycarbonyl, acyl, thio, alkylthio, alkylsulfonyl, alkylsulfinyl,sulfonamido, alkylsulfonamido, carbamoyl, thiocarbamoyl, mono ordialkylcarbamoyl, amino, mono- or dialkylamino, aryl, aryloxy, arylthio,heteroaryl, heteraryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy,aralkyl, heteroaralkyl, or alkyl optionally substituted with one, two orthree substituents selected from halo, hydroxy, carboxy, alkoxycarbonyl,alkylthio, alkylsulfonyl, amino, or substituted amino;

R³⁷ is hydrogen, alkyl, halo, nitro, cyano, hydroxy, alkoxy,alkoxycarbonyl, acyl, thio, alkylthio, amino, mono- or dialkylamino,aryl, aryloxy, arylthio, heteroaryl, heteraryloxy, heteroarylthio,heterocyclyl, heterocyclyloxy, aralkyl, heteroaralkyl, or alkyloptionally substituted with one, two or three substituents selected fromhalo, hydroxy, carboxy, alkoxycarbonyl, alkylthio, alkylsulfonyl, amino,or substituted amino; and

R³⁸ is hydrogen, alkyl, halo, hydroxy, alkoxy, or a covalent bondattaching the ligand to a linker provided that at least one of R³⁸ andR⁴³ attaches the ligand to a linker;

R³⁹ is hydrogen, alkyl, halo, hydroxy, alkoxy, or substituted alkyl; or

(9) a compound of formula (I):

wherein:

R⁴⁶ is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, orheterocycle;

R⁴⁷ is alkyl, substituted alkyl, aryl, acyl, heterocycle, or —COOR⁴⁹where R⁴⁹ is alkyl; or

R⁴⁶ and R⁴⁷ together with the nitrogen atom to which they are attachedform heterocycle;

R⁴⁸ is a covalent bond that attaches the ligand to a linker;

R⁴⁹ is alkyl; and pharmaceutically acceptable salts, individual isomers,mixture of isomers, and prodrugs thereof provided that at least one ofthe ligands is a muscarinic receptor antagonist.

Preferably, each ligand, L, that is a muscarinic receptor antagonist inthe multibinding compound of Formula (I) is independently selected froma group consisting of Darifenacin, Tolterodine, Oxybutynin, YM-46303,YM-58790, 5-(2-isopropylimidazol-1-yl)-3,3-diphenyl-2(3H)furanone,5-(imidazol-1-ylmethyl)-3,3-diphenyl-2(3H)furanone which is linked to alinker at the 2-position of imidazole ring,5-(N-ethylaminomethyl)-3,3-diphenyl-2(3H)furanone which is linked to alinker via the secondary amino group, 3,3-diphenyl-2(3H)furanone whichis linked to a linker at the 5-position of the furanone ring (disclosedin J. Med. Chem., 35, 4415-4424, 1992),3-[4-(2-chlorobenzyl)piperazin-1-yl)-1-cyclobutyl-1-phenyl-2-propanonewhich is linked to a linker via the phenyl ring of the benzyl moiety,3-(piperazin-1-yl)-1-cyclobutyl-1-phenyl-2-propanone which is linked toa linker via the piperazine ring,3-[4-(benzylpiperazin-1-yl)-1-cyclobutyl-1-phenyl-2-propanone which islinked to a linker via the phenyl ring of the benzyl moiety,3-[4-benzylpiperazin-1-yl)-1,1-diphenyl-2-propanone which is linked to alinker via the phenyl ring of the benzyl moiety,3-(piperazin-1-yl)-1,1-diphenyl-2-propanone which is linked to a linkervia the piperazine ring (disclosed in J. Med. Chem., 36, 610-616, 1993),the derivatives thereof.

Preferably, each linker, X, in the multibinding compound of Formula (I)independently has the formula:

—X^(a)Z-(Y^(a)-Z)_(m)-Y^(b)-Z-X^(a)—

wherein

m is an integer of from 0 to 20;

X^(a) at each separate occurrence is selected from the group consistingof —O—, —S—, —NR—, —C(O)—, —C(O)O—, —C(O)NR—, —C(S), —C(S)O—, —C(S)NR—or a covalent bond where R is as defined below;

Z at each separate occurrence is selected from the group consisting ofalkylene, substituted alkylene, cycloalkylene, substitutedcylcoalkylene, alkenylene, substituted alkenylene, alkynylene,substituted alkynylene, cycloalkenylene, substituted cycloalkenylene,arylene, heteroarylene, heterocyclene, or a covalent bond;

Y^(a) and Y^(b) at each separate occurrence are selected from the groupconsisting of —O—, —C(O)—, —OC(O)—, —C(O)O—, —NR—, —S(O)n—, —C(O)NR′—,—NR′C(O)—, —NR′C(O)NR′—, —NR′C(S)NR′—, —C(═NR′)—NR′—, —NR′—C(═NR′)—,—OC(O)—NR′—, —N′—C(O)—O—, —N═C(X^(a))—NR—, —NR′—C(X^(a))═N—,—P(O)(OR′)—O—, —O—P(O)(OR′)—, —S(O)_(n)CR′R″—, —S(O)_(n)—NR′—,—NR′—S(O)_(n)—, —S—S—, and a covalent bond; where n is 0, 1 or 2; and R,R′ and R″ at each separate occurrence are selected from the groupconsisting of hydrogen, alkyl, substituted alkyl, cycloalkyl,substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl,substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryland heterocyclic.

In a third aspect, this invention provides a pharmaceutical compositioncomprising a pharmaceutically acceptable carrier and an effective amountof a multibinding compound comprising from 2 to 10 ligands covalentlyattached to one or more linkers, wherein each of said ligands whereineach of said ligands comprises, independently of each other, amuscarinic receptor antagonist or an allosteric modulator of amuscarinic receptor provided that at least one of said ligands is amuscarinic receptor antagonist, and pharmaceutically acceptable saltsthereof.

In a fourth aspect, this invention provides a method of treatingdiseases mediated by a muscarinic receptor in a mammal, said methodcomprising administering to said mammal a therapeutically effectiveamount of a pharmaceutical composition comprising a pharmaceuticallyacceptable carrier and a multibinding compound comprising from 2 to 10ligands covalently attached to one or more linkers, wherein each of saidligands, comprises, independently of each other, a muscarinic receptorantagonist or an allosteric modulator of a muscarinic receptor providedthat at least one of said ligands is a muscarinic receptor antagonist,and pharmaceutically acceptable salts thereof.

In a fifth aspect, this invention is directed to general syntheticmethods for generating large libraries of diverse multimeric compoundswhich multimeric compounds are candidates for possessing multibindingproperties for a muscarinic receptor. The diverse multimeric compoundlibraries provided by this invention are synthesized by combining alinker or linkers with a ligand or ligands to provide for a library ofmultimeric compounds wherein the linker and ligand each havecomplementary functional groups permitting covalent linkage. The libraryof linkers is preferably selected to have diverse properties such asvalency, linker length, linker geometry and rigidity, hydrophilicity orhydrophobicity, amphiphilicity, acidity, basicity and polarization. Thelibrary of ligands is preferably selected to have diverse attachmentpoints on the same ligand, different functional groups at the same siteof otherwise the same ligand, and the like.

This invention is also directed to libraries of diverse multimericcompounds which multimeric compounds are candidates for possessingmultibinding properties for a muscarinic receptor. These libraries areprepared via the methods described above and permit the rapid andefficient evaluation of what molecular constraints impart multibindingproperties to a ligand or a class of ligands targeting a muscarinicreceptor.

Accordingly, in one of its method aspects, this invention is directed toa method for identifying multimeric ligand compounds possessingmultibinding properties for a muscarinic receptor which methodcomprises:

(a) identifying a ligand or a mixture of ligands wherein each ligandcontains at least one reactive functionality;

(b) identifying a library of linkers wherein each linker in said librarycomprises at least two functional groups having complementary reactivityto at least one of the reactive functional groups of the ligand;

(c) preparing a multimeric ligand compound library by combining at leasttwo stoichiometric equivalents of the ligand or mixture of ligandsidentified in (a) with the library of linkers identified in (b) underconditions wherein the complementary functional groups react to form acovalent linkage between said linker and at least two of said ligands;and

(d) assaying the multimeric ligand compounds produced in (c) above toidentify multimeric ligand compounds possessing multibinding propertiesfor a muscarinic receptor.

In another of its method aspects, this invention is directed to a methodfor identifying multimeric ligand compounds possessing multibindingproperties for a muscarinic receptor which method comprises:

(a) identifying a library of ligands wherein each ligand contains atleast one reactive functionality;

(b) identifying a linker or mixture of linkers wherein each linkercomprises at least two functional groups having complementary reactivityto at least one of the reactive functional groups of the ligand;

(c) preparing a multimeric ligand compound library by combining at leasttwo stoichiometric equivalents of the library of ligands identified in(a) with the linker or mixture of linkers identified in (b) underconditions wherein the complementary functional groups react to form acovalent linkage between said linker and at least two of said ligands;and

(d) assaying the multimeric ligand compounds produced in (c) above toidentify multimeric ligand compounds possessing multibinding propertiesfor a muscarinic receptor.

The preparation of the multimeric ligand compound library is achieved byeither the sequential or concurrent combination of the two or morestoichiometric equivalents of the ligands identified in (a) with thelinkers identified in (b). Sequential addition is preferred when amixture of different ligands is employed to ensure heterodimeric ormultimeric compounds are prepared. Concurrent addition of the ligandsoccurs when at least a portion of the multimer compounds prepared arehomomultimeric compounds.

The assay protocols recited in (d) can be conducted on the multimericligand compound library produced in (c) above, or preferably, eachmember of the library is isolated by preparative liquid chromatographymass spectrometry (LCMS).

In one of its composition aspects, this invention is directed to alibrary of multimeric ligand compounds which may possess multivalentproperties for a muscarinic receptor which library is prepared by themethod comprising:

(a) identifying a ligand or a mixture of ligands wherein each ligandcontains at least one reactive functionality;

(b) identifying a library of linkers wherein each linker in said librarycomprises at least two functional groups having complementary reactivityto at least one of the reactive functional groups of the ligand; and

(c) preparing a multimeric ligand compound library by combining at leasttwo stoichiometric equivalents of the ligand or mixture of ligandsidentified in (a) with the library of linkers identified in (b) underconditions wherein the complementary functional groups react to form acovalent linkage between said linker and at least two of said ligands.

In another of its composition aspects, this invention is directed to alibrary of multimeric ligand compounds which may possess multivalentproperties for a muscarinic receptor which library is prepared by themethod comprising:

(a) identifying a library of ligands wherein each ligand contains atleast one reactive functionality;

(b) identifying a linker or mixture of linkers wherein each linkercomprises at least two functional groups having complementary reactivityto at least one of the reactive functional groups of the ligand; and

(c) preparing a multimeric ligand compound library by combining at leasttwo stoichiometric equivalents of the library of ligands identified in(a) with the linker or mixture of linkers identified in (b) underconditions wherein the complementary functional groups react to form acovalent linkage between said linker and at least two of said ligands.

In a preferred embodiment, the library of linkers employed in either themethods or the library aspects of this invention is selected from thegroup comprising flexible linkers, rigid linkers, hydrophobic linkers,hydrophilic linkers, linkers of different geometry, acidic linkers,basic linkers, linkers of different polarization and amphiphiliclinkers. For example, in one embodiment, each of the linkers in thelinker library may comprise linkers of different chain length and/orhaving different complementary reactive groups. Such linker lengths canpreferably range from about 2 to 100 Å, more preferably 2-25°A.

In another preferred embodiment, the ligand or mixture of ligands isselected to have reactive functionality at different sites on saidligands in order to provide for a range of orientations of said ligandon said multimeric ligand compounds. Such reactive functionalityincludes, by way of example, carboxylic acids, carboxylic acid halides,carboxyl esters, amines, halides, isocyanates, vinyl unsaturation,ketones, aldehydes, thiols, alcohols, anhydrides, and precursorsthereof. It is understood, of course, that the reactive functionality onthe ligand is selected to be complementary to at least one of thereactive groups on the linker so that a covalent linkage can be formedbetween the linker and the ligand.

In other embodiments, the multimeric ligand compound is homomeric (i.e.,each of the ligands is the same, although it may be attached atdifferent points) or heterodimeric (i.e., at least one of the ligands isdifferent from the other ligands).

In addition to the combinatorial methods described herein, thisinvention provides for an interative process for rationally evaluatingwhat molecular constraints impart multibinding properties to a class ofmultimeric compounds or ligands targeting a muscarinic receptor.Specifically, this method aspect is directed to a method for identifyingmultimeric ligand compounds possessing multibinding properties for amuscarinic receptor which method comprises:

(a) preparing a first collection or iteration of multimeric compoundswhich is prepared by contacting at least two stoichiometric equivalentsof the ligand or mixture of ligands which target a receptor with alinker or mixture of linkers wherein said ligand or mixture of ligandscomprises at least one reactive functionality and said linker or mixtureof linkers comprises at least two functional groups having complementaryreactivity to at least one of the reactive functional groups of theligand wherein said contacting is conducted under conditions wherein thecomplementary functional groups react to form a covalent linkage betweensaid linker and at least two of said ligands;

(b) assaying said first collection or iteration of multimeric compoundsto assess which if any of said multimeric compounds possess multibindingproperties for a muscarinic receptor;

(c) repeating the process of (a) and (b) above until at least onemultimeric compound is found to possess multibinding properties for amuscarinic receptor;

(d) evaluating what molecular constraints imparted multibindingproperties to the multimeric compound or compounds found in the firstiteration recited in (a)-(c) above;

(e) creating a second collection or iteration of multimeric compoundswhich elaborates upon the particular molecular constraints impartingmultibinding properties to the multimeric compound or compounds found insaid first iteration;

(f) evaluating what molecular constraints imparted enhanced multibindingproperties to the multimeric compound or compounds found in the secondcollection or iteration recited in (e) above;

(g) optionally repeating steps (e) and (f) to further elaborate uponsaid molecular constraints.

Preferably, steps (e) and (f) are repeated at least two times, morepreferably at from 2-50 times, even more preferably from 3 to 50 times,and still more preferably at least 5-50 times.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates examples of multibinding compounds comprising 2ligands attached in different formats to a linker.

FIG. 2 illustrates examples of multibinding compounds comprising 3ligands attached in different formats to a linker.

FIG. 3 illustrates examples of multibinding compounds comprising 4ligands attached in different formats to a linker.

FIG. 4 illustrates examples of multibinding compounds comprising >4ligands attached in different formats to a linker.

DETAILED DESCRIPTION OF THE INVENTION Definitions

This invention is directed to multibinding compounds which aremuscarinic receptor antagonists, pharmaceutical compositions containingsuch compounds and methods for treating diseases mediated by amuscarinic receptor in mammals. When discussing such compounds,compositions or methods, the following terms have the following meaningsunless otherwise indicated. Any undefined terms have their artrecognized meanings.

The term “alkyl” refers to a monoradical branched or unbranchedsaturated hydrocarbon chain preferably having from 1 to 40 carbon atoms,more preferably 1 to 10 carbon atoms, and even more preferably 1 to 6carbon atoms. This term is exemplified by groups such as methyl, ethyl,n-propyl, iso-propyl, n-butyl, iso-butyl, n-hexyl, n-decyl, tetradecyl,and the like.

The term “substituted alkyl” refers to an alkyl group as defined abovewherein one or more carbon atoms in the alkyl chain have been optionallyreplaced with a heteroatom such as —O—, —S(O)n- (where n is 0 to 2),—NR— (where R is hydrogen or alkyl) and having from 1 to 5 substituentsselected from the group consisting of alkoxy, substituted alkoxy,cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-aryl,—SO₂-heteroaryl, and —NR^(a)R^(b), wherein R^(a) and R^(b) may be thesame or different and are chosen from hydrogen, optionally substitutedalkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl andheterocyclic. This term is exemplified by groups such as hydroxymethyl,hydroxyethyl, hydroxypropyl, 2-aminoethyl, 3-aminopropyl,2-methylaminoethyl, 3-dimethylaminopropyl, 2-sulfonamidoethyl,2-carboxyethyl, and the like.

The term “alkylene” refers to a diradical of a branched or unbranchedsaturated hydrocarbon chain, preferably having from 1 to 40 carbonatoms, more preferably 1 to 10 carbon atoms and even more preferably 1to 6 carbon atoms. This term is exemplified by groups such as methylene(—CH₂—), ethylene (—CH₂CH₂—), the propylene isomers (e.g., —CH₂CH₂CH₂—and —CH(CH₃)CH₂—) and the like.

The term “substituted alkylene” refers to an alkylene group, as definedabove, having from 1 to 5 substituents, and preferably 1 to 3substituents, selected from the group consisting of alkoxy, substitutedalkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino,aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl,keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy,thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl,aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy,hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl,—SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryland —SO₂-heteroaryl. Additionally, such substituted alkylene groupsinclude those where 2 substituents on the alkylene group are fused toform one or more cycloalkyl, substituted cycloalkyl, cycloalkenyl,substituted cycloalkenyl, aryl, heterocyclic or heteroaryl groups fusedto the alkylene group. Preferably such fused groups contain from 1 to 3fused ring structures.

The term “alkylaminoalkyl”, “alkylaminoalkenyl” and “alkylaminoalkynyl”refers to the groups R^(a)NHR^(b)— where R^(a) is alkyl group as definedabove and R^(b) is alkylene, alkenylene or alkynylene group as definedabove. Such groups are exemplified by 3-methylaminobutyl,4-ethylamino-1,1-dimethylbutyn-1-yl, 4-ethylaminobutyn-1-yl, and thelike.

The term “alkaryl” or “aralkyl” refers to the groups -alkylene-aryl and-substituted alkylene-aryl where alkylene, substituted alkylene and arylare defined herein. Such alkaryl groups are exemplified by benzyl,phenethyl and the like.

The term “alkoxy” refers to the groups alkyl-O—, alkenyl-O—,cycloalkyl-O—, cycloalkenyl-O—, and alkynyl-O—, where alkyl, alkenyl,cycloalkyl, cycloalkenyl, and alkynyl are as defined herein. Preferredalkoxy groups are alkyl-O— and include, by way of example, methoxy,ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy,n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.

The term “substituted alkoxy” refers to the groups substituted alkyl-O—,substituted alkenyl-O—, substituted cycloalkyl-O—, substitutedcycloalkenyl-O—, and substituted alkynyl-O— where substituted alkyl,substituted alkenyl, substituted cycloalkyl, substituted cycloalkenyland substituted alkynyl are as defined herein.

The term “haloalkoxy” refers to the groups alkyl-O— wherein one or morehydrogen atoms on the alkyl group have been substituted with a halogroup and include, by way of examples, groups such as trifluoromethoxy,and the like.

The term “alkylalkoxy” refers to the groups -alkylene-O-alkyl,alkylene-O-substituted alkyl, substituted alkylene-O-alkyl, andsubstituted alkylene-O-substituted alkyl wherein alkyl, substitutedalkyl, alkylene and substituted alkylene are as defined herein.Preferred alkylalkoxy groups are alkylene-O-alkyl and include, by way ofexample, methylenemethoxy (—CH₂OCH₃), ethylenemethoxy (—CH₂CH₂OCH₃),n-propylene-iso-propoxy (—CH₂CH₂CH₂OCH(CH₃)₂), methylene-t-butoxy(—CH₂—O—C(CH₃)₃), and the like.

The term “alkylthioalkoxy” refers to the group -alkylene-S-alkyl,alkylene-S-substituted alkyl, substituted alkylene-S-alkyl andsubstituted alkylene-S-substituted alkyl wherein alkyl, substitutedalkyl, alkylene and substituted alkylene are as defined herein.Preferred alkylthioalkoxy groups are alkylene-S-alkyl and include, byway of example, methylenethiomethoxy (—CH₂SCH₃), ethylenethiomethoxy(—CH₂CH₂SCH₃), n-propylene-iso-thiopropoxy (—CH₂CH₂CH₂SCH(CH₃)₂),methylene-t-thiobutoxy (—CH₂SC(CH₃)₃), and the like.

The term “alkenyl” refers to a monoradical of a branched or unbranchedunsaturated hydrocarbon group preferably having from 2 to 40 carbonatoms, more preferably 2 to 10 carbon atoms and even more preferably 2to 6 carbon atoms and having at least 1 and preferably from 1-6 sites ofvinyl unsaturation. Preferred alkenyl groups include ethenyl (—CH═CH₂),n-propenyl (—CH₂CH═CH₂), iso-propenyl (—C(CH₃)═CH₂), and the like.

The term “substituted alkenyl” refers to an alkenyl group as definedabove having from 1 to 5 substituents, and preferably 1 to 3substituents, selected from the group consisting of alkoxy, substitutedalkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino,aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl,keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy,thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl,aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy,hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl,—SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryland —SO₂-heteroaryl.

The term “alkenylene” refers to a diradical of a branched or unbranchedunsaturated hydrocarbon group preferably having from 2 to 40 carbonatoms, more preferably 2 to 10 carbon atoms and even more preferably 2to 6 carbon atoms and having at least 1 and preferably from 1-6 sites ofvinyl unsaturation. This term is exemplified by groups such asethenylene (—CH═CH—), the propenylene isomers (e.g., —CH₂CH═CH— or—C(CH₃)═CH—), and the like.

The term “substituted alkenylene” refers to an alkenylene group asdefined above having from 1 to 5 substituents, and preferably from 1 to3 substituents, selected from the group consisting of alkoxy,substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl,substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substitutedamino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen,hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy,thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substitutedthioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic,heterocyclooxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl,—SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl,—SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl. Additionally,such substituted alkenylene groups include those where 2 substituents onthe alkenylene group are fused to form one or more cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl,heterocyclic or heteroaryl groups fused to the alkenylene group.

The term “alkynyl” refers to a monoradical of an unsaturated hydrocarbonpreferably having from 2 to 40 carbon atoms, more preferably 2 to 20carbon atoms and even more preferably 2 to 6 carbon atoms and having atleast 1 and preferably from 1-6 sites of acetylene (triple bond)unsaturation. Preferred alkynyl groups include ethynyl (—C≡CH),propargyl (—CH₂C≡CH), and the like.

The term “substituted alkynyl” refers to an alkynyl group as definedabove having from 1 to 5 substituents, and preferably 1 to 3substituents, selected from the group consisting of alkoxy, substitutedalkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino,aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl,keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy,thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl,aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy,hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl,—SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl,and —SO₂-heteroaryl.

The term “alkynylene” refers to a diradical of an unsaturatedhydrocarbon preferably having from 2 to 40 carbon atoms, more preferably2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms andhaving at least 1 and preferably from 1-6 sites of acetylene (triplebond) unsaturation. Preferred alkynylene groups include ethynylene(—C≡C—), propargylene (—CH₂C≡C—), and the like.

The term “substituted alkynylene” refers to an alkynylene group asdefined above having from 1 to 5 substituents, and preferably 1 to 3substituents, selected from the group consisting of alkoxy, substitutedalkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino,aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl,keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy,thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl,aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy,hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl,—SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryland —SO₂-heteroaryl.

The term “acyl” refers to the groups HC(O)—, alkyl-C(O)—, substitutedalkyl-C(O)—, cycloalkyl-C(O)—, substituted cycloalkyl-C(O)—,cycloalkenyl-C(O)—, substituted cycloalkenyl-C(O)—, aryl-C(O)—,heteroaryl-C(O)— and heterocyclic-C(O)— where alkyl, substituted alkyl,cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, aryl, heteroaryl, and heterocyclic are as defined herein.

The term “acylamino” or “aminocarbonyl” refers to the group —C(O)NRRwhere each R is independently hydrogen, alkyl, substituted alkyl, aryl,heteroaryl, heterocyclic or where both R groups are joined to form aheterocyclic group (e.g., morpholino) wherein alkyl, substituted alkyl,aryl, heteroaryl, and heterocyclic are as defined herein.

The term “aminoacyl” refers to the group —NRC(O)R where each R isindependently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, orheterocyclic wherein alkyl, substituted alkyl, aryl, heteroaryl, andheterocyclic are as defined herein.

The term “aminoacyloxy” or “alkoxycarbonylamino” refers to the group—NRC(O)OR where each R is independently hydrogen, alkyl, substitutedalkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substitutedalkyl, aryl, heteroaryl, and heterocyclic are as defined herein.

The term “acyloxy” refers to the groups alkyl-C(O)O—, substitutedalkyl-C(O)O—, cycloalkyl-C(O)O—, substituted cycloalkyl-C(O)O—,aryl-C(O)O—, heteroaryl-C(O)O—, and heterocyclic-C(O)O— wherein alkyl,substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl,and heterocyclic are as defined herein.

The term “aryl” refers to an unsaturated aromatic carbocyclic group offrom 6 to 20 carbon atoms having a single ring (e.g., phenyl) ormultiple condensed (fused) rings (e.g., naphthyl or anthryl). Preferredaryls include phenyl, naphthyl and the like. Unless otherwiseconstrained by the definition for the aryl substituent, such aryl groupscan optionally be substituted with from 1 to 5 substituents, preferably1 to 3 substituents, selected from the group consisting of acyloxy,hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl,cycloalkenyl, substituted alkyl, substituted alkoxy, substitutedalkenyl, substituted alkynyl, substituted cycloalkyl, substitutedcycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl,aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halo, nitro,heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, aminoacyloxy,oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy,thioheteroaryloxy, —SO-alkyl, —SO-substituted alkyl, —SO-aryl,—SO-heteroaryl, —SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl,—SO₂-heteroaryl and trihalomethyl. Preferred aryl substituents includealkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy.

The term “aryloxy” refers to the group aryl-O— wherein the aryl group isas defined above including optionally substituted aryl groups as alsodefined above.

The term “arylene” refers to the diradical derived from aryl (includingsubstituted aryl) as defined above and is exemplified by 1,2-phenylene,1,3-phenylene, 1,4-phenylene, 1,2-naphthylene and the like.

The term “amino” refers to the group —NH₂.

The term “substituted amino” refers to the group —NRR where each R isindependently selected from the group consisting of hydrogen, alkyl,substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl,substituted alkynyl, aryl, heteroaryl, and heterocyclic provided thatboth R's are not hydrogen.

The term “carboxyalkyl” or “alkoxycarbonyl” refers to the groups“—C(O)O-alkyl”, “—C(O)O-substituted alkyl”, “—C(O)O-cycloalkyl”,“—C(O)O-substituted cycloalkyl”, “—C(O)O-alkenyl”, “—C(O)O-substitutedalkenyl”, “—C(O)O-alkynyl” and “—C(O)O-substituted alkynyl” where alkyl,substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,substituted alkenyl, alkynyl and substituted alkynyl alkynyl are asdefined herein.

The term “cycloalkyl” refers to cyclic alkyl groups of from 3 to 20carbon atoms having a single cyclic ring or multiple condensed rings.Such cycloalkyl groups include, by way of example, single ringstructures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, andthe like, or multiple ring structures such as adamantanyl, and the like.

The term “substituted cycloalkyl” refers to cycloalkyl groups havingfrom 1 to 5 substituents, and preferably 1 to 3 substituents, selectedfrom the group consisting of alkoxy, substituted alkoxy, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl,acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl,—SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl.

The term “cycloalkenyl” refers to cyclic alkenyl groups of from 4 to 20carbon atoms having a single cyclic ring and at least one point ofinternal unsaturation. Examples of suitable cycloalkenyl groups include,for instance, cyclobut-2-enyl, cyclopent-3-enyl, cyclooct-3-enyl, andthe like.

The term “substituted cycloalkenyl” refers to cycloalkenyl groups havingfrom 1 to 5 substituents, and preferably 1 to 3 substituents, selectedfrom the group consisting of alkoxy, substituted alkoxy, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl,acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy,oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl,carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy,thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl,—SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl.

The term “halo” or “halogen” refers to fluoro, chloro, bromo and iodo.

The term “heteroaryl” refers to an aromatic group of from 1 to 15 carbonatoms and 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfurwithin at least one ring (if there is more than one ring). Unlessotherwise constrained by the definition for the heteroaryl substituent,such heteroaryl groups can be optionally substituted with 1 to 5substituents, preferably 1 to 3 substituents, selected from the groupconsisting of acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl,alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substitutedalkoxy, substituted alkenyl, substituted alkynyl, substitutedcycloalkyl, substituted cycloalkenyl, amino, substituted amino,aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl,carboxylalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy,heterocyclic, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy,substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl,—SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl,—SO₂-substituted alkyl, —SO₂-aryl, —SO₂-heteroaryl and trihalomethyl.Preferred aryl substituents include alkyl, alkoxy, halo, cyano, nitro,trihalomethyl, and thioalkoxy. Such heteroaryl groups can have a singlering (e.g., pyridyl or furyl) or multiple condensed rings (e.g.,indolizinyl or benzothienyl). Preferred heteroaryls include pyridyl,pyrrolyl and furyl.

The term “heteroaralkyl” refers to the groups -alkylene-heteroaryl wherealkylene and heteroaryl are defined herein. Such heteroaralkyl groupsare exemplified by pyridylmethyl, pyridylethyl, indolylmethyl, and thelike.

The term “heteroaryloxy” refers to the group heteroaryl-O—.

The term “heteroarylene” refers to the diradical group derived fromheteroaryl (including substituted heteroaryl), as defined above, and isexemplified by the groups 2,6-pyridylene, 2,4-pyridiylene,1,2-quinolinylene, 1,8-quinolinylene, 1,4-benzofuranylene,2,5-pyridinylene, 2,5-indolenyl, and the like.

The term “heterocycle” or “heterocyclic” or refers to a monoradicalsaturated unsaturated group having a single ring or multiple condensedrings, from 1 to 40 carbon atoms and from 1 to 10 hetero atoms,preferably 1 to 4 heteroatoms, selected from nitrogen, sulfur,phosphorus, and/or oxygen within the ring. Unless otherwise constrainedby the definition for the heterocyclic substituent, such heterocyclicgroups can be optionally substituted with 1 to 5, and preferably 1 to 3substituents, selected from the group consisting of alkoxy, substitutedalkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substitutedcycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino,aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl,keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy,thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl,aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy,hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl,—SO-aryl, —SO-heteroaryl, —SO₂-alkyl, —SO₂-substituted alkyl, —SO₂-aryland —SO₂-heteroaryl. Such heterocyclic groups can have a single ring ormultiple condensed rings. Preferred heterocyclics include morpholino,piperidinyl, and the like.

Examples of nitrogen heteroaryls and heterocycles include, but are notlimited to, pyrrole, thiophene, furan, imidazole, pyrazole, pyridine,pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole,indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine,naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine,carbazole, carboline, phenanthridine, acridine, phenanthroline,isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine,imidazolidine, imidazoline, pyrrolidine, piperidine, piperazine,indoline, morpholine, tetrahydrofuranyl, tetrahydrothiophene, and thelike as well as N-alkoxy-nitrogen containing heterocycles.

The term “heterocyclooxy” refers to the group heterocyclic-O—.

The term “thioheterocyclooxy” refers to the group heterocyclic-S—.

The term “heterocyclene” refers to the diradical group formed from aheterocycle, as defined herein, and is exemplified by the groups2,6-morpholino, 2,5-morpholino and the like.

“Heterocycloamino” means a saturated monovalent cyclic group of 4 to 8ring atoms, wherein at least one ring atom is N and optionally containsone or two additional ring heteroatoms selected from the groupconsisting of N, O, or S(O)n (where n is an integer from 0 to 2), theremaining ring atoms being C, where one or two C atoms may optionally bereplaced by a carbonyl group. The heterocycloamino ring may be fused toa cycloalkyl, aryl or heteroaryl ring, and it may be optionallysubstituted with one or more substituents, preferably one or twosubstituents, selected from alkyl, substituted alkyl, cycloalkyl, aryl,aralkyl, heteroaryl, heteroaralkyl, halo, cyano, acyl, amino,substituted amino, acylamino, —OR (where R is hydrogen, alkyl, alkenyl,cycloalkyl, acyl, aryl, heteroaryl, aralkyl, or heteroaralkyl), or—S(O)nR [where n is an integer from 0 to 2 and R is hydrogen (providedthat n is 0), alkyl, alkenyl, cycloalkyl, amino, heterocyclo, aryl,heteroaryl, aralkyl, or heteroaralkyl]. More specifically the termheterocycloamino includes, but is not limited to, pyrrolidino,piperidino, morpholino, piperazino, indolino, or thiomorpholino, and thederivatives thereof.

The term “oxyacylamino” or “aminocarbonyloxy” refers to the group—OC(O)NRR where each R is independently hydrogen, alkyl, substitutedalkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substitutedalkyl, aryl, heteroaryl and heterocyclic are as defined herein.

The term “spiro-attached cycloalkyl group” refers to a cycloalkyl groupattached to another ring via one carbon atom common to both rings.

The term “thiol” refers to the group —SH.

The term “thioalkoxy” or “alkylthio” refers to the group —S-alkyl.

The term “substituted thioalkoxy” refers to the group —S-substitutedalkyl.

The term “thioaryloxy” refers to the group aryl-S— wherein the arylgroup is as defined above including optionally substituted aryl groupsalso defined above.

The term “thioheteroaryloxy” refers to the group heteroaryl-S— whereinthe heteroaryl group is as defined above including optionallysubstituted aryl groups as also defined above.

As to any of the above groups which contain one or more substituents, itis understood, of course, that such groups do not contain anysubstitution or substitution patterns which are sterically impracticaland/or synthetically non-feasible. In addition, the compounds of thisinvention include all stereochemical isomers arising from thesubstitution of these compounds.

The term “pharmaceutically-acceptable salt” refers to salts which retainthe biological effectiveness and properties of the multibindingcompounds of this invention and which are not biologically or otherwiseundesirable. In many cases, the multibinding compounds of this inventionare capable of forming acid and/or base salts by virtue of the presenceof amino and/or carboxyl groups or groups similar thereto.

Pharmaceutically-acceptable base addition salts can be prepared frominorganic and organic bases. Salts derived from inorganic bases, includeby way of example only, sodium, potassium, lithium, ammonium, calciumand magnesium salts. Salts derived from organic bases include, but arenot limited to, salts of primary, secondary and tertiary amines, such asalkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines,di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenylamines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines,di(substituted alkenyl) amines, tri(substituted alkenyl) amines,cycloalkyl amines, di(cycloalkyl) amines, tri(cycloallyl) amines,substituted cycloalkyl amines, disubstituted cycloalkyl amine,trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkenyl)amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines,disubstituted cycloalkenyl amine, trisubstituted cycloalkenyl amines,aryl amines, diaryl amines, triaryl amines, heteroaryl amines,diheteroaryl amines, triheteroaryl amines, heterocyclic amines,diheterocyclic amines, triheterocyclic amines, mixed di- and tri-amineswhere at least two of the substituents on the amine are different andare selected from the group consisting of alkyl, substituted alkyl,alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl,cycloalkenyl, substituted cycloalkenyl, aryl; heteroaryl, heterocyclic,and the like. Also included are amines where the two or threesubstituents, together with the amino nitrogen, form a heterocyclic orheteroaryl group. Examples of suitable amines include, by way of exampleonly, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl)amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol,tromethamine, lysine, arginine, histidine, caffeine, procaine,hydrabamine, choline, betaine, ethylenediamine, glucosamine,N-alkylglucamines, theobromine, purines, piperazine, piperidine,morpholine, N-ethylpiperidine, and the like. It should also beunderstood that other carboxylic acid derivatives would be useful in thepractice of this invention, for example, carboxylic acid amides,including carboxamides, lower alkyl carboxamides, dialkyl carboxamides,and the like.

Pharmaceutically acceptable acid addition salts may be prepared frominorganic and organic acids. Salts derived from inorganic acids includehydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like. Salts derived from organic acids includeacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid,malic acid, malonic acid, succinic acid, maleic acid, fumaric acid,tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid,salicylic acid, and the like.

The term “pharmaceutically-acceptable cation” refers to the cation of apharmaceutically-acceptable salt.

The term “library” refers to at least 3, preferably from 10² to 10⁹ andmore preferably from 10² to 10⁴ multimeric compounds. Preferably, thesecompounds are prepared as a multiplicity of compounds in a singlesolution or reaction mixture which permits facile synthesis thereof. Inone embodiment, the library of multimeric compounds can be directlyassayed for multibinding properties. In another embodiment, each memberof the library of multimeric compounds is first isolated and,optionally, characterized. This member is then assayed for multibindingproperties.

The term “collection” refers to a set of multimeric compounds which areprepared either sequentially or concurrently (e.g., combinatorially).The collection comprises at least 2 members; preferably from 2 to 10⁹members and still more preferably from 10 to 10⁴ members.

The term “multimeric compound” refers to compounds comprising from 2 to10 ligands covalently connected through at least one linker whichcompounds may or may not possess multibinding properties (as definedherein).

The term “pseudohalide” refers to functional groups which react indisplacement reactions in a manner similar to a halogen. Such functionalgroups include, by way of example, mesyl, tosyl, azido and cyano groups.

The term “protecting group” or “blocking group” refers to any groupwhich when bound to one or more hydroxyl, thiol, amino or carboxylgroups of the compounds (including intermediates thereof) preventsreactions from occurring at these groups and which protecting group canbe removed by conventional chemical or enzymatic steps to reestablishthe hydroxyl, thiol, amino or carboxyl group. The particular removableblocking group employed is not critical and preferred removable hydroxylblocking groups include conventional substituents such as allyl, benzyl,acetyl, chloroacetyl, thiobenzyl, benzylidine, phenacyl,t-butyl-diphenylsilyl and any other group that can be introducedchemically onto a hydroxyl functionality and later selectively removedeither by chemical or enzymatic methods in mild conditions compatiblewith the nature of the product. Preferred removable thiol blockinggroups include disulfide groups, acyl groups, benzyl groups, and thelike. Preferred removable amino blocking groups include conventionalsubstituents such as t-butyoxycarbonyl (t-BOC), benzyloxycarbonyl (CBZ),fluorenylmethoxy-carbonyl (FMOC), allyloxycarbonyl (ALOC), and the likewhich can be removed by conventional conditions compatible with thenature of the product. Preferred carboxyl protecting groups includeesters such as methyl, ethyl, propyl, t-butyl etc. which can be removedby mild conditions compatible with the nature of the product.

The term “optional” or “optionally” means that the subsequentlydescribed event, circumstance or substituent may or may not occur, andthat the description includes instances where said event or circumstanceoccurs and instances where it does not.

The term “ligand” as used herein denotes a compound that is a muscarinicreceptor antagonist or an allosteric modulator of a muscarinic receptor.The specific region or regions of the ligand that is (are) recognized bythe receptor is designated as the “ligand domain”. A ligand may beeither capable of binding to the receptor by itself, or may require thepresence of one or more non-ligand components for binding (e.g., Ca⁺²,Mg⁺² or a water molecule is required for the binding of a ligand tovarious ligand binding sites). Examples of ligands useful in thisinvention are described herein. Those skilled in the art will appreciatethat portions of the ligand structure that are not essential forspecific molecular recognition and binding activity may be variedsubstantially, replaced or substituted with unrelated structures (forexample, with ancillary groups as defined below) and, in some cases,omitted entirely without affecting the binding interaction. The primaryrequirement for a ligand is that it has a ligand domain as definedabove. It is understood that the term ligand is not intended to belimited to compounds known to be useful in binding to muscarinicreceptor (e.g., known drugs). Those skilled in the art will understandthat the term ligand can equally apply to a molecule that is notnormally associated with receptor binding properties. In addition, itshould be noted that ligands that exhibit marginal activity or lackuseful activity as monomers can be highly active as multivalentcompounds because of the benefits conferred by multivalency.

The term “multibinding compound or agent” refers to a compound that iscapable of multivalency, as defined below, and which has 2-10 ligandscovalently bound to one or more linkers which may be the same ordifferent. Multibinding compounds provide a biological and/ortherapeutic effect greater than the aggregate of unlinked ligandsequivalent thereto which are made available for binding. That is to saythat the biological and/or therapeutic effect of the ligands attached tothe multibinding compound is greater than that achieved by the sameamount of unlinked ligands made available for binding to the ligandbinding sites (receptors). The phrase “increased biological ortherapeutic effect” includes, for example: increased affinity, increasedselectivity for target, increased specificity for target, increasedpotency, increased efficacy, decreased toxicity, improved duration ofactivity or action, decreased side effects, increased therapeutic index,improved bioavailibity, improved pharmacokinetics, improved activityspectrum, and the like. The multibinding compounds of this inventionwill exhibit at least one and preferably more than one of theabove-mentioned affects.

The term “univalency” as used herein refers to a single bindinginteraction between one ligand as defined herein with one ligand bindingsite as defined herein. It should be noted that a compound havingmultiple copies of a ligand (or ligands) exhibit univalency when onlyone ligand is interacting with a ligand binding site. Examples ofunivalent interactions are depicted below.

The term “multivalency” as used herein refers to the concurrent bindingof from 2 to 10 linked ligands (which may be the same or different) andtwo or more corresponding receptors (ligand binding sites) on one ormore receptors which may be the same or different.

For example, two ligands connected through a linker that bindconcurrently to two ligand binding sites would be considered asbivalency; three ligands thus connected would be an example oftrivalency. An example of trivalent binding, illustrating a multibindingcompound bearing three ligands versus a monovalent binding interaction,is shown below:

It should be understood that all compounds that contain multiple copiesof a ligand attached to a linker or to linkers do not necessarilyexhibit the phenomena of multivalency, i.e., that the biological and/ortherapeutic effect of the multibinding agent is greater than the sum ofthe aggregate of unlinked ligands made available for binding to theligand binding site (receptor). For multivalency to occur, the ligandsthat are connected by a linker or linkers have to be presented to theirligand binding sites by the linker(s) in a specific manner in order tobring about the desired ligand-orienting result, and thus produce amultibinding event.

The term “potency” refers to the minimum concentration at which a ligandis able to achieve a desirable biological or therapeutic effect. Thepotency of a ligand is typically proportional to its affinity for itsligand binding site. In some cases, the potency may be non-linearlycorrelated with its affinity. In comparing the potency of two drugs,e.g., a multibinding agent and the aggregate of its unlinked ligand, thedose-response curve of each is determined under identical testconditions (e.g., in an in vitro or in vivo assay, in an appropriateanimal model). The finding that the multibinding agent produces anequivalent biological or therapeutic effect at a lower concentrationthan the aggregate unlinked ligand is indicative of enhanced potency.

The term “selectivity” or “specificity” is a measure of the bindingpreferences of a ligand for different ligand binding sites (receptors).The selectivity of a ligand with respect to its target ligand bindingsite relative to another ligand binding site is given by the ratio ofthe respective values of K_(d) (i.e., the dissociation constants foreach ligand-receptor complex) or, in cases where a biological effect isobserved below the K_(d), the ratio of the respective EC₅₀'s (i.e., theconcentrations that produce 50% of the maximum response for the ligandinteracting with the two distinct ligand binding sites (receptors)).

The term “ligand binding site” denotes the site on the muscarinicreceptor that recognizes a ligand domain and provides a binding partnerfor the ligand. The ligand binding site may be defined by monomeric ormultimeric structures. This interaction may be capable of producing aunique biological effect, for example, agonism, antagonism, modulatoryeffects, may maintain an ongoing biological event, and the like.

It should be recognized that the ligand binding sites of the receptorthat participate in biological multivalent binding interactions areconstrained to varying degrees by their intra- and inter-molecularassociations (e.g., such macromolecular structures may be covalentlyjoined to a single structure, noncovalently associated in a multimericstructure, embedded in a membrane or polymeric matrix, and so on) andtherefore have less translational and rotational freedom than if thesame structures were present as monomers in solution.

The terms “agonism” and “antagonism” are well known in the art. The term“modulatory effect” refers to the ability of the ligand to change theactivity of an agonist or antagonist through binding to a ligand bindingsite.

The term “allosteric modulator” as used herein denotes a compound thatcan regulate the activity of a muscarinic receptor. The allostericmodulator can regulate the activity of a muscarinic receptor in severalways i.e., by increasing the affinity of a muscarinic receptor for itsantagonists (see., Nedoma, J. S. et al., Synaptic Transmitters andReceptors (S. Tucek, ed.) Academia, Prague/Wiley, Chichester, 1987,108-112; and Tucek, S. et al., Mol. Pharmacol. 1990, 38:674-680; Dong,G. Z. et al, J. Pharmacol. Exp. Ther. 1995, 274:378-384; Dong, G. Z. etal., Biomed. Res. 1995, 16:327-335; Proska, J. and Tucek, S., Mol.Pharmacol. 1995, 48:696-702; and Proska, J. and Tucek, S., Eur. J. ofPharmacol. 1996, 201-205) or decreasing the affinity of a muscarinicreceptor for its agonists (see., Clark, A. L. and Mitchelson, F., Br. J.Pharmacol. 1976, 58:323-331; Christopoulos, A. and Mitchelson, F., Mol.Pharmacol. 1994, 46:105-114; and Tucek S. and Proska, J., TiPS. 1995,Vol. (16), 205-212). It can also regulate the a muscarinic receptor'sactivity by effecting the association or dissociation of a muscarinicreceptor agonist or antagonist as described in Trankle, C. et al., Mol.Pharmacol. 1998, 53:304-312; and Holzgrabe, U. and Mohr, K., DDT. 1998,Vol. 3. No. 5. 214-222. Compounds that effect the affinity of muscarinicreceptors for their natural ligand are well known in the art. Forexample, gallamine inhibits the binding of [3H]—(−)—N-methylscopolamineand other specific ligands to muscarinic receptors (see., Fryer, A. Dand El-Fakahany, E. D., 1998, Membrane Biochem., 8, 122; and Jacoby, E.E., et al. 1993, J. Clin. Invest., 91, 1314).

The term “inert organic solvent” or “inert organic solvent” means asolvent which is inert under the conditions of the reaction beingdescribed in conjunction therewith including, by way of example only,benzene, toluene, acetonitrile, tetrahydrofuran, dimethylformamide,chloroform, methylene chloride, diethyl ether, ethyl acetate, acetone,methylethyl ketone, methanol, ethanol, propanol, isopropanol, t-butanol,dioxane, pyridine, and the like. Unless specified to the contrary, thesolvents used in the reactions described herein are inert solvents.

The term “treatment” refers to any treatment of a pathologic conditionin a mammal, particularly a human, and includes:

(i) preventing the pathologic condition from occurring in a subjectwhich may be predisposed to the condition but has not yet been diagnosedwith the condition and, accordingly, the treatment constitutesprophylactic treatment for the disease condition;

(ii) inhibiting the pathologic condition, i.e., arresting itsdevelopment;

(iii) relieving the pathologic condition, i.e., causing regression ofthe pathologic condition; or

(iv) relieving the conditions mediated by the pathologic condition.

The term “pathologic condition which is modulated by treatment with aligand” covers all disease states (i.e., pathologic conditions) whichare generally acknowledged in the art to be usefully treated with aligand for the muscarinic receptors in general, and those disease stateswhich have been found to be usefully treated by a specific multibindingcompound of our invention. Such disease states include, by way ofexample only, the treatment of a mammal afflicted with chronicobstructive pulmonary disease, chronic bronchitis, irritable bowelsyndrome, urinary incontinence, and the like.

The term “therapeutically effective amount” refers to that amount ofmultibinding compound which is sufficient to effect treatment, asdefined above, when administered to a mammal in need of such treatment.The therapeutically effective amount will vary depending upon thesubject and disease condition being treated, the weight and age of thesubject, the severity of the disease condition, the manner ofadministration and the like, which can readily be determined by one ofordinary skill in the art.

The term “linker”, identified where appropriate by the symbol ‘X’ refersto a group or groups that covalently attaches from 2 to 10 ligands (asidentified above) in a manner that provides for a compound capable ofmultivalency. Among other features, the linker is a ligand-orientingentity that permits attachment of multiple copies of a ligand (which maybe the same or different) thereto. In some cases, the linker may itselfbe biologically active. Additionally, the linker can be either a chiralor achiral molecule. The term “linker” does not, however, extend tocover solid inert supports such as beads, glass particles, fibers, andthe like. But it is understood that the multibinding compounds of thisinvention can be attached to a solid support if desired. For example,such attachment to solid supports can be made for use in separation andpurification processes and similar applications.

The extent to which multivalent binding is realized depends upon theefficiency with which the linker or linkers that joins the ligandspresents these ligands to the array of available ligand binding sites.Beyond presenting these ligands for multivalent interactions with ligandbinding sites, the linker or linkers spatially constrains theseinteractions to occur within dimensions defined by the linker orlinkers. Thus, the structural features of the linker (valency, geometry,orientation, size, flexibility, chemical composition, etc.) are featuresof multibinding agents that play an important role in determining theiractivities.

The linkers used in this invention are selected to allow multivalentbinding of ligands to the ligand binding sites of a muscarinic receptor,whether such sites are located interiorly, both interiorly and on theperiphery of the enzyme structure, or at any intermediate positionthereof.

“Pro-drugs” means any compound which releases an active parent drugaccording to Formula (I) in vivo when such prodrug is administered to amammalian subject. Prodrugs of a compound of Formula (I) are prepared bymodifying functional groups present in the compound of Formula (I) insuch a way that the modifications may be cleaved in vivo to release theparent compound. Prodrugs include compounds of Formula (I) wherein ahydroxy, amino, or sulfhydryl group in compound (I) is bonded to anygroup that may be cleaved in vivo to regenerate the free hydroxyl,amino, or sulfhydryl group, respectively. Examples of prodrugs include,but are not limited to esters (e.g., acetate, formate, and benzoatederivatives), carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxyfunctional groups in compounds of Formula (I), and the like.

PREFERRED EMBODIMENTS

While the broadest definition of this invention is set forth in theSummary of the Invention, certain compounds of Formula (I) arepreferred.

(A) A preferred group is a bivalent multibinding compound of Formula (I)shown below:

L^(a)-X-L^(b)

(A) Within this group a preferred group of compounds is that whereinligands, L^(a) and L^(b), are muscarinic receptor antagonists and areindependently selected from the group consisting of:(1) a compound of formula (a):

wherein:

A is aryl or heteroaryl, preferably phenyl or pyridine, more preferablyphenyl;

B″ is —CH₂—, —O— or —NH—, preferably —O—;

R¹ is hydrogen or alkyl, preferably hydrogen, methyl, or ethyl, morepreferably hydrogen;

R² is selected from a group consisting of (i), (ii), (iii), or “Het”:

wherein:

----- is an optional double bond;

n₁ is 3 or 4;

n₂ is 1 or 2;

V is —CH— or —NR⁴— (wherein R⁴ is hydrogen, alkyl, substituted alkyl,aryl, or heteroaryl), preferably —CH—;

“Het” is a heteroaryl ring, preferably pyrrolyl, pyridinyl, orimidazolyl which optionally attach the ligand to a linker;

R³ is hydrogen or alkyl, preferably hydrogen or methyl, more preferablyhydrogen;

R⁵ is hydrogen, alkyl, aryl, aralkyl, heteroaralkyl, or a covalent bondattaching the ligand to a linker, preferably hydrogen, methyl, phenyloptionally substituted with alkyl, alkoxy, halo, hydroxy, carboxy, oramino, benzyl optionally substituted with alkyl, alkoxy, halo, hydroxy,carboxy, or amino or a covalent bond attaching the ligand to a linker,more preferably hydrogen or a covalent bond attaching the ligand to alinker;

R⁶, R⁷, and R⁸ are, independently of each other, hydrogen, halo,hydroxy, alkoxy, haloalkoxy, carboxy, alkoxycarbonyl, alkyl optionallysubstituted with one, two or three substituents selected from halo,hydroxy, carboxy, alkoxycarbonyl, alkylthio, alkylsulfonyl, amino,substituted amino, or a covalent bond attaching the ligand to a linker,preferably R⁶, R⁷, and R⁸ are, independently of each other, hydrogen,alkyl, nitro, hydroxy, amino, or a covalent bond attaching the ligand toa linker, most preferably R⁶, R⁷, and R⁸ are hydrogen or one of R⁶, R⁷,and R⁸ attaches the ligand to a linker; preferably

R² is:

wherein R⁶, R⁷, and R⁸ are hydrogen;

K is a bond or an alkylene group, preferably a bond or a methylenegroup, more preferably a bond;

K″ is a bond, —C(O)—, —S(O)_(n4)— (where n₄ is an integer of from 0 to2), or an alkylene group optionally substituted with a hydroxyl group,preferably a bond or a methylene group, more preferably a bond; and

B is a heterocycloamino group which optionally attaches the ligand to alinker, preferably B is a group selected from a group consisting of:

wherein:

n₁₃ and n₁₄ are, independently of each other, an integer of from 0 to 4provided that n₁₃+n₁₄ are integer of from 3 to 5;

n₁₅ and n₁₇ are, independently of each other, an integer of from 0 to 4provided that n₁₅+n₁₇ are integer of from 3 to 5;

n₁₆ is an integer of from 0 to 3 provided that n₁₅+n₁₆ are an integer offrom 3 to 5;

n₁₈, n₁₉ and n₂₀ are, independently of each other, an integer of from 0to 3 provided that n¹⁸+n₁₉+n₂₀ are 2 or 3;

n₂₁ is an integer of from 1 to 3;

W^(a) and W^(c) are, independently of each other:

where:

n₂₂ is 0 or 1;

R⁵³ and R⁵⁴ are, independently of each other, hydrogen, alkyl, alkenyl,alkynyl, cycloalkylalkyl, aralkyl, or heterocyclylalkyl or a covalentbond attaching the ligand to a linker;

R⁵⁵ is alkyl, alkenyl or alkynyl; and

W^(b) is —N(O)n₂₃ or —N⁺—R⁵⁶ where n₂₃ is 0 or 1, and R⁵⁶ is alkyl,alkenyl, alkynyl, or aralkyl, or a covalent bond attaching the ligand toa linker, more preferably B is:

(a) pyrrolidine, piperidine, 4-methylpiperidine, or hexahydroazepineoptionally attaching the ligand to a linker, preferably piperidin-4-ylor 4-methylpiperidin-4-yl wherein the nitrogen at the 1 positionoptionally attaches the ligand to a linker;

(b) quinuclidine, 1-azabicyclo[2.2.1]heptyl, or 1-azabicyclo[3.2.1]octyloptionally attaching the ligand to a linker wherein a bridge head carbonatom or a carbon atom adjacent thereto is the binding position with theoxygen atom; preferably quinuclidin-3-yl, quinuclidin-4-yl wherein thenitrogen optionally attaches the ligand to a linker; or

(c) a ring represented by the following general formulae:

wherein W^(c) is as defined above, most preferably B is piperidine or4-methyl-piperidine wherein the nitrogen atom of said piperidine or4-methylpiperidine ring attaches the ligand to a linker; or(2) a compound of formula (b):

wherein:

C is an aryl or heteroaryl ring, preferably phenyl,2-hydroxy-5-methylphenyl, or pyridine;

R⁹ is hydrogen, hydroxy, cyano, aminocarbonyl which optionally links theligand to a linker, alkyl substituted with one, two or threesubstituents selected from halo, hydroxy, carboxy, alkoxycarbonyl,alkylthio, alkylsulfonyl, amino, substituted amino, or a covalent bondattaching the ligand to a linker, preferably hydrogen, hydroxy,hydroxymethyl, or aminocarbonyl which optionally links the ligand to alinker;

R¹⁰ is hydrogen, aryl or cycloalkyl, preferably hydrogen, phenyl,cyclobutyl, cyclopentyl, or cyclohexyl;

Q is a single bond, —COCH₂—, —O—, —C(O)NH—, —NHC(O)O—, —NHC(O)NH—, or—C(O)O—;

Q″ is selected from the group consisting of:

(i) monoalkylaminoalkyl, monoalkylaminoalkenyl, monoalkylaminoalkynyl,preferably 2-N-methylaminoethyl, 2-N-ethylaminoethyl,3-methylaminobutyl, 2-N-isopropylaminoethyl, 4-ethylaminobutyn-1-yl, or5-N-ethylamino-2-methylpentyn-2-yl wherein the nitrogen atom of theamino group optionally links the ligand to a linker;

(ii) carboxy which optionally links the ligand to a linker;

(iii) a group of formula (Iv):

where:

E is a covalent bond attaching the ligand to a linker or —CH₂—CH₂—R¹¹

wherein:

R¹¹ is a group of formula:

and

(iv) a group of formula:

wherein:

n₆ is 0 or 1;

R¹⁴ is a covalent bond attaching the ligand to a linker;

R⁵¹ is hydrogen or alkyl; and

J is —(CH₂)₂—;

(3) a compound of formula (c):

wherein:

G′ is pyrrolidine, piperidine, or

wherein said G′ groups optionally attach the ligand to a linker;

n₇ is an 0 or 1 provided that when the nitrogen atom of the quinclidinering attaches the ligand to a linker then n₇ is 0;

n₈ is 2;

g is an integer of from 0 or 1, preferably 0;

R¹⁵ is hydrogen, halogen, nitro, cyano, hydroxy, alkoxy, carboxy,alkoxycarbonyl, acyl, thio, alkylthio, alkylsulfonyl, alkylsulfinyl,sulfonamido, alkylsulfonamido, carbamoyl, thiocarbamoyl, mono ordialkylcarbamoyl, amino, mono- or dialkylamino, methylenedioxy,ethylenedioxy, alkyl optionally substituted with one, two or threesubstituents selected from halo, hydroxy, carboxy, alkoxycarbonyl,alkylthio, alkylsulfonyl, amino, or substituted amino, or a covalentbond attaching the ligand to a linker, preferably hydrogen, halogen,alkyl, alkoxy, or hydroxy, or a covalent bond attaching the ligand to alinker;

G is aryl, heteroaryl, heterocyclyl, or cycloalkyl which optionallyattaches the ligand to a linker, preferably phenyl, pyridin-4-yl,pyridin-3-yl, pyridin-2-yl, thiophen-2-yl, thiophen-3-yl, furan-2-yl,4-chlorophenyl, cyclohexyl, 2-, 3-, or 4-fluorophenyl, 2-, 3-, or4-methylphenyl, 2-, 3-, or 4-nitrophenyl, 2-, 3-, or 4-aminophenyl,3,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 4-ethylphenyl,24-isopropylphenyl, 3-ethylaminophenyl, 2-methylaminophenyl,3-dimethylaminophenyl, 4-methoxycarbonylphenyl, 4-thiolphenyl,4-methylthiophenyl, 4-methylsulfoxidephenyl, 4-methylsulfonylphenyl,N-methylpiperidin-4-yl, pyrrol-2-yl, oxazol-2-yl, quinolin-4-yl,isoquinolin-4-yl, benzofuran-2-yl, benzothiophen-3-yl, morpholin-4-yl,piperazin-1-yl, piperidin-4-yl, dichlorophenyl, 4-aminomethylphenyl,4-hydroxymethylphenyl, cyclopentyl which optionally link the ligand to alinker, preferably G is a phenyl ring which optionally attaches theligand to a linker; and

G″ is a single bond or an alkylene group, preferably a single bond or amethylene group, preferably G″ is a bond;

(4) a compound of formula (e):

wherein:

n₅₂ is 0 or 1;

R¹⁶ is alkyl or a covalent bond attaching the ligand to a linker,preferably methyl or a covalent bond linking the ligand to a linker;

R¹⁷, R¹⁸, and R¹⁹ are, independently of each other, hydrogen, alkyl,alkoxy, hydroxy or a covalent bond linking the ligand to a linker, morepreferably hydrogen, methyl, methoxy, hydroxy, or a covalent bondlinking the ligand to a linker, even more preferably R¹⁷ is either metaor para to the —OR¹⁶ group and is hydrogen, hydroxy, or methyl or acovalent bond linking the ligand to a linker; R¹⁸ is hydrogen; and R¹⁹is hydrogen or hydroxy, preferably hydrogen;

R²⁰ and R²¹ are, independently of each other, hydrogen, alkyl or acovalent bond linking the ligand to a linker; or R²⁰ and R²¹ togetherwith the nitrogen atom to which they are attached form aheterocycloamino ring which optionally attaches the ligand to a linker,preferably R²⁰ and R²¹ are N,N-di(isopropyl)amino,N-methyl-N-tert-butylamino, 2,2,6,6-tetramethylpiperidino,N-methyl-N-adamantylamino which optionally attaches the ligand to alinker, or one of R²⁰ and R²¹ is hydrogen or alkyl and the other is acovalent bond attaching the ligand to a linker, more preferablyN,N-(isopropyl)amino, N-methyl-N-tert-butylamino, or one of R²⁰ and R²¹is hydrogen, methyl, or ethyl and the other is a covalent bond attachingthe ligand to a linker; or

(5) a compound of formula (f):

wherein:

R²² is hydrogen or halo, preferably R²² is hydrogen or fluoro, morepreferably hydrogen;

R²³ is alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, orheterocyclylalkyl, preferably cyclobutyl, cyclopentyl, cyclohexyl,adamantyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl,piperazin-1-ylmethyl wherein the nitrogen at the 4-position of thepiperazine ring is optionally substituted with a substituent selectedfrom fluoro, hydroxy, nitro, methoxy, methyl, or trifluoromethyl, orphenyl, naphthyl, or pyridyl optionally substituted with 1-3substituents selected from fluoro, hydroxy, nitro, methoxy, methyl,trifluoromethyl, methylcarbonyl, or amino, more preferably R²³ iscyclohexyl;

R²⁴ is hydroxy, halo, or a covalent bond attaching the ligand to alinker, preferably hydrogen, fluoro or a covalent bond attaching theligand to a linker, preferably hydroxy or a covalent bond attaching theligand to a linker;

R²⁵ and R²⁶ are, independently of each other, hydrogen, alkyl, aralkyl,or a covalent bond attaching the ligand to a linker, or R²⁵ and R²⁶together with the nitrogen atom to which they are attached form aheterocycloamino group which optionally attaches the ligand to a linker,preferably hydrogen, methyl, ethyl, phenylethyl, or a covalent bondattaching the ligand to a linker, more preferably R²⁵ and R²⁶ are,independently of each other, hydrogen, methyl, ethyl, or a covalent bondattaching the ligand to a linker; and

the linker, X, is a compound of formula:

—X^(a)-Z-(Y^(a)-Z)_(m-Y) ^(b)-Z-X^(a)—

wherein:

m is an integer of from 0 to 20;

X^(a) at each separate occurrence is selected from the group consistingof —O—, —S—, —NR—, —C(O)—, —C(O)O—, —C(O)NR—, —C(S), —C(S)O—, —C(S)NR—or a covalent bond where R is as defined below;

Z at each separate occurrence is selected from the group consisting ofalkylene, substituted alkylene, cycloalkylene, substitutedcylcoalkylene, alkenylene, substituted alkenylene, alkynylene,substituted alkynylene, cycloalkenylene, substituted cycloalkenylene,arylene, heteroarylene, heterocyclene, or a covalent bond;

Y^(a) and Y^(b) at each separate occurrence are selected from the groupconsisting of —O—, —C(O)—, —OC(O)—, —C(O)O—, —NR—, —S(O)n—, —C(O)NR′—,—NR′C(O)—, —NR′C(O)NR′—, —NR′C(S)NR′—, —C(═NR′)—NR′—, —NR′—C(═NR′)—,—OC(O)—NR′—, —NR′—C(O)—O—, —N═C(X^(a))—NR′—, —NR′—C(X^(a))═N—,—P(O)(OR′)—O—, —O—P(O)(OR′)—, —S(O)_(n)CR′R″—, —S(O)_(n)—NR′—,—NR′—S(O)_(n)—, —S—S—, and a covalent bond; where n is 0, 1 or 2; and R,R′ and R″ at each separate occurrence are selected from the groupconsisting of hydrogen, alkyl, substituted alkyl, cycloalkyl,substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl,substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryland heterocyclic; preferably

Within the above preferred and more preferred groups, an even morepreferred group of compounds is where the L^(a) and L^(b) areindependently selected from the group consisting of:

wherein the arrow indicates the point of attachment of the ligand,L^(a), to a linker;

Particularly preferred compounds within this group are where the L^(a)and L^(b) are independently selected from the group consisting of:

wherein the arrow indicates the point of attachment of the ligand,L^(a), to a linker; and the linker is selected from the group consistingof:

(B) Another more preferred group of compounds is that wherein ligand,La, is a muscarinic receptor antagonist selected from is selected fromthe group consisting of:(1) a compound of formula (a):

wherein:

A is aryl or heteroaryl, preferably phenyl or pyridine, more preferablyphenyl;

B″ is —CH₂—, —O— or —NH—, preferably —O—;

R¹ is hydrogen or alkyl, preferably hydrogen, methyl, or ethyl, morepreferably hydrogen;

R² is selected from a group consisting of (i), (ii), (iii), or “Het”:

wherein:

----- is an optional double bond;

n₁ is 3 or 4;

n₂ is 1 or 2;

V is —CH— or —NR⁴— (wherein R⁴ is hydrogen, alkyl, substituted alkyl,aryl, or heteroaryl), preferably —CH—;

“Het” is a heteroaryl ring, preferably pyrrolyl, pyridinyl, orimidazolyl which optionally attaches the ligand to a linker;

R³ is hydrogen or alkyl, preferably hydrogen or methyl, more preferablyhydrogen;

R⁵ is hydrogen, alkyl, aryl, aralkyl, heteroaralkyl, or a covalent bondattaching the ligand to a linker, preferably hydrogen, methyl, phenyloptionally substituted with alkyl, alkoxy, halo, hydroxy, carboxy, oramino, benzyl optionally substituted with alkyl, alkoxy, halo, hydroxy,carboxy, or amino or a covalent bond attaching the ligand to a linker,more preferably hydrogen or a covalent bond attaching the ligand to alinker;

R⁶, R⁷, and R⁸ are, independently of each other, hydrogen, halo,hydroxy, alkoxy, haloalkoxy, carboxy, alkoxycarbonyl, alkyl optionallysubstituted with one, two or three substituents selected from halo,hydroxy, carboxy, alkoxycarbonyl, alkylthio, alkylsulfonyl, amino, orsubstituted amino, or a covalent bond attaching the ligand to a linker,preferably R⁶, R⁷, and R⁸ are, independently of each other, hydrogen,alkyl, nitro, hydroxy, amino, or a covalent bond attaching the ligand toa linker, most preferably R⁶, R⁷, and R⁸ are hydrogen or one of R⁶, R⁷,and R⁸ attaches the ligand to a linker; preferably

R² is:

wherein R⁶, R⁷, and R⁸ are hydrogen;

K is a bond or an alkylene group, preferably a bond or a methylenegroup, more preferably a bond;

K″ is a bond, —C(O)—, —S(O)_(n4)— (where n₄ is an integer of from 0 to2), or an alkylene group optionally substituted with a hydroxyl group,preferably a bond or a methylene group, more preferably a bond; and

B is a heterocycloamino group which optionally attaches the ligand to alinker, preferably B is a group selected from a group consisting of:

wherein:

n₁₃ and n₁₄ are, independently of each other, an integer of from 1 to 4provided that n₁₃+n₁₄ are integer of from 3 to 5;

n₁₅ and n₁₇ are, independently of each other, an integer of from 1 to 4provided that n₁₅+n₁₇ are integer of from 3 to 5;

n₁₆ is an integer of from 1 to 3 provided that n₁₅+n₁₆ are an integer offrom 3 to 5;

n₁₈, n₁₉ and n₂₀ are, independently of each other, an integer of from 0to 3 provided that n₁₈+n₁₉+n₂₀ are 2 or 3;

n₂₁ is an integer of from 1 to 3;

W^(a) and W^(c) are, independently of each other:

where:

n₂₂ is 0 or 1;

R⁵³ and R⁵⁴ are, independently of each other, hydrogen, alkyl, alkenyl,alkynyl, cycloalkylalkyl, aralkyl, or heterocyclylalkyl or a covalentbond attaching the ligand to a linker;

R⁵⁵ is alkyl, alkenyl or alkynyl; and

W^(b) is —N(O)n₂₃ or —N⁺—R⁵⁶ where n₂₃ is 0 or 1, and R⁵⁶ is alkyl,alkenyl, alkynyl, or aralkyl, or a covalent bond attaching the ligand toa linker, more preferably B is:

(a) pyrrolidine, piperidine, 4-methylpiperidine, or hexahydroazepineoptionally attaching the ligand to a linker, preferably piperidin-4-ylor 4-methylpiperidin-4-yl wherein the nitrogen at the 1 positionoptionally attaches the ligand to a linker;

(b) quinuclidine, 1-azabicyclo[2.2.1]heptyl, or 1-azabicyclo[3.2.1]octyloptionally attaching the ligand to a linker wherein a bridge head carbonatom or a carbon atom adjacent thereto is the binding position with theoxygen atom; preferably quinuclidin-3-yl, quinuclidin-4-yl wherein thenitrogen optionally attaches the ligand to a linker; or

(c) a ring represented by the following general formulae:

wherein W^(c) is as defined above, most preferably B is piperidine or4-methyl-piperidine wherein the nitrogen atom of said piperidine or4-methylpiperidine ring attaches the ligand to a linker; or(2) a compound of formula (b):

wherein:

C is an aryl or heteroaryl ring, preferably phenyl,2-hydroxy-5-methylphenyl, or pyridine;

R⁹ is hydrogen, hydroxy, cyano, aminocarbonyl which optionally links theligand to a linker, alkyl substituted with one, two or threesubstituents selected from halo, hydroxy, carboxy, alkoxycarbonyl,alkylthio, alkylsulfonyl, amino, substituted amino, or a covalent bondattaching the ligand to a linker, preferably hydrogen, hydroxy,hydroxymethyl, or aminocarbonyl which optionally links the ligand to alinker;

R¹⁰ is hydrogen, aryl or cycloalkyl, preferably hydrogen, phenyl,cyclobutyl, cyclopentyl, or cyclohexyl;

Q is a single bond, —O—, —COCH₂—, —C(O)NH—, —NHC(O)O—, —NHC(O)NH—, or—C(O)O—;

Q″ is selected from the group consisting of:

(i) monoalkylaminoalkyl, monoalkylaminoalkenyl, monoalkylaminoalkynyl,preferably 2-N-methylaminoethyl, 2-N-ethylaminoethyl,3-methylaminobutyl, 2-N-isopropylaminoethyl, 4-ethylaminobutyn-1-yl, or5-N-ethylamino-2-methylpentyn-2-yl wherein the nitrogen atom of theamino group optionally links the ligand to a linker;

(ii) carboxy which optionally links the ligand to a linker;

(iii) a group of formula (Iv):

where:

E is a covalent bond attaching the ligand to a linker or —CH₂—CH₂—R¹¹

wherein:

R¹¹ is a group of formula:

and

(iv) a group of formula:

wherein:

n₆ is 0 or 1;

R¹⁴ is a covalent bond attaching the ligand to a linker;

R⁵¹ is hydrogen or alkyl; and

J is —(CH₂)₂—;

(3) a compound of formula (c):

wherein:

G′ is pyrrolidine, piperidine, or

wherein said G′ groups optionally attach the ligand to a linker;

n₇ is an 0 or 1 provided that when the nitrogen atom of the quinclidinering attaches the ligand to a linker then n₇ is 0;

n₈ is 2;

g is an integer of from 0 or 1, preferably 0;

R¹⁵ is hydrogen, halogen, nitro, cyano, hydroxy, alkoxy, carboxy,alkoxycarbonyl, acyl, thio, alkylthio, alkylsulfonyl, alkylsulfinyl,sulfonamido, alkylsulfonamido, carbamoyl, thiocarbamoyl, mono ordialkylcarbamoyl, amino, mono- or dialkylamino, methylenedioxy,ethylenedioxy, alkyl optionally substituted with one, two or threesubstituents selected from halo, hydroxy, carboxy, alkoxycarbonyl,alkylthio, alkylsulfonyl, amino, or substituted amino, or a covalentbond attaching the ligand to a linker, preferably hydrogen, halogen,alkyl, alkoxy, or hydroxy, or a covalent bond attaching the ligand to alinker;

G is aryl, heteroaryl, heterocyclyl, or cycloalkyl which optionallyattaches the ligand to a linker, preferably phenyl, pyridin-4-yl,pyridin-3-yl, pyridin-2-yl, thiophen-2-yl, thiophen-3-yl, furan-2-yl,4-chlorophenyl, cyclohexyl, 2-, 3-, or 4-fluorophenyl, 2-, 3-, or4-methylphenyl, 2-, 3-, or 4-nitrophenyl, 2-, 3-, or 4-aminophenyl,3,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 4-ethylphenyl,24-isopropylphenyl, 3-ethylaminophenyl, 2-methylaminophenyl,3-dimethylaminophenyl, 4-methoxycarbonylphenyl, 4-thiolphenyl,4-methylthiophenyl, 4-methylsulfoxidephenyl, 4-methylsulfonylphenyl,N-methylpiperidin-4-yl, pyrrol-2-yl, oxazol-2-yl, quinolin-4-yl,isoquinolin-4-yl, benzofuran-2-yl, benzothiophen-3-yl, morpholin-4-yl,piperazin-1-yl, piperidin-4-yl, dichlorophenyl, 4-aminomethylphenyl,4-hydroxymethylphenyl, cyclopentyl which optionally link the ligand to alinker, preferably G is a phenyl ring which optionally attaches theligand to a linker; and

G″ is a single bond or an alkylene group, preferably a single bond or amethylene group, preferably G″ is a bond;

(4) a compound of formula (e):

wherein:

n₅₂ is 0 or 1;

R¹⁶ is alkyl or a covalent bond attaching the ligand to a linker,preferably methyl or a covalent bond linking the ligand to a linker;

R¹⁷, R¹⁸, and R¹⁹ are, independently of each other, hydrogen, alkyl,alkoxy, hydroxy or a covalent bond linking the ligand to a linker, morepreferably hydrogen, methyl, methoxy, hydroxy, or a covalent bondlinking the ligand to a linker, even more preferably R¹⁷ is either metaor para to the —OR¹⁶ group and is hydrogen, hydroxy, or methyl or acovalent bond linking the ligand to a linker; R¹⁸ is hydrogen; and R¹⁹is hydrogen or hydroxy, preferably hydrogen;

R²⁰ and R²¹ are, independently of each other, hydrogen, alkyl or acovalent bond linking the ligand to a linker; or R²⁰ and R²¹ togetherwith the nitrogen atom to which they are attached form aheterocycloamino ring which optionally attaches the ligand to a linker,preferably R²⁰ and R²¹ are N,N-di(isopropyl)amino,N-methyl-N-tert-butylamino, 2,2,6,6-tetramethylpiperidino,N-methyl-N-adamantylamino which optionally attaches the ligand to alinker, or one of R²⁰ and R²¹ is hydrogen or alkyl and the other is acovalent bond attaching the ligand to a linker, more preferablyN,N-di(isopropyl)amino, N-methyl-N-tert-butylamino, or one of R²⁰ andR²¹ is hydrogen, methyl, or ethyl and the other is a covalent bondattaching the ligand to a linker; or

(5) a compound of formula (f):

wherein:

R²² is hydrogen or halo, preferably R²² is hydrogen or fluoro, morepreferably hydrogen;

R²³ is alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, orheterocyclylalkyl, preferably cyclobutyl, cyclopentyl, cyclohexyl,adamantyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl,piperazin-1-ylmethyl wherein the nitrogen at the 4-position of thepiperazine ring is optionally substituted with a substituent selectedfrom fluoro, hydroxy, nitro, methoxy, methyl, or trifluoromethyl, orphenyl, naphthyl, or pyridyl optionally substituted with 1-3substituents selected from fluoro, hydroxy, nitro, methoxy, methyl,trifluoromethyl, methylcarbonyl, or amino, more preferably R²³ iscyclohexyl;

R²⁴ is hydroxy, halo, or a covalent bond attaching the ligand to alinker, preferably hydrogen, fluoro or a covalent bond attaching theligand to a linker, preferably hydroxy or a covalent bond attaching theligand to a linker;

R²⁵ and R²⁶ are, independently of each other, hydrogen, alkyl, aralkyl,or a covalent bond attaching the ligand to a linker, or R²⁵ and R²⁶together with the nitrogen atom to which they are attached form aheterocycloamino group which optionally attaches the ligand to a linker,preferably hydrogen, methyl, ethyl, phenylethyl, or a covalent bondattaching the ligand to a linker, more preferably R²⁵ and R²⁶ are,independently of each other, hydrogen, methyl, ethyl, or a covalent bondattaching the ligand to a linker;

L^(b), is an allosteric modulator of a muscarinic receptor and isselected from the group consisting of:

(6) a compound of formula (g):

wherein:

D″ is alkylene, preferably —(CH₂)n₄₃- where n₄₃ is an integer of from1-10, preferably 2-8, more preferably 2-4;

D is —NR³¹R³², —(R³³R³⁴R³⁵)M⁻ or —OR³² where R³¹, R³³, and R³⁴ are,independently of each other, hydrogen, alkyl, or aralkyl, and R³² andR³⁵ represent a covalent bond attaching the ligand to a linker,preferably D is —NR³¹R³² or —N⁺(R³³R³⁴R³⁵)M⁻ where R³¹, R³³, and R³⁴are, independently of each other, hydrogen or methyl, and R³² and R³⁵represent a covalent bond attaching the ligand to a linker, morepreferably R³¹, R³³, and R³⁴ methyl, and R³² and R³⁵ represent acovalent bond attaching the ligand to a linker;

R²⁷ is hydrogen, halo, nitro, cyano, hydroxy, alkoxy, carboxy,alkoxycarbonyl, acyl, thio, alkylthio, alkylsulfonyl, alkylsulfinyl,sulfonamido, alkylsulfonamido, carbamoyl, thiocarbamoyl, mono ordialkylcarbamoyl, amino, mono- or dialkylamino, aryl, aryloxy, arylthio,heteroaryl, heteraryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy,aralkyl, heteroaralkyl, or alkyl optionally substituted with one, two orthree substituents selected from halo, hydroxy, carboxy, alkoxycarbonyl,alkylthio, alkylsulfonyl, amino, or substituted amino, preferablyhydrogen;

R²⁸ is hydrogen, halo, nitro, cyano, hydroxy, alkoxy, carboxy,alkoxycarbonyl, acyl, thio, alkylthio, alkylsulfonyl, alkylsulfinyl,sulfonamido, alkylsulfonamido, carbamoyl, thiocarbamoyl, mono ordialkylcarbamoyl, amino, mono- or dialkylamino, or alkyl optionallysubstituted with one, two or three substituents selected from halo,hydroxy, carboxy, alkoxycarbonyl, alkylthio, alkylsulfonyl, amino, orsubstituted amino, preferably hydrogen;

R²⁹ and R³⁰ are, independently of each other, hydrogen, alkyl,haloalkyl, halo, nitro, cyano, hydroxy, alkoxy, alkoxycarbonyl, acyl,thio, alkylthio, amino, mono- or dialkylamino, preferably hydrogen; or

one of R²⁷, R²⁸, R²⁹, or R³⁰ together with the adjacent group forms amethylenedioxy or ethylenedioxy group;

(7) a compound of formula (h):

wherein:

n₁₁ is an integer of from 1 to 7, preferably 1;

n₁₂ is an integer of from 0 to 7, preferably 6;

F is —NR⁴⁰—, —O—, —S—, or —CHR⁴¹— wherein R⁴⁰ and R⁴¹ are, independentlyof each other, hydrogen or alkyl, preferably F is —O—;

F″ is a covalent bond, —OR⁴³, —NR⁴²R⁴³ wherein R⁴² is hydrogen or alkyl,or N⁺(R⁴³R⁴⁴R⁴⁵) wherein R⁴⁴ and R⁴⁵ are alkyl, and R⁴³ is a covalentbond attaching the ligand to a linker, preferably F″ is —O—, —NH—,N(CH₃)— or —N(CH₃)₂—, more preferably —NH—, N(CH₃)— or —N(CH₃)₂— whereinthe nitrogen atom attaches the ligand to a linker;

R³⁶ is hydrogen, halo, nitro, cyano, hydroxy, alkoxy, carboxy,alkoxycarbonyl, acyl, thio, alkylthio, alkylsulfonyl, alkylsulfinyl,sulfonamido, alkylsulfonamido, carbamoyl, thiocarbamoyl, mono ordialkylcarbamoyl, amino, mono- or dialkylamino, aryl, aryloxy, arylthio,heteroaryl, heteraryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy,aralkyl, heteroaralkyl, or alkyl optionally substituted with one, two orthree substituents selected from halo, hydroxy, carboxy, alkoxycarbonyl,alkylthio, alkylsulfonyl, amino, or substituted amino, preferablyhydrogen;

R³⁷ is hydrogen, halo, nitro, cyano, hydroxy, alkoxy, alkoxycarbonyl,acyl, thio, alkylthio, amino, mono- or dialkylamino, aryl, aryloxy,arylthio, heteroaryl, heteraryloxy, heteroarylthio, heterocyclyl,heterocyclyloxy, aralkyl, heteroaralkyl, or alkyl optionally substitutedwith one, two or three substituents selected from halo, hydroxy,carboxy, alkoxycarbonyl, alkylthio, alkylsulfonyl, amino, or substitutedamino, preferably R³⁷ is ortho to the —(CHR³⁸)— group and is hydrogen oralkoxy, more preferably methoxy;

R³⁸ is hydrogen, alkyl, halo, hydroxy, or alkoxy, preferably hydrogen;and

R³⁹ is hydrogen; or

(9) a compound of formula (I):

wherein:

R⁴⁶ is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, orheterocycle;

R⁴⁷ is alkyl, substituted alkyl, aryl, acyl, heterocycle, or —COOR⁴⁹where R⁴⁹ is alkyl; or

R⁴⁶ and R⁴⁷ together with the nitrogen atom to which they are attachedform heterocycle;

R⁴⁸ is a covalent bond that attaches the ligand to a linker;

R⁴⁹ is alkyl; preferably the compounds shown in table below wherein thenitrogen atom of the secondary aliphatic amino group is attached to alinker via a covalent bond and further wherein the nitrogen atom of thesecondary aliphatic amino group is optionally substituted with a methylgroup to form a quaternary ammonium salt,

and

the linker, X, is a compound of formula:

—X^(a)-Z-(Y^(a)-Z)_(m)-Y^(b)-Z-X^(a)—

wherein:

m is an integer of from 0 to 20;

X^(a) at each separate occurrence is selected from the group consistingof —O—, —S—, —NR—, —C(O)—, —C(O)O—, —C(O)NR—, —C(S), —C(S)O—, —C(S)NR—or a covalent bond where R is as defined below;

Z at each separate occurrence is selected from the group consisting ofalkylene, substituted alkylene, cycloalkylene, substitutedcylcoalkylene, alkenylene, substituted alkenylene, alkynylene,substituted alkynylene, cycloalkenylene, substituted cycloalkenylene,arylene, heteroarylene, heterocyclene, or a covalent bond;

Y^(a) and Y^(b) at each separate occurrence are selected from the groupconsisting of —O—, —C(O)—, —OC(O)—, —C(O)O—, —NR—, —S(O)n—, —C(O)NR′—,—NR′C(O)—, —NR′C(O)NR′—, —NR′C(S)NR′—, —C(═NR′)—NR′—, —NR′—C(═NR′)—,—OC(O)—NR′—, —NR′—C(O)—O—, —N═C(X^(a))—NR′—, —NR′—C(X)═N—,—P(O)(OR′)—O—, —O—P(O)(OR′)—, —S(O)_(n)CR′R″—, —S(O)_(n)—NR′—,—NR′—S(O)_(n)—, —S—S—, and a covalent bond; where n is 0, 1 or 2; and R,R′ and R″ at each separate occurrence are selected from the groupconsisting of hydrogen, alkyl, substituted alkyl, cycloalkyl,substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl,substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryland heterocyclic; preferably

Within these preferred groups, a more preferred group of compounds isthat wherein:

L^(a) is selected from the group consisting of:

wherein the arrow indicates the point of attachment of the ligand,L^(a), to a linker; and

L^(b) is selected from the group consisting of:

wherein the arrow indicates the point of attachment of the ligand,L^(b), to a linker.

Particularly preferred compounds within this group are where the L^(a)is selected from the group consisting of:

L^(b), is selected from the group consisting of:

wherein the arrow indicates the point of attachment of the ligand L^(a)and L^(b) to a linker; andand the linker is selected from the group consisting of:

General Synthetic Scheme

Compounds of this invention can be made by the methods depicted in thereaction schemes shown below.

The starting materials and reagents used in preparing these compoundsare either available from commercial suppliers such as Aldrich ChemicalCo., (Milwaukee, Wis., USA), Bachem (Torrance, Calif., USA),Emka-Chemie, or Sigma (St. Louis, Mo., USA) or are prepared by methodsknown to those skilled in the art following procedures set forth inreferences such as Fieser and Fieser's Reagents for Organic Synthesis,Volumes 1-15 (John Wiley and Sons, 1991); Rodd's Chemistry of CarbonCompounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers,1989), Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991),March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition),and Larock's Comprehensive Organic Transformations (VCH Publishers Inc.,1989).

The starting materials and the intermediates of the reaction may beisolated and purified if desired using conventional techniques,including but not limited to filtration, distillation, crystallization,chromatography, and the like. Such materials may be characterized usingconventional means, including physical constants and spectral data.

Furthermore, it will be appreciated that where typical or preferredprocess conditions (i.e., reaction temperatures, times, mole ratios ofreactants, solvents, pressures, etc.) are given, other processconditions can also be used unless otherwise stated. Optimum reactionconditions may vary with the particular reactants or solvent used, butsuch conditions can be determined by one skilled in the art by routineoptimization procedures.

Additionally, as will be apparent to those skilled in the art,conventional protecting groups may be necessary to prevent certainfunctional groups from undergoing undesired reactions. The choice of asuitable protecting group for a particular functional group as well assuitable conditions for protection and deprotection are well known inthe art. For example, numerous protecting groups, and their introductionand removal, are described in T. W. Greene and G. M. Wuts, ProtectingGroups in Organic Synthesis, Second Edition, Wiley, New York, 1991, andreferences cited therein.

These schemes are merely illustrative of some methods by which thecompounds of this invention can be synthesized, and variousmodifications to these schemes can be made and will be suggested to oneskilled in the art having referred to this disclosure.

Preparation of a Multibinding Compound of Formula (I)

A bivalent multibinding compound of Formula (I) can be prepared bycovalently attaching the ligands, L, to a linker, X, as shown in SchemeI below.

In general, a bivalent multibinding compound of Formula (I) can beprepared, as shown above, by covalently attaching the ligand, L, that isa muscarinic receptor antagonist or a muscarinic receptor modulatorprovided at least one of the ligand is a muscarinic receptor antagonistto a linker, X, where FG¹ and FG² represent a functional group such ashalo, amino, hydroxy, thio, aldehyde, ketone, carboxy, carboxyderivatives such as acid halide, ester, amido, and the like.

The ligands are covalently attached to the linker using conventionalchemical techniques providing for covalent linkage of the ligand to thelinker. Reaction chemistries resulting in such linkages are well knownin the art and involve the use of complementary functional groups on thelinker and ligand as shown in Table I below.

TABLE I Representative Complementary Binding Chemistries First ReactiveGroup Second Reactive Group Linkage carboxyl amine amide sulfonyl halideamine sulfonamide hydroxyl alkyl/aryl halide ether hydroxyl isocyanateurethane amine epoxide β-hydroxyamine amine alkyl/aryl halide alkylaminehydroxyl carboxyl ester

Reaction between a carboxylic acid of either the linker or the ligandand a primary or secondary amine of the ligand or the linker in thepresence of suitable, well-known activating agents such asdicyclohexylcarbodiimide, results in formation of an amide bondcovalently linking the ligand to the linker; reaction between an aminegroup of either the linker or the ligand and a sulfonyl halide of theligand or the linker, in the presence of a base such as triethylamine,pyridine, and the like, results in formation of a sulfonamide bondcovalently linking the ligand to the linker; and reaction between analcohol or phenol group of either the linker or the ligand and an alkylor aryl halide of the ligand or the linker in the presence of a basesuch as triethylamine, pyridine, and the like, results in formation ofan ether bond covalently linking the ligand to the linker.

Any compound which inhibits a muscarinic receptor or is an allostericmodulator of a muscarinic receptor can be used as a ligand in thisinvention. As discussed in further detail below, numerous antagonistsand allosteric modulators of muscarinic receptor are known in the artand any of these known compounds or derivatives thereof may be employedas ligands in this invention. Typically, a compound selected for use asa ligand will have at least one functional group, such as an amino,hydroxyl, thiol or carboxyl group and the like, which allows thecompound to be readily coupled to the linker. Compounds having suchfunctionality are either known in the art or can be prepared by routinemodification of known compounds using conventional reagents andprocedures. The patents and publications set forth below providenumerous examples of suitably functionalized muscarinic receptorantagonist, allosteric modulators and intermediates thereof which may beused as ligands in this invention. For example,

a ligand having formula (a):

wherein A is a phenyl or pyridine ring and other groups are as definedabove, can be prepared by the procedures described in EP 747 355; Naito,R. et al, Chem. Pharm. Bull. 1998, 46(8), 1286.

A ligand having formula (b):

wherein the groups C and R¹⁰ are phenyl, R⁹ is cyano or aminocarbonyl, Qis a bond, and Q″ is a group of formula

wherein E is as defined above, can be prepared by the proceduresdescribed in U.S. Pat. No. 5,096,890 and Drugs of the Future, 1996,21(11), 1105. Such ligands include Darifenacin and the derivativesthereof.

A ligand having formula (b):

wherein C and R¹⁰ are phenyl, R⁹ is hydrogen, Q is —NHC(O)O— and Q″ is agroup of formula (v) or (vi)

wherein n₆, J, R¹², R¹³, and R¹⁴ are as defined above, can be preparedby the procedures described in U.S. Pat. No. 3,505,337, EP 418 716,Drugs of the Future, 1997, 22(2) 135, EP 603229, PCT Application No. WO93/06098, Naito, R et al, Chem. Pharm. Bull. 1998, 46(8), 1274, NinomiyaK et al, Tetrahedron, 1974, 30, 2251 and PCT Application No. WO92/06958. Such ligands include Tiotropium, Ipratropium, Revatropate,Atropine, YM-58790, and the derivatives thereof.

A ligand having formula (c):

wherein n₈, R¹⁵, G, G′, and G″ are as defined above, can be prepared bythe procedures described in EP 801 067. Such ligands include YM-53705,and the derivatives thereof.

A ligand having formula (d):

wherein n⁹, n¹⁰, S, P and P″ are as defined above, can be prepared bythe procedures described in JP 258 250;

A ligand having formula (e):

wherein n₅₂ is 1, R¹⁶-R²¹ are as defined above, can be prepared by theprocedures described in EP 325 571 and Drugs of the Future, 1997, 22(7),733. Such ligands include Tolterodine and the derivatives thereof.

A ligand having formula (f):

wherein R²²-²⁶ are as defined above, can be prepared by the proceduresdescribed in EP 251126. Such ligands include Oxybutynin and thederivatives thereof.

A ligand having formula (g):

wherein R²⁷-R³⁰, D and D″ are as defined above, can be prepared by theprocedures described in Kostenis, E. et al. Eur. J. Med. Chem., 1994,Vol. 29, 947. Such ligands include allosteric modulator W-84 andderivatives thereof.

A ligand having formula (h):

wherein n₁₁, n₁₂, F, F″, and R³⁶-R³⁹ are as defined above can beprepared by the procedures well known in the art e.g., Quaglia, W., etal., IL FARMACO, 46(3), 417-434, (1991); Melchiorre, C., et al., J. Med.Chem., 32, 79-84, (1989); Minarini, A., et al., IL FARMACO, 46(10),1167-1178, (1991); Alvarez, M., et al., J. Med. Chem., 30, 1186-1193(1987); and Melchiorre, C., et al., J. Med. Chem., 30, 201-204, (1987).

Methods (a)-(e) below illustrate synthesis of bivalent multibindingcompounds of Formula (I). They are given to enable those skilled in theart to more clearly understand the present invention. They should not beconsidered as limiting the scope of the invention, but merely as beingillustrative and representative thereof.

Methods (a) and (b) below illustrate synthesis of a bivalent compound ofFormula (I) wherein the ligands are selected from a compound of formula(a).

Method (a)

Method (b)

In method (a), reaction of an amine of formula 1 or an isocyanate offormula 2 with a heterocycloamino group of formula 3 where PG is asuitable amino protecting group (such as tert-butoxycarbonyl, benzyl,and the like) gives a compound of formula (a). The reaction is carriedout in the presence of a base such as sodium hydride, sodium methoxide,and the like. Suitable solvents include inert organic organic solventssuch as tetrahydrofuran, dimethylformamide, dichloromethane, and thelike. Amines and isocyanates of formula 1 and 2 are commerciallyavailable or can be prepared by methods well known in the art. Forexample, 2-biphenylisocyanate and 2-aminobiphenyl are commerciallyavailable.

Compound (a) is then converted to a bivalent muitibinding compound ofFormula (I) by first removing the protecting group on the nitrogen andthen reacting it with a linker of formula 5. The nature of the FG² groupdepends on the type of linker group desired. For example, if X is analkylene chain then FG² would preferably be halide. If the attachment of(a) to the linker is via an amido group then FG² would preferably be acarboxy group or a carboxylic acid derivative such as acid chloride,ester, and the like. Compounds of formula 5 are commercially availableor they can be prepared by methods well known in the art. For example,1,2-dichloroethane, 1,2-dibromoethane, 1,2-dibromopropane, phthalic acidare commercially available. Suitable solvents include inert organicorganic solvents such as tetrahydrofuran, dimethylformamide,dichloromethane, and the like.

Alternatively, a compound of Formula (I) can be prepared as shown inMethod (b) above. In this method, 2 equivalents of a heterocycloaminogroup of formula 3 is reacted with one equivalent of a linker of formula5 as described previously to give a dihydroxy compound of formula 5which is then converted to a compound of Formula (I) by reacting it withan amine 1 or an isocyanate of formula 2 as described in method (a)above.

Method (c) and (d) below illustrate synthesis of a bivalent multibindingcompound of Formula (I) wherein the ligands are selected from a compoundof formula (c) where G is phenyl.

Method (c)

Method (d)

In method (c), a 2-phenylethylamine of formula 7 is condensed withbenzoic acid to give an amide of formula 8. The reaction is carried outin the presence of a coupling agent such as dicyclohexylcarbodiimide,and the like. Cyclization of 8 followed by hydrogenation of theresulting imine 9 provides a tetrahydroisoquinoline of formula 10.Reaction of 10 with 4-nitrophenyl-chloroformate provides a carbamate offormula 11 which is then reacted with a hydroxyamine of formula 12 togive a compound of formula (c). Treatment of 2 equivalents of compound(c) with one equivalent of formula 5 provides a bivalent multibindingcompound of Formula (I).

Method (d) illustrates synthesis of a bivalent multibinding compound ofFormula (I) with a different point of attachment to the linker.

Method (e) below illustrate synthesis of a bivalent multibindingcompound of Formula (I) wherein the one of the ligand is selected from aa muscarinic receptor antagonist ((selected from compound of formula(a)) and the other is a modulator of a muscarinic receptor ((selectedfrom a compound of formula (g)).

Method (e)

A bivalent multibinding compound of Formula (I) wherein the one of theligands is selected from a compound of formula (a) (a muscarinicreceptor antagonist) and the other is selected from a compound offormula (g) (a modulator of a muscarinic receptor) can be prepared byfirst reacting one equivalent of a compound of (g) where D is —NR³¹R³²(where R³¹ and R³² are as defined above) with a linking compound offormula 5 to give a compound of formula 13. Compound 13 is then reactedwith a compound of formula (a) to give a bivalent multibinding compoundof Formula (I). A compound of formula (g) can be prepared fromcommercially available phthalimides. For example, a compound of formula(g) where D″ is propyl and D is dimethylamino group can be prepared byreacting commercially available N-(3-bromopropyl)phthalimide withdimethylamine.

It will be apparent to one skilled in the art that the above chemistriesare not limited to preparing bivalent multibinding compounds of Formula(I) and can be used to prepare tri-, tetra-, etc., multibindingcompounds of Formula (I).

The linker is attached to the ligand at a position that retains liganddomain-ligand binding site interaction and specifically which permitsthe ligand domain of the ligand to orient itself to bind to the ligandbinding site. Such positions and synthetic protocols for linkage arewell known in the art. The term linker embraces everything that is notconsidered to be part of the ligand.

The relative orientation in which the ligand domains are displayedderives from the particular point or points of attachment of the ligandsto the linker, and on the framework geometry. The determination of whereacceptable substitutions can be made on a ligand is typically based onprior knowledge of structure-activity relationships (SAR) of the ligandand/or congeners and/or structural information about ligand-receptorcomplexes (e.g., X-ray crystallography, NMR, and the like). Suchpositions and the synthetic methods for covalent attachment are wellknown in the art. Following attachment to the selected linker (orattachment to a significant portion of the linker, for example 2-10atoms of the linker), the univalent linker-ligand conjugate may betested for retention of activity in the relevant assay.

The linker, when covalently attached to multiple copies of the ligands,provides a biocompatible, substantially non-immunogenic multibindingcompound. The biological activity of the multibinding compound is highlysensitive to the valency, geometry, composition, size, flexibility orrigidity, etc. of the linker and, in turn, on the overall structure ofthe multibinding compound, as well as the presence or absence of anionicor cationic charge, the relative hydrophobicity/hydrophilicity of thelinker, and the like on the linker. Accordingly, the linker ispreferably chosen to maximize the biological activity of themultibinding compound. The linker may be chosen to enhance thebiological activity of the molecule. In general, the linker may bechosen from any organic molecule construct that orients two or moreligands to their ligand binding sites to permit multivalency. In thisregard, the linker can be considered as a “framework” on which theligands are arranged in order to bring about the desiredligand-orienting result, and thus produce a multibinding compound.

For example, different orientations can be achieved by including in theframework groups containing mono- or polycyclic groups, including aryland/or heteroaryl groups, or structures incorporating one or morecarbon-carbon multiple bonds (alkenyl, alkenylene, alkynyl or alkynylenegroups). Other groups can also include oligomers and polymers which arebranched- or straight-chain species. In preferred embodiments, rigidityis imparted by the presence of cyclic groups (e.g., aryl, heteroaryl,cycloalkyl, heterocyclic, etc.). In other preferred embodiments, thering is a six or ten member ring. In still further preferredembodiments, the ring is an aromatic ring such as, for example, phenylor naphthyl.

Different hydrophobic/hydrophilic characteristics of the linker as wellas the presence or absence of charged moieties can readily be controlledby the skilled artisan. For example, the hydrophobic nature of a linkerderived from hexamethylene diamine (H₂N(CH₂)₆NH₂) or related polyaminescan be modified to be substantially more hydrophilic by replacing thealkylene group with a poly(oxyalkylene) group such as found in thecommercially available “Jeffamines”.

Different frameworks can be designed to provide preferred orientationsof the ligands. Such frameworks may be represented by using an array ofdots (as shown below) wherein each dot may potentially be an atom, suchas C, O, N, S, P, H, F, Cl, Br, and F or the dot may alternativelyindicate the absence of an atom at that position. To facilitate theunderstanding of the framework structure, the framework is illustratedas a two dimensional array in the following diagram, although clearlythe framework is a three dimensional array in practice:

Each dot is either an atom, chosen from carbon, hydrogen, oxygen,nitrogen, sulfur, phosphorus, or halogen, or the dot represents a pointin space (i.e., an absence of an atom). As is apparent to the skilledartisan, only certain atoms on the grid have the ability to act as anattachment point for the ligands, namely, C, O, N, S and P.

Atoms can be connected to each other via bonds (single, double or triplebonds with acceptable resonance and tautomeric forms), with regard tothe usual constraints of chemical bonding. Ligands may be attached tothe framework via single, double or triple bonds (with chemicallyacceptable tautomeric and resonance forms). Multiple ligand groups (2 to10) can be attached to the framework such that the minimal, shortestpath distance between adjacent ligand groups does not exceed 100 atoms.Preferably, the linker connections to the ligand is selected such thatthe maximum spatial distance between two adjacent ligands is no morethan 100 Å.

An example of a linker as presented by the grid is shown below for abiphenyl construct.

Nodes (1,2), (2,0), (4,4), (5,2), (4,0), (6,2), (7,4), (9,4), (10,2),(9,0), (7,0) all represent carbon atoms. Node (10,0) represents achlorine atom. All other nodes (or dots) are points in space (i.e.,represent an absence of atoms).

Nodes (1,2) and (9,4) are attachment points. Hydrogen atoms are affixedto nodes (2,4), (4,4), (4,0), (2,0), (7,4), (10,2) and (7,0). Nodes(5,2) and (6,2) are connected by a single bond.

The carbon atoms present are connected by either a single or doublebonds, taking into consideration the principle of resonance and/ortautomerism.

The intersection of the framework (linker) and the ligand group, andindeed, the framework (linker) itself can have many different bondingpatterns. Examples of acceptable patterns of three contiguous atomarrangements are shown in the following diagram:

C C C N C C O C C S C C P C C C C N N C N O C N S C N P C N C C O N C OO C O S C O P C O C C S N C S O C S S C S P C S C C P N C P O C P S C PP C P C N C N N C O N C S N C P N C C N N N N N O N N S N N P N N C N ON N O O N O S N O P N O C N S N N S O N S S N S P N S C N P N N P O N PS N P P N P C O C N O C O O C S O C P O C C O O N O N O O N S O N P O NC O C N O O O O O S O O P O O C O P N O P O O S S O S P O S C S C N S CO O P S O P P O P C S N N S N O S C S S C P S C C S O N S O O S N S S NP S N C S S N S S O S O S S O P S O C S P N S P O S S S S S P S S C P CN P C O S P S S P P S P C P N N P N O P C S P C P P C C P O N P O O P NS P N P P N C P S N P S O P O S P O P P O C P P N P P O P S S P S P P SO P P S P P P P P

One skilled in the art would be able to identify bonding patterns thatwould produce multivalent compounds. Methods for producing these bondingarrangements are described in March, “Advanced Organic Chemistry”, 4thEdition, Wiley-Interscience, New York, N.Y. (1992). These arrangementsare described in the grid of dots shown in the scheme above. All of thepossible arrangements for the five most preferred atoms are shown. Eachatom has a variety of acceptable oxidation states. The bondingarrangements underlined are less acceptable and are not preferred.

Examples of molecular structures in which the above bonding patternscould be employed as components of the linker are shown below.

The identification of an appropriate framework geometry and size forligand domain presentation are important steps in the construction of amultibinding compound with enhanced activity. Systematic spatialsearching strategies can be used to aid in the identification ofpreferred frameworks through an iterative process. FIG. 4 illustrates auseful strategy for determining an optimal framework display orientationfor ligand domains. Various other strategies are known to those skilledin the art of molecular design and can be used for preparing compoundsof this invention.

As shown in FIG. 3, display vectors around similar central corestructures such as a phenyl structure (Panel A) and a cyclohexanestructure (Panel B) can be varied, as can the spacing of the liganddomain from the core structure (i.e., the length of the attachingmoiety). It is to be noted that core structures other than those shownhere can be used for determining the optimal framework displayorientation of the ligands. The process may require the use of multiplecopies of the same central core structure or combinations of differenttypes of display cores.

The above-described process can be extended to trimers (FIG. 3) andcompound of higher valency. (FIG. 4)

Assays of each of the individual compounds of a collection generated asdescribed above will lead to a subset of compounds with the desiredenhanced activities (e.g., potency, selectivity, etc.). The analysis ofthis subset using a technique such as Ensemble Molecular Dynamics willprovide a framework orientation that favors the properties desired. Awide diversity of linkers is commercially available (see, e.g.,Available Chemical Directory (ACD)). Many of the linkers that aresuitable for use in this invention fall into this category. Other can bereadily synthesized by methods well known in the art and/or aredescribed below.

Having selected a preferred framework geometry, the physical propertiesof the linker can be optimized by varying the chemical compositionthereof. The composition of the linker can be varied in numerous ways toachieve the desired physical properties for the multibinding compound.

It can therefore be seen that there is a plethora of possibilities forthe composition of a linker. Examples of linkers include aliphaticmoieties, aromatic moieties, steroidal moieties, peptides, and the like.Specific examples are peptides or polyamides, hydrocarbons, aromaticgroups, ethers, lipids, cationic or anionic groups, or a combinationthereof.

Examples are given below, but it should be understood that variouschanges may be made and equivalents may be substituted without departingfrom the true spirit and scope of the invention. For example, propertiesof the linker can be modified by the addition or insertion of ancillarygroups into or onto the linker, for example, to change the solubility ofthe multibinding compound (in water, fats, lipids, biological fluids,etc.), hydrophobicity, hydrophilicity, linker flexibility, antigenicity,stability, and the like. For example, the introduction of one or morepoly(ethylene glycol) (PEG) groups onto or into the linker enhances thehydrophilicity and water solubility of the multibinding compound,increases both molecular weight and molecular size and, depending on thenature of the unPEGylated linker, may increase the in vivo retentiontime. Further PEG may decrease antigenicity and potentially enhances theoverall rigidity of the linker.

Ancillary groups which enhance the water solubility/hydrophilicity ofthe linker and, accordingly, the resulting multibinding compounds areuseful in practicing this invention. Thus, it is within the scope of thepresent invention to use ancillary groups such as, for example, smallrepeating units of ethylene glycols, alcohols, polyols (e.g., glycerin,glycerol propoxylate, saccharides, including mono-, oligosaccharides,etc.), carboxylates (e.g., small repeating units of glutamic acid,acrylic acid, etc.), amines (e.g., tetraethylenepentamine), and thelike) to enhance the water solubility and/or hydrophilicity of themultibinding compounds of this invention. In preferred embodiments, theancillary group used to improve water solubility/hydrophilicity will bea polyether.

The incorporation of lipophilic ancillary groups within the structure ofthe linker to enhance the lipophilicity and/or hydrophobicity of themultibinding compounds described herein is also within the scope of thisinvention. Lipophilic groups useful with the linkers of this inventioninclude, by way of example only, aryl and heteroaryl groups which, asabove, may be either unsubstituted or substituted with other groups, butare at least substituted with a group which allows their covalentattachment to the linker. Other lipophilic groups useful with thelinkers of this invention include fatty acid derivatives which do notform bilayers in aqueous medium until higher concentrations are reached.

Also within the scope of this invention is the use of ancillary groupswhich result in the multibinding compound being incorporated or anchoredinto a vesicle or other membranous structure such as a liposome or amicelle. The term “lipid” refers to any fatty acid derivative that iscapable of forming a bilayer or a micelle such that a hydrophobicportion of the lipid material orients toward the bilayer while ahydrophilic portion orients toward the aqueous phase. Hydrophiliccharacteristics derive from the presence of phosphato, carboxylic,sulfato, amino, sulfhydryl, nitro and other like groups well known inthe art. Hydrophobicity could be conferred by the inclusion of groupsthat include, but are not limited to, long chain saturated andunsaturated aliphatic hydrocarbon groups of up to 20 carbon atoms andsuch groups substituted by one or more aryl, heteroaryl, cycloalkyl,and/or heterocyclic group(s). Preferred lipids are phosphglycerides andsphingolipids, representative examples of which includephosphatidylcholine, phosphatidylethanolamine, phosphatidylserine,phosphatidylinositol, phosphatidic acid, palmitoyleoylphosphatidylcholine, lysophosphatidylcholine,lysophosphatidyl-ethanolamine, dipalmitoylphosphatidylcholine,dioleoylphosphatidylcholine, distearoyl-phosphatidylcholine ordilinoleoylphosphatidylcholine could be used. Other compounds lackingphosphorus, such as sphingolipid and glycosphingolipid families are alsowithin the group designated as lipid. Additionally, the amphipathiclipids described above may be mixed with other lipids includingtriglycerides and sterols.

The flexibility of the linker can be manipulated by the inclusion ofancillary groups which are bulky and/or rigid. The presence of bulky orrigid groups can hinder free rotation about bonds in the linker or bondsbetween the linker and the ancillary group(s) or bonds between thelinker and the functional groups. Rigid groups can include, for example,those groups whose conformational lability is restrained by the presenceof rings and/or multiple bonds within the group, for example, aryl,heteroaryl, cycloalkyl, cycloalkenyl, and heterocyclic groups. Othergroups which can impart rigidity include polypeptide groups such asoligo- or polyproline chains.

Rigidity can also be imparted electrostatically. Thus, if the ancillarygroups are either positively or negatively charged, the similarlycharged ancillary groups will force the presenter linker into aconfiguration affording the maximum distance between each of the likecharges. The energetic cost of bringing the like-charged groups closerto each other will tend to hold the linker in a configuration thatmaintains the separation between the like-charged ancillary groups.Further ancillary groups bearing opposite charges will tend to beattracted to their oppositely charged counterparts and potentially mayenter into both inter- and intramolecular ionic bonds. This non-covalentmechanism will tend to hold the linker into a conformation which allowsbonding between the oppositely charged groups. The addition of ancillarygroups which are charged, or alternatively, bear a latent charge whendeprotected, following addition to the linker, include deprotectation ofa carboxyl, hydroxyl, thiol or amino group by a change in pH, oxidation,reduction or other mechanisms known to those skilled in the art whichresult in removal of the protecting group, is within the scope of thisinvention.

Rigidity may also be imparted by internal hydrogen bonding or byhydrophobic collapse.

Bulky groups can include, for example, large atoms, ions (e.g., iodine,sulfur, metal ions, etc.) or groups containing large atoms, polycyclicgroups, including aromatic groups, non-aromatic groups and structuresincorporating one or more carbon-carbon multiple bonds (i.e., alkenesand alkynes). Bulky groups can also include oligomers and polymers whichare branched- or straight-chain species. Species that are branched areexpected to increase the rigidity of the structure more per unitmolecular weight gain than are straight-chain species.

In preferred embodiments, rigidity is imparted by the presence of cyclicgroups (e.g., aryl, heteroaryl, cycloalkyl, heterocyclic, etc.). Inother preferred embodiments, the linker comprises one or moresix-membered rings. In still further preferred embodiments, the ring isan aryl group such as, for example, phenyl or naphthyl.

In view of the above, it is apparent that the appropriate selection of alinker group providing suitable orientation, restricted/unrestrictedrotation, the desired degree of hydrophobicity/hydrophilicity, etc. iswell within the skill of the art. Eliminating or reducing antigenicityof the multibinding compounds described herein is also within the scopeof this invention. In certain cases, the antigenicity of a multibindingcompound may be eliminated or reduced by use of groups such as, forexample, poly(ethylene glycol).

As explained above, the multibinding compounds described herein comprise2-10 ligands attached to a linker that attaches the ligands in such amanner that they are presented to the enzyme for multivalentinteractions with ligand binding sites thereon/therein. The linkerspatially constrains these interactions to occur within dimensionsdefined by the linker. This and other factors increases the biologicalactivity of the multibinding compound as compared to the same number ofligands made available in monobinding form.

The compounds of this invention are preferably represented by theempirical Formula (L)_(p)(X)_(q) where L, X, p and q are as definedabove. This is intended to include the several ways in which the ligandscan be linked together in order to achieve the objective ofmultivalency, and a more detailed explanation is described below.

As noted previously, the linker may be considered as a framework towhich ligands are attached. Thus, it should be recognized that theligands can be attached at any suitable position on this framework, forexample, at the termini of a linear chain or at any intermediateposition.

The simplest and most preferred multibinding compound is a bivalentcompound which can be represented as L-X-L, where each L isindependently a ligand which may be the same or different and each X isindependently the linker. Examples of such bivalent compounds areprovided in FIG. 1 where each shaded circle represents a ligand. Atrivalent compound could also be represented in a linear fashion, i.e.,as a sequence of repeated units L-X-L-X-L, in which L is a ligand and isthe same or different at each occurrence, as can X. However, a trimercan also be a radial multibinding compound comprising three ligandsattached to a central core, and thus represented as (L)₃X, where thelinker X could include, for example, an aryl or cycloalkyl group.Illustrations of trivalent and tetravalent compounds of this inventionare found in FIGS. 2 and 3 respectively where, again, the shaded circlesrepresent ligands. Tetravalent compounds can be represented in a lineararray, e.g.,

L-X-L-X-L-X-L

in a branched array, e.g.,

(a branched construct analogous to the isomers of butane—n-butyl,iso-butyl, sec-butyl, and t-butyl) or in a tetrahedral array, e.g.,

where X and L are as defined herein. Alternatively, it could berepresented as an alkyl, aryl or cycloalkyl derivative as above withfour (4) ligands attached to the core linker.

The same considerations apply to higher multibinding compounds of thisinvention containing 5-10 ligands as illustrated in FIG. 4 where, asbefore, the shaded circles represent ligands. However, for multibindingagents attached to a central linker such as aryl or cycloalkyl, there isa self-evident constraint that there must be sufficient attachment siteson the linker to accommodate the number of ligands present; for example,a benzene ring could not directly accommodate more than 6 ligands,whereas a multi-ring linker (e.g., biphenyl) could accommodate a largernumber of ligands.

The above described compounds may alternatively be represented as cyclicchains of the form:

and variants thereof.

All of the above variations are intended to be within the scope of theinvention defined by the Formula (L)_(p)(X)_(q)

With the foregoing in mind, a preferred linker may be represented by thefollowing formula:

—X^(a)-Z-(Y^(a)-Z)_(m)-Y^(b)-Z-X^(a)—

in which:

m is an integer of from 0 to 20;

X^(a) at each separate occurrence is selected from the group consistingof —O—, —S—, —NR—, —C(O)—, —C(O)O—, —C(O)NR—, —C(S), —C(S)O—, —C(S)NR—or a covalent bond where R is as defined below;

Z is at each separate occurrence is selected from the group consistingof alkylene, substituted alkylene, cycloalkylene, substitutedcylcoalkylene, alkenylene, substituted alkenylene, alkynylene,substituted alkynylene, cycloalkenylene, substituted cycloalkenylene,arylene, heteroarylene, heterocyclene, or a covalent bond;

Y^(a) and Y^(b) at each separate occurrence are selected from the groupconsisting of —O—, —C(O)—, —OC(O)—, —C(O)O—, —NR—, —S(O)n—, —C(O)NR′—,—NR′C(O)—, —NR′C(O)NR′—, —NR′C(S)NR′—, —C(═NR′)—NR′—, —NR′—C(═NR′)—,—OC(O)—NR′—, —NR′—C(O)—O—, —N═C(X^(a))—NR′—, —NR′—C(X^(a))═N—,—P(O)(OR′)—O—, —O—P(O)(OR′)—, —S(O)_(n)CR′R″—, —S(O)_(n)—NR′—,—NR′—S(O)_(n)—, —S—S—, and a covalent bond; where n is 0, 1 or 2; and R,R′ and R″ at each separate occurrence are selected from the groupconsisting of hydrogen, alkyl, substituted alkyl, cycloalkyl,substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl,substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryland heterocyclic.

Additionally, the linker moiety can be optionally substituted at anyatom therein by one or more alkyl, substituted alkyl, cycloalkyl,substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl,substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryland heterocyclic group.

In view of the above description of the linker, it is understood thatthe term “linker” when used in combination with the term “multibindingcompound” includes both a covalently contiguous single linker (e.g.,L-X-L) and multiple covalently non-contiguous linkers (L-X-L-X-L) withinthe multibinding compound.

Combinatorial Libraries

The methods described above lend themselves to combinatorial approachesfor identifying multimeric compounds which possess multibindingproperties.

Specifically, factors such as the proper juxtaposition of the individualligands of a multibinding compound with respect to the relevant array ofbinding sites on a target or targets is important in optimizing theinteraction of the multibinding compound with its target(s) and tomaximize the biological advantage through multivalency. One approach isto identify a library of candidate multibinding compounds withproperties spanning the multibinding parameters that are relevant for aparticular target. These parameters include: (1) the identity ofligand(s), (2) the orientation of ligands, (3) the valency of theconstruct, (4) linker length, (5) linker geometry, (6) linker physicalproperties, and (7) linker chemical functional groups.

Libraries of multimeric compounds potentially possessing multibindingproperties (i.e., candidate multibinding compounds) and comprising amultiplicity of such variables are prepared and these libraries are thenevaluated via conventional assays corresponding to the ligand selectedand the multibinding parameters desired. Considerations relevant to eachof these variables are set forth below:

Selection of Ligand(s):

A single ligand or set of ligands is (are) selected for incorporationinto the libraries of candidate multibinding compounds which library isdirected against a particular biological target or targets, i.e.,antagonism of a muscarinic receptor. The only requirement for theligands chosen is that they are capable of interacting with the selectedtarget(s). Thus, ligands may be known drugs, modified forms of knowndrugs, substructures of known drugs or substrates of modified forms ofknown drugs (which are competent to interact with the target), or othercompounds. Ligands are preferably chosen based on known favorableproperties that may be projected to be carried over to or amplified inmultibinding forms. Favorable properties include demonstrated safety andefficacy in human patients, appropriate PK/ADME profiles, syntheticaccessibility, and desirable physical properties such as solubility, logP, etc. However, it is crucial to note that ligands which display anunfavorable property from among the previous list may obtain a morefavorable property through the process of multibinding compoundformation; i.e., ligands should not necessarily be excluded on such abasis. For example, a ligand that is not sufficiently potent at aparticular target so as to be efficacious in a human patient may becomehighly potent and efficacious when presented in multibinding form. Aligand that is potent and efficacious but not of utility because of anon-mechanism-related toxic side effect may have increased therapeuticindex (increased potency relative to toxicity) as a multibindingcompound. Compounds that exhibit short in vivo half-lives may haveextended half-lives as multibinding compounds. Physical properties ofligands that limit their usefulness (e.g. poor bioavailability due tolow solubility, hydrophobicity, hydrophilicity) may be rationallymodulated in multibinding forms, providing compounds with physicalproperties consistent with the desired utility.

Orientation Selection of Ligand Attachment Points and Linking Chemistry

Several points are chosen on each ligand at which to attach the ligandto the linker. The selected points on the ligand/linker for attachmentare functionalized to contain complementary reactive functional groups.This permits probing the effects of presenting the ligands to theirreceptor(s) in multiple relative orientations, an important multibindingdesign parameter. The only requirement for choosing attachment points isthat attaching to at least one of these points does not abrogateactivity of the ligand. Such points for attachment can be identified bystructural information when available. For example, inspection of aco-crystal structure of a protease inhibitor bound to its target allowsone to identify one or more sites where linker attachment will notpreclude the enzyme:inhibitor interaction. Alternatively, evaluation ofligand/target binding by nuclear magnetic resonance will permit theidentification of sites non-essential for ligand/target binding. See,for example, Fesik, et al., U.S. Pat. No. 5,891,643. When suchstructural information is not available, utilization ofstructure-activity relationships (SAR) for ligands will suggestpositions where substantial structural variations are and are notallowed. In the absence of both structural and SAR information, alibrary is merely selected with multiple points of attachment to allowpresentation of the ligand in multiple distinct orientations. Subsequentevaluation of this library will indicate what positions are suitable forattachment.

It is important to emphasize that positions of attachment that doabrogate the activity of the monomeric ligand may also be advantageouslyincluded in candidate multibinding compounds in the library providedthat such compounds bear at least one ligand attached in a manner whichdoes not abrogate intrinsic activity. This selection derives from, forexample, heterobivalent interactions within the context of a singletarget molecule. For example, consider a receptor antagonist ligandbound to its target receptor, and then consider modifying this ligand byattaching to it a second copy of the same ligand with a linker whichallows the second ligand to interact with the same receptor molecule atsites proximal to the antagonist binding site, which include elements ofthe receptor that are not part of the formal antagonist binding siteand/or elements of the matrix surrounding the receptor such as themembrane. Here, the most favorable orientation for interaction of thesecond ligand molecule with the receptor/matrix may be achieved byattaching it to the linker at a position which abrogates activity of theligand at the formal antagonist binding site. Another way to considerthis is that the SAR of individual ligands within the context of amultibinding structure is often different from the SAR of those sameligands in momomeric form.

The foregoing discussion focused on bivalent interactions of dimericcompounds bearing two copies of the same ligand joined to a singlelinker through different attachment points, one of which may abrogatethe binding/activity of the monomeric ligand. It should also beunderstood that bivalent advantage may also be attained withheterodimeric constructs bearing two different ligands that bind tocommon or different targets. For example, a 5HT₄ receptor antagonist anda bladder-selective muscarinic M₃ antagonist may be joined to a linkerthrough attachment points which do not abrogate the binding affinity ofthe monomeric ligands for their respective receptor sites. The dimericcompound may achieve enhanced affinity for both receptors due tofavorable interactions between the 5HT₄ ligand and elements of the M₃receptor proximal to the formal M₃ antagonist binding site and betweenthe M₃ ligand and elements of the 5HT₄ receptor proximal to the formal5HT₄ antagonist binding site. Thus, the dimeric compound may be morepotent and selective antagonist of overactive bladder and a superiortherapy for urinary urge incontinence.

Once the ligand attachment points have been chosen, one identifies thetypes of chemical linkages that are possible at those points. The mostpreferred types of chemical linkages are those that are compatible withthe overall structure of the ligand (or protected forms of the ligand)readily and generally formed, stable and intrinsically inocuous undertypical chemical and physiological conditions, and compatible with alarge number of available linkers. Amide bonds, ethers, amines,carbamates, ureas, and sulfonamides are but a few examples of preferredlinkages.

Linkers Spanning Relevant Multibinding Parameters Through Selection ofValency, Linker Length, Linker Geometry Rigidity, Physical Properties,and Chemical Functional Groups

In the library of linkers employed to generate the library of candidatemultibinding compounds, the selection of linkers employed in thislibrary of linkers takes into consideration the following factors:

Valency:

In most instances the library of linkers is initiated with divalentlinkers. The choice of ligands and proper juxtaposition of two ligandsrelative to their binding sites permits such molecules to exhibit targetbinding affinities and specificities more than sufficient to conferbiological advantage. Furthermore, divalent linkers or constructs arealso typically of modest size such that they retain the desirablebiodistribution properties of small molecules.

Linker Length:

Linkers are chosen in a range of lengths to allow the spanning of arange of inter-ligand distances that encompass the distance preferablefor a given divalent interaction. In some instances the preferreddistance can be estimated rather precisely from high-resolutionstructural information of targets, typically enzymes and solublereceptor targets. In other instances where high-resolution structuralinformation is not available (such as 7™ G-protein coupled receptors),one can make use of simple models to estimate the maximum distancebetween binding sites either on adjacent receptors or at differentlocations on the same receptor. In situations where two binding sitesare present on the same target (or target subunit for multisubunittargets), preferred linker distances are 2-20 Å, with more preferredlinker distances of 3-12 Å. In situations where two binding sites resideon separate (e.g., protein) target sites, preferred linker distances are20-100 Å, with more preferred distances of 30-70 Å.

Linker Geometry and Rigidity:

The combination of ligand attachment site, linker length, linkergeometry, and linker rigidity determine the possible ways in which theligands of candidate multibinding compounds may be displayed in threedimensions and thereby presented to their binding sites. Linker geometryand rigidity are nominally determined by chemical composition andbonding pattern, which may be controlled and are systematically variedas another spanning function in a multibinding array. For example,linker geometry is varied by attaching two ligands to the ortho, meta,and para positions of a benzene ring, or in cis- or trans-arrangementsat the 1,1- vs. 1,2- vs. 1,3- vs. 1,4- positions around a cyclohexanecore or in cis- or trans-arrangements at a point of ethyleneunsaturation. Linker rigidity is varied by controlling the number andrelative energies of different conformational states possible for thelinker. For example, a divalent compound bearing two ligands joined by1,8-octyl linker has many more degrees of freedom, and is therefore lessrigid than a compound in which the two ligands are attached to the 4,4′positions of a biphenyl linker.

Linker Physical Properties

The physical properties of linkers are nominally determined by thechemical constitution and bonding patterns of the linker, and linkerphysical properties impact the overall physical properties of thecandidate multibinding compounds in which they are included. A range oflinker compositions is typically selected to provide a range of physicalproperties (hydrophobicity, hydrophilicity, amphiphilicity,polarization, acidity, and basicity) in the candidate multibindingcompounds. The particular choice of linker physical properties is madewithin the context of the physical properties of the ligands they joinand preferably the goal is to generate molecules with favorable PK/ADMEproperties. For example, linkers can be selected to avoid those that aretoo hydrophilic or too hydrophobic to be readily absorbed and/ordistributed in vivo.

Linker Chemical Functional Groups:

Linker chemical functional groups are selected to be compatible with thechemistry chosen to connect linkers to the ligands and to impart therange of physical properties sufficient to span initial examination ofthis parameter.

Combinatorial Synthesis

Having chosen a set of n ligands (n being determined by the sum of thenumber of different attachment points for each ligand chosen) and mlinkers by the process outlined above, a library of (n!)m candidatedivalent multibinding compounds is prepared which spans the relevantmultibinding design parameters for a particular target. For example, anarray generated from two ligands, one which has two attachment points(A1, A2) and one which has three attachment points (B1, B2, B3) joinedin all possible combinations provide for at least 15 possiblecombinations of multibinding compounds:

A1-A1 A1-A2 A1-B1 A1-B2 A1-B3 A2-A2 A2-B1 A2-B2 A2-B3 B1-B1 B1-B2 B1-B3B2-B2 B2-B3 B3-B3

When each of these combinations is joined by 10 different linkers, alibrary of 150 candidate multibinding compounds results.

Given the combinatorial nature of the library, common chemistries arepreferably used to join the reactive functionalies on the ligands withcomplementary reactive functionalities on the linkers. The librarytherefore lends itself to efficient parallel synthetic methods. Thecombinatorial library can employ solid phase chemistries well known inthe art wherein the ligand and/or linker is attached to a solid support.Alternatively and preferably, the combinatorial library is prepared inthe solution phase. After synthesis, candidate multibinding compoundsare optionally purified before assaying for activity by, for example,chromatographic methods (e.g., HPLC).

Analysis of Array by Biochemical, Analytical, Pharmacological, andComputational Methods:

Various methods are used to characterize the properties and activitiesof the candidate multibinding compounds in the library to determinewhich compounds possess multibinding properties. Physical constants suchas solubility under various solvent conditions and logD/clogD values canbe determined. A combination of NMR spectroscopy and computationalmethods is used to determine low-energy conformations of the candidatemultibinding compounds in fluid media. The ability of the members of thelibrary to bind to the desired target and other targets is determined byvarious standard methods, which include radioligand displacement assaysfor receptor and ion channel targets, and kinetic inhibition analysisfor many enzyme targets. In vitro efficacy, such as for receptoragonists and antagonists, ion channel blockers, and antimicrobialactivity, can also be determined. Pharmacological data, including oralabsorption, everted gut penetration, other pharmacokinetic parametersand efficacy data can be determined in appropriate models. In this way,key structure-activity relationships are obtained for multibindingdesign parameters which are then used to direct future work.

The members of the library which exhibit multibinding properties, asdefined herein, can be readily determined by conventional methods. Firstthose members which exhibit multibinding properties are identified byconventional methods as described above including conventional assays(both in vitro and in vivo).

Second, ascertaining the structure of those compounds which exhibitmultibinding properties can be accomplished via art recognizedprocedures. For example, each member of the library can be encrypted ortagged with appropriate information allowing determination of thestructure of relevant members at a later time. See, for example, Dower,et al., International Patent Application Publication No. WO 93/06121;Brenner, et al., Proc. Natl. Acad. Sci., USA, 89:5181 (1992); Gallop, etal., U.S. Pat. No. 5,846,839; each of which are incorporated herein byreference in its entirety. Alternatively, the structure of relevantmultivalent compounds can also be determined from soluble and untaggedlibraries of candidate multivalent compounds by methods known in the artsuch as those described by Hindsgaul, et al., Canadian PatentApplication No. 2,240,325 which was published on Jul. 11, 1998. Suchmethods couple frontal affinity chromatography with mass spectroscopy todetermine both the structure and relative binding affinities ofcandidate multibinding compounds to receptors.

The process set forth above for dimeric candidate multibinding compoundscan, of course, be extended to trimeric candidate compounds and higheranalogs thereof.

Follow-Up Synthesis and Analysis of Additional Array(s):

Based on the information obtained through analysis of the initiallibrary, an optional component of the process is to ascertain one ormore promising multibinding “lead” compounds as defined by particularrelative ligand orientations, linker lengths, linker geometries, etc.Additional libraries can then be generated around these leads to providefor further information regarding structure to activity relationships.These arrays typically bear more focused variations in linker structurein an effort to further optimize target affinity and/or activity at thetarget (antagonism, partial agonism, etc.), and/or alter physicalproperties. By iterative redesign/analysis using the novel principles ofmultibinding design along with classical medicinal chemistry,biochemistry, and pharmacology approaches, one is able to prepare andidentify optimal multibinding compounds that exhibit biologicaladvantage towards their targets and as therapeutic agents.

To further elaborate upon this procedure, suitable divalent linkersinclude, by way of example only, those derived from dicarboxylic acids,disulfonylhalides, dialdehydes, diketones, dihalides, diisocyanates,diamines, diols, mixtures of carboxylic acids, sulfonylhalides,aldehydes, ketones, halides, isocyanates, amines and diols. In eachcase, the carboxylic acid, sulfonylhalide, aldehyde, ketone, halide,isocyanate, amine and diol functional group is reacted with acomplementary functionality on the ligand to form a covalent linkage.Such complementary functionality is well known in the art as illustratedin the following table:

Complementary Binding Chemistries

First Reactive Group Second Reactive Group Linkage hydroxyl isocyanateurethane amine epoxide β-amine hydroxyamine sulfonyl halide sulfonamidecarboxyl acid amine amide hydroxyl alkyl/aryl halide ether aldehydeamine/NaCNBH₃ amine ketone amine/NaCNBH₃ amine amine isocyanate urea

The following table illustrates, by way of examples, starting materials(identified as X-1 through X-418) that can be used to prepare linkersincorporated in the multibinding compounds of this invention utilizingthe chemistry described above. For example, 1,10-decanedicarboxylicacid, X1, can be reacted with 2 equivalents of a ligand carrying anamino group in the presence of a coupling reagent such as DCC to providea bivalent multibinding compound of formula (I) wherein the ligands arelinked via 1,10-decanediamido linking group.

Representative ligands for use in this invention include, by way ofexample, L-1 through L-9 wherein L-1 is selected from a compound offormula (a) L-2 is selected from a compound of formula (b), L-3 isselected from a compound of formula (c), L-4 is selected from a compoundof formula (d), L-5 is selected from a compound of formula (e), L-6 isselected from a compound of formula (f), L-7 is selected from a compoundof formula (g), and L-8 is selected from a compound of formula (h), andL-9 is selected from a compound of formula (I) provided that at leastone of the ligands is selected from ligands L-1 through L-5.

Combinations of ligands (L) and linkers (X) per this invention include,by way example only, homo- and hetero-dimers wherein a first ligand isselected from L-1 through L-5 and the second ligand is selected from L-1through L-9 and linker is selected from the following:

L-1/X-1- L-1/X-2- L-1/X-3- L-1/X-4- L-1/X-5- L-1/X-6- L-1/X-7- L-1/X-8-L-1/X-9- L-1/X-10- L-1/X-11- L-1/X-12- L-1/X-13- L-1/X-14- L-1/X-15-L-1/X-16- L-1/X-17- L-1/X-18- L-1/X-19- L-1/X-20- L-1/X-21- L-1/X-22-L-1/X-23- L-1/X-24- L-1/X-25- L-1/X-26- L-1/X-27- L-1/X-28- L-1/X-29-L-1/X-30- L-1/X-31- L-1/X-32- L-1/X-33- L-1/X-34- L-1/X-35- L-1/X-36-L-1/X-37- L-1/X-38- L-1/X-39- L-1/X-40- L-1/X-41- L-1/X-42- L-1/X-43-L-1/X-44- L-1/X-45- L-1/X-46- L-1/X-47- L-1/X-48- L-1/X-49- L-1/X-50-L-1/X-51- L-1/X-52- L-1/X-53- L-1/X-54- L-1/X-55- L-1/X-56- L-1/X-57-L-1/X-58- L-1/X-59- L-1/X-60- L-1/X-61- L-1/X-62- L-1/X-63- L-1/X-64-L-1/X-65- L-1/X-66- L-1/X-67- L-1/X-68- L-1/X-69- L-1/X-70- L-1/X-71-L-1/X-72- L-1/X-73- L-1/X-74- L-1/X-75- L-1/X-76- L-1/X-77- L-1/X-78-L-1/X-79- L-1/X-80- L-1/X-81- L-1/X-82- L-1/X-83- L-1/X-84- L-1/X-85-L-1/X-86- L-1/X-87- L-1/X-88- L-1/X-89- L-1/X-90- L-1/X-91- L-1/X-92-L-1/X-93- L-1/X-94- L-1/X-95- L-1/X-96- L-1/X-97- L-1/X-98- L-1/X-99-L-1/X-100- L-1/X-101- L-1/X-102- L-1/X-103- L-1/X-104- L-1/X-105-L-1/X-106- L-1/X-107- L-1/X-108- L-1/X-109- L-1/X-110- L-1/X-111-L-1/X-112- L-1/X-113- L-1/X-114- L-1/X-115- L-1/X-116- L-1/X-117-L-1/X-118- L-1/X-119- L-1/X-120- L-1/X-121- L-1/X-122- L-1/X-123-L-1/X-124- L-1/X-125- L-1/X-126- L-1/X-127- L-1/X-128- L-1/X-129-L-1/X-130- L-1/X-131- L-1/X-132- L-1/X-133- L-1/X-134- L-1/X-135-L-1/X-136- L-1/X-137- L-1/X-138- L-1/X-139- L-1/X-140- L-1/X-141-L-1/X-142- L-1/X-143- L-1/X-144- L-1/X-145- L-1/X-146- L-1/X-147-L-1/X-148- L-1/X-149- L-1/X-150- L-1/X-151- L-1/X-152- L-1/X-153-L-1/X-154- L-1/X-155- L-1/X-156- L-1/X-157- L-1/X-158- L-1/X-159-L-1/X-160- L-1/X-161- L-1/X-162- L-1/X-163- L-1/X-164- L-1/X-165-L-1/X-166- L-1/X-167- L-1/X-168- L-1/X-169- L-1/X-170- L-1/X-171-L-1/X-172- L-1/X-173- L-1/X-174- L-1/X-175- L-1/X-176- L-1/X-177-L-1/X-178- L-1/X-179- L-1/X-180- L-1/X-181- L-1/X-182- L-1/X-183-L-1/X-184- L-1/X-185- L-1/X-186- L-1/X-187- L-1/X-188- L-1/X-189-L-1/X-190- L-1/X-191- L-1/X-192- L-1/X-193- L-1/X-194- L-1/X-195-L-1/X-196- L-1/X-197- L-1/X-198- L-1/X-199- L-1/X-200- L-1/X-201-L-1/X-202- L-1/X-203- L-1/X-204- L-1/X-205- L-1/X-206- L-1/X-207-L-1/X-208- L-1/X-209- L-1/X-210- L-1/X-211- L-1/X-212- L-1/X-213-L-1/X-214- L-1/X-215- L-1/X-216- L-1/X-217- L-1/X-218- L-1/X-219-L-1/X-220- L-1/X-221- L-1/X-222- L-1/X-223- L-1/X-224- L-1/X-225-L-1/X-226- L-1/X-227- L-1/X-228- L-1/X-229- L-1/X-230- L-1/X-231-L-1/X-232- L-1/X-233- L-1/X-234- L-1/X-235- L-1/X-236- L-1/X-237-L-1/X-238- L-1/X-239- L-1/X-240- L-1/X-241- L-1/X-242- L-1/X-243-L-1/X-244- L-1/X-245- L-1/X-246- L-1/X-247- L-1/X-248- L-1/X-249-L-1/X-250- L-1/X-251- L-1/X-252- L-1/X-253- L-1/X-254- L-1/X-255-L-1/X-256- L-1/X-257- L-1/X-258- L-1/X-259- L-1/X-260- L-1/X-261-L-1/X-262- L-1/X-263- L-1/X-264- L-1/X-265- L-1/X-266- L-1/X-267-L-1/X-268- L-1/X-269- L-1/X-270- L-1/X-271- L-1/X-272- L-1/X-273-L-1/X-274- L-1/X-275- L-1/X-276- L-1/X-277- L-1/X-278- L-1/X-279-L-1/X-280- L-1/X-281- L-1/X-282- L-1/X-283- L-1/X-284- L-1/X-285-L-1/X-286- L-1/X-287- L-1/X-288- L-1/X-289- L-1/X-290- L-1/X-291-L-1/X-292- L-1/X-293- L-1/X-294- L-1/X-295- L-1/X-296- L-1/X-297-L-1/X-298- L-1/X-299- L-1/X-300- L-1/X-301- L-1/X-302- L-1/X-303-L-1/X-304- L-1/X-305- L-1/X-306- L-1/X-307- L-1/X-308- L-1/X-309-L-1/X-310- L-1/X-311- L-1/X-312- L-1/X-313- L-1/X-314- L-1/X-315-L-1/X-316- L-1/X-317- L-1/X-318- L-1/X-319- L-1/X-320- L-1/X-321-L-1/X-322- L-1/X-323- L-1/X-324- L-1/X-325- L-1/X-326- L-1/X-327-L-1/X-328- L-1/X-329- L-1/X-330- L-1/X-331- L-1/X-332- L-1/X-333-L-1/X-334- L-1/X-335- L-1/X-336- L-1/X-337- L-1/X-338- L-1/X-339-L-1/X-340- L-1/X-341- L-1/X-342- L-1/X-343- L-1/X-344- L-1/X-345-L-1/X-346- L-1/X-347- L-1/X-348- L-1/X-349- L-1/X-350- L-1/X-351-L-1/X-352- L-1/X-353- L-1/X-354- L-1/X-355- L-1/X-356- L-1/X-357-L-1/X-358- L-1/X-359- L-1/X-360- L-1/X-361- L-1/X-362- L-1/X-363-L-1/X-364- L-1/X-365- L-1/X-366- L-1/X-367- L-1/X-368- L-1/X-369-L-1/X-370- L-1/X-371- L-1/X-372- L-1/X-373- L-1/X-374- L-1/X-375-L-1/X-376- L-1/X-377- L-1/X-378- L-1/X-379- L-1/X-380- L-1/X-381-L-1/X-382- L-1/X-383- L-1/X-384- L-1/X-385- L-1/X-386- L-1/X-387-L-1/X-388- L-1/X-389- L-1/X-390- L-1/X-391- L-1/X-392- L-1/X-393-L-1/X-394- L-1/X-395- L-1/X-396- L-1/X-397- L-1/X-398- L-1/X-399-L-1/X-400- L-1/X-401- L-1/X-402- L-1/X-403- L-1/X-404- L-1/X-405-L-1/X-406- L-1/X-407- L-1/X-408- L-1/X-409- L-1/X-410- L-1/X-411-L-1/X-412- L-1/X-413- L-1/X-414- L-1/X-415- L-1/X-416- L-1/X-417-L-1/X-418- L-2/X-1- L-2/X-2- L-2/X-3- L-2/X-4- L-2/X-5- L-2/X-6-L-2/X-7- L-2/X-8- L-2/X-9- L-2/X-10- L-2/X-11- L-2/X-12- L-2/X-13-L-2/X-14- L-2/X-15- L-2/X-16- L-2/X-17- L-2/X-18- L-2/X-19- L-2/X-20-L-2/X-21- L-2/X-22- L-2/X-23- L-2/X-24- L-2/X-25- L-2/X-26- L-2/X-27-L-2/X-28- L-2/X-29- L-2/X-30- L-2/X-31- L-2/X-32- L-2/X-33- L-2/X-34-L-2/X-35- L-2/X-36- L-2/X-37- L-2/X-38- L-2/X-39- L-2/X-40- L-2/X-41-L-2/X-42- L-2/X-43- L-2/X-44- L-2/X-45- L-2/X-46- L-2/X-47- L-2/X-48-L-2/X-49- L-2/X-50- L-2/X-51- L-2/X-52- L-2/X-53- L-2/X-54- L-2/X-55-L-2/X-56- L-2/X-57- L-2/X-58- L-2/X-59- L-2/X-60- L-2/X-61- L-2/X-62-L-2/X-63- L-2/X-64- L-2/X-65- L-2/X-66- L-2/X-67- L-2/X-68- L-2/X-69-L-2/X-70- L-2/X-71- L-2/X-72- L-2/X-73- L-2/X-74- L-2/X-75- L-2/X-76-L-2/X-77- L-2/X-78- L-2/X-79- L-2/X-80- L-2/X-81- L-2/X-82- L-2/X-83-L-2/X-84- L-2/X-85- L-2/X-86- L-2/X-87- L-2/X-88- L-2/X-89- L-2/X-90-L-2/X-91- L-2/X-92- L-2/X-93- L-2/X-94- L-2/X-95- L-2/X-96- L-2/X-97-L-2/X-98- L-2/X-99- L-2/X-100- L-2/X-101- L-2/X-102- L-2/X-103-L-2/X-104- L-2/X-105- L-2/X-106- L-2/X-107- L-2/X-108- L-2/X-109-L-2/X-110- L-2/X-111- L-2/X-112- L-2/X-113- L-2/X-114- L-2/X-115-L-2/X-116- L-2/X-117- L-2/X-118- L-2/X-119- L-2/X-120- L-2/X-121-L-2/X-122- L-2/X-123- L-2/X-124- L-2/X-125- L-2/X-126- L-2/X-127-L-2/X-128- L-2/X-129- L-2/X-130- L-2/X-131- L-2/X-132- L-2/X-133-L-2/X-134- L-2/X-135- L-2/X-136- L-2/X-137- L-2/X-138- L-2/X-139-L-2/X-140- L-2/X-141- L-2/X-142- L-2/X-143- L-2/X-144- L-2/X-145-L-2/X-146- L-2/X-147- L-2/X-148- L-2/X-149- L-2/X-150- L-2/X-151-L-2/X-152- L-2/X-153- L-2/X-154- L-2/X-155- L-2/X-156- L-2/X-157-L-2/X-158- L-2/X-159- L-2/X-160- L-2/X-161- L-2/X-162- L-2/X-163-L-2/X-164- L-2/X-165- L-2/X-166- L-2/X-167- L-2/X-168- L-2/X-169-L-2/X-170- L-2/X-171- L-2/X-172- L-2/X-173- L-2/X-174- L-2/X-175-L-2/X-176- L-2/X-177- L-2/X-178- L-2/X-179- L-2/X-180- L-2/X-181-L-2/X-182- L-2/X-183- L-2/X-184- L-2/X-185- L-2/X-186- L-2/X-187-L-2/X-188- L-2/X-189- L-2/X-190- L-2/X-191- L-2/X-192- L-2/X-193-L-2/X-194- L-2/X-195- L-2/X-196- L-2/X-197- L-2/X-198- L-2/X-199-L-2/X-200- L-2/X-201- L-2/X-202- L-2/X-203- L-2/X-204- L-2/X-205-L-2/X-206- L-2/X-207- L-2/X-208- L-2/X-209- L-2/X-210- L-2/X-211-L-2/X-212- L-2/X-213- L-2/X-214- L-2/X-215- L-2/X-216- L-2/X-217-L-2/X-218- L-2/X-219- L-2/X-220- L-2/X-221- L-2/X-222- L-2/X-223-L-2/X-224- L-2/X-225- L-2/X-226- L-2/X-227- L-2/X-228- L-2/X-229-L-2/X-230- L-2/X-231- L-2/X-232- L-2/X-233- L-2/X-234- L-2/X-235-L-2/X-236- L-2/X-237- L-2/X-238- L-2/X-239- L-2/X-240- L-2/X-241-L-2/X-242- L-2/X-243- L-2/X-244- L-2/X-245- L-2/X-246- L-2/X-247-L-2/X-248- L-2/X-249- L-2/X-250- L-2/X-251- L-2/X-252- L-2/X-253-L-2/X-254- L-2/X-255- L-2/X-256- L-2/X-257- L-2/X-258- L-2/X-259-L-2/X-260- L-2/X-261- L-2/X-262- L-2/X-263- L-2/X-264- L-2/X-265-L-2/X-266- L-2/X-267- L-2/X-268- L-2/X-269- L-2/X-270- L-2/X-271-L-2/X-272- L-2/X-273- L-2/X-274- L-2/X-275- L-2/X-276- L-2/X-277-L-2/X-278- L-2/X-279- L-2/X-280- L-2/X-281- L-2/X-282- L-2/X-283-L-2/X-284- L-2/X-285- L-2/X-286- L-2/X-287- L-2/X-288- L-2/X-289-L-2/X-290- L-2/X-291- L-2/X-292- L-2/X-293- L-2/X-294- L-2/X-295-L-2/X-296- L-2/X-297- L-2/X-298- L-2/X-299- L-2/X-300- L-2/X-301-L-2/X-302- L-2/X-303- L-2/X-304- L-2/X-305- L-2/X-306- L-2/X-307-L-2/X-308- L-2/X-309- L-2/X-310- L-2/X-311- L-2/X-312- L-2/X-313-L-2/X-314- L-2/X-315- L-2/X-316- L-2/X-317- L-2/X-318- L-2/X-319-L-2/X-320- L-2/X-321- L-2/X-322- L-2/X-323- L-2/X-324- L-2/X-325-L-2/X-326- L-2/X-327- L-2/X-328- L-2/X-329- L-2/X-330- L-2/X-331-L-2/X-332- L-2/X-333- L-2/X-334- L-2/X-335- L-2/X-336- L-2/X-337-L-2/X-338- L-2/X-339- L-2/X-340- L-2/X-341- L-2/X-342- L-2/X-343-L-2/X-344- L-2/X-345- L-2/X-346- L-2/X-347- L-2/X-348- L-2/X-349-L-2/X-350- L-2/X-351- L-2/X-352- L-2/X-353- L-2/X-354- L-2/X-355-L-2/X-356- L-2/X-357- L-2/X-358- L-2/X-359- L-2/X-360- L-2/X-361-L-2/X-362- L-2/X-363- L-2/X-364- L-2/X-365- L-2/X-366- L-2/X-367-L-2/X-368- L-2/X-369- L-2/X-370- L-2/X-371- L-2/X-372- L-2/X-373-L-2/X-374- L-2/X-375- L-2/X-376- L-2/X-377- L-2/X-378- L-2/X-379-L-2/X-380- L-2/X-381- L-2/X-382- L-2/X-383- L-2/X-384- L-2/X-385-L-2/X-386- L-2/X-387- L-2/X-388- L-2/X-389- L-2/X-390- L-2/X-391-L-2/X-392- L-2/X-393- L-2/X-394- L-2/X-395- L-2/X-396- L-2/X-397-L-2/X-398- L-2/X-399- L-2/X-400- L-2/X-401- L-2/X-402- L-2/X-403-L-2/X-404- L-2/X-405- L-2/X-406- L-2/X-407- L-2/X-408- L-2/X-409-L-2/X-410- L-2/X-411- L-2/X-412- L-2/X-413- L-2/X-414- L-2/X-415-L-2/X-416- L-2/X-417- L-2/X-418-and so on, substituting L-2 with L-3 through L-8.

Utility, Testing, and Administration Utility

The multibinding compounds of this invention are muscarinic receptorantagonists, in particular M₃ muscarinic receptor antagonists.Accordingly, the multibinding compounds and pharmaceutical compositionsof this invention are useful in the treatment and prevention of diseasesmediated by these receptors such as chronic obstructive pulmonarydisease⁵⁻⁶, asthma, irritable bowel syndrome⁷, urinary incontinence⁷⁻⁸,rhinitis, spasmodic colitis, chronic cystitis, and alzheimer's disease,senile dementia, glaucoma, schizophrenia, gastroesophogeal refluxdisease, cardiac arrhythmia, hyper salvation syndromes, and the like.

Testing

The ability of the compounds of formula (I) to inhibit a muscarinicreceptor, such as M₃ subtype may be demonstrated by a variety of invitro assays and in vivo assays described in biological examples 1-6below.

Pharmaceutical Formulations

When employed as pharmaceuticals, the compounds of this invention areusually administered in the form of pharmaceutical compositions. Thesecompounds can be administered by a variety of routes including oral,rectal, transdermal, subcutaneous, intravenous, intramuscular, andintranasal. These compounds are effective as both injectable and oralcompositions. Such compositions are prepared in a manner well known inthe pharmaceutical art and comprise at least one active compound.

This invention also includes pharmaceutical compositions which contain,as the active ingredient, one or more of the compounds described hereinassociated with pharmaceutically acceptable carriers. In making thecompositions of this invention, the active ingredient is usually mixedwith an excipient, diluted by an excipient or enclosed within such acarrier which can be in the form of a capsule, sachet, paper or othercontainer. When the excipient serves as a diluent, it can be a solid,semi-solid, or liquid material, which acts as a vehicle, carrier ormedium for the active ingredient. Thus, the compositions can be in theform of tablets, pills, powders, lozenges, sachets, cachets, elixirs,suspensions, emulsions, solutions, syrups, aerosols (as a solid or in aliquid medium), ointments containing, for example, up to 10% by weightof the active compound, soft and hard gelatin capsules, suppositories,sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, it may be necessary to mill the activecompound to provide the appropriate particle size prior to combiningwith the other ingredients. If the active compound is substantiallyinsoluble, it ordinarily is milled to a particle size of less than 200mesh. If the active compound is substantially water soluble, theparticle size is normally adjusted by milling to provide a substantiallyuniform distribution in the formulation, e.g. about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose,sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates,tragacanth, gelatin, calcium silicate, microcrystalline cellulose,polyvinylpyrrolidone, cellulose, sterile water, syrup, and methylcellulose. The formulations can additionally include: lubricating agentssuch as talc, magnesium stearate, and mineral oil; wetting agents;emulsifying and suspending agents; preserving agents such as methyl- andpropylhydroxy-benzoates; sweetening agents; and flavoring agents. Thecompositions of the invention can be formulated so as to provide quick,sustained or delayed release of the active ingredient afteradministration to the patient by employing procedures known in the art.

The compositions are preferably formulated in a unit dosage form, eachdosage containing from about 0.001 to about 1 g, more usually about 1 toabout 30 mg, of the active ingredient. The term “unit dosage forms”refers to physically discrete units suitable as unitary dosages forhuman subjects and other mammals, each unit containing a predeterminedquantity of active material calculated to produce the desiredtherapeutic effect, in association with a suitable pharmaceuticalexcipient. Preferably, the compound of Formula (I) above is employed atno more than about 20 weight percent of the pharmaceutical composition,more preferably no more than about 15 weight percent, with the balancebeing pharmaceutically inert carrier(s).

The active compound is effective over a wide dosage range and isgenerally administered in a pharmaceutically effective amount. It, willbe understood, however, that the amount of the compound actuallyadministered will be determined by a physician, in the light of therelevant circumstances, including the condition to be treated, thechosen route of administration, the actual compound administered and itsrelative activity, the age, weight, and response of the individualpatient, the severity of the patient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal activeingredient is mixed with a pharmaceutical excipient to form a solidpreformulation composition containing a homogeneous mixture of acompound of the present invention. When referring to thesepreformulation compositions as homogeneous, it is meant that the activeingredient is dispersed evenly throughout the composition so that thecomposition may be readily subdivided into equally effective unit dosageforms such as tablets, pills and capsules. This solid preformulation isthen subdivided into unit dosage forms of the type described abovecontaining from, for example, 0.1 to about 500 mg of the activeingredient of the present invention.

The tablets or pills of the present invention may be coated or otherwisecompounded to provide a dosage form affording the advantage of prolongedaction. For example, the tablet or pill can comprise an inner dosage andan outer dosage component, the latter being in the form of an envelopeover the former. The two components can be separated by an enteric layerwhich serves to resist disintegration in the stomach and permit theinner component to pass intact into the duodenum or to be delayed inrelease. A variety of materials can be used for such enteric layers orcoatings, such materials including a number of polymeric acids andmixtures of polymeric acids with such materials as shellac, cetylalcohol, and cellulose acetate.

The liquid forms in which the novel compositions of the presentinvention may be incorporated for administration orally or by injectioninclude aqueous solutions, suitably flavored syrups, aqueous or oilsuspensions, and flavored emulsions with edible oils such as corn oil,cottonseed oil, sesame oil, coconut oil, or peanut oil, as well aselixirs and similar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions andsuspensions in pharmaceutically acceptable, aqueous or organic solvents,or mixtures thereof, and powders. The liquid or solid compositions maycontain suitable pharmaceutically acceptable excipients as describedsupra. Preferably the compositions are administered by the oral or nasalrespiratory route for local or systemic effect. Compositions inpreferably pharmaceutically acceptable solvents may be nebulized by useof inert gases. Nebulized solutions may be inhaled directly from thenebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine.Solution, suspension, or powder compositions may be administered,preferably orally or nasally, from devices which deliver the formulationin an appropriate manner.

EXAMPLES

The following preparations and examples are given to enable thoseskilled in the art to more clearly understand and to practice thepresent invention. They should not be considered as limiting the scopeof the invention, but merely as being illustrative and representativethereof.

In the examples below, the following abbreviations have the followingmeanings. Unless otherwise stated, all temperatures are in degreesCelsius. If an abbreviation is not defined, it has its generallyaccepted meaning.

g=gram

mg=milligram

min=minute

ml=milliliter

mmol=millimol

Synthetic Examples Example 1 Synthesis of4-piperidyl-N-(2-biphenylyl)carbamate

Step 1

In a 50 ml sealed tube was added 2-biphenylylisocyanate (8 g, 41 mmol)in anhydrous acetonitrile (40 mL). To this solution was addedN-benzyl-4-piperidinol (9.8 g, 51.25 mmol) and the tube was partiallyimmersed in a silicon oil bath and heated to 85° C. After 16 h, thereaction mixture was cooled and concentrated in vacuo to give a1-benzyl-4-piperidyl N-(2-biphenylyl)carbamate which was used in thenext step without further purification.

Step 2

1-Benzyl-4-piperidyl N-(2-biphenylyl)carbamate (12.5 g, 32.3 mmol) wasdissolved in anhydrous methanol (150 mL) and formic acid (25 mL, 660mmol) and the solution was flushed with gaseous nitrogen for 15 min. 10%Palladium on carbon (3 g) was added and the reaction mixture was stirredunder nitrogen atmosphere. After 18 h, the reaction mixture was filteredthrough Celite® and the filtrate was concentrated to give a yellowsolid. The solid was partitioned between 0.1 N hydrochloric acid (300mL) and diethyl ether (300 mL). The aqueous layer was washed withdiethyl ether and then basified with 1 N sodium hydroxide solution to pH12. A white solid precipitated out which was extracted into ethylacetate. The ethyl acetate layer was dried over magnesium sulfate andevaporated to dryness to give 4-piperidyl N-(2-biphenylyl)carbamate as acolorless solid (6.63 g, 69%). MS=296.9 MH+.

Example 2 Synthesis of 4-piperidyl benzhydrylcarbamate

Step 1

1-Benzyl-4-piperidinol (2.09 g, 10.9 mmol) and 4-nitrophenylchloroformate (2.2 g, 10.9 mmol) were dissolved in anhydrousacetonitrile (10 mL). To this solution was added diisopropylethylanine(1.4 g, 10.9 mmol) and the resulting yellow solution was stirred at roomtemperature. After 3 h, aminodiphenylmethane (2 g, 10.9 mmol) was addedand the reaction mixture was heated at 65° C. After 3 h, the reactionmixture was cooled to room temperature and stirred for an additional 12h. The resulting solid was filtered, washed with cold acetonitrile togive 1-benzyl-4-piperidylbenzhydryl carbamate (1.3 g, 50%) as acolorless solid which was used in the next step without furtherpurification.

Step 2 1-benzyl-4-piperidyl benzhydrylcarbamate (1.1 g, 4.5 mmol) wasdissolved in anhydrous methanol (15 mL) and formic acid (5 mL, 132 mmol)and the solution was flushed with gaseous nitrogen for 15 min. 10%Palladium on carbon (0.3 g) was added and the reaction mixture wasstirred under nitrogen atmosphere. After 18 h, the reaction mixture wasfiltered through Celite® and the filtrate was concentrated to give ayellow solid. The solid was partitioned between 0.1 N hydrochloric acid(300 mL) and diethyl ether (300 mL). The aqueous layer was washed withdiethyl ether and then basified with 1 N sodium hydroxide solution to pH12. A white solid precipitated out which was extracted into ethylacetate. The ethyl acetate layer was dried over magnesium sulfate andevaporated to dryness to give 4-piperidyl benzhydrylcarbamate as acolorless solid (0.65 g, 78%). MS=311.3 MH+. Example 3 Synthesis ofN—[N-(3,3-dimethyl)-N-(6-bromohexyl)aminopropyl)phthalimide quaternaryammonium salt

Step 1

N-(3-bromopropyl)phthalimide (10 g, 37.3 mmol) was dissolved in dryacetonitrile (100 mL) and a solution of dimethylamine in tetrahydrofuran(56 mL, 111 mmol, 2 M) was added. The flask was fitted with a refluxcondenser and the solution was heated at reflux. After 22 h, thereaction mixture was concentrated in vacuo to give a yellow oil whichwas partitioned between ethyl acetate and 1 M sodium carbonate solutionsaturated with sodium chloride. The organic phase was collected andwashed with brine, dried over potassium carbonate, filtered andconcentrated to give a yellow oil. The oil was dissolved in methanol (25mL) and p-toluenesulfonic acid (7.80 g, 41 mmol) was added. The solutionwas diluted with ether to crystallizeN-(3,3-dimethylaminopropyl)phthalimide as the p-toluenesulfonic acidsalt (8.0 g). MS (M-OTs)⁺ 233.1.

Step 2

p-Toluenesulfonic acid salt of N-(3-dimethylaminopropyl)phthalimide(0.42 g, 0.98 mmol) was partitioned between ethyl acetate and 1 M sodiumcarbonate. The aqueous phase was separated, saturated with sodiumchloride and then extracted with ethyl acetate. The organic layers werewashed with water and brine, dried over potassium carbonate, filteredand concentrated in vacuo to give an oil. The oil was dissolved in dryacetonitrile (10 mL) and 1,6-dibromohexane (1.21 g, 4.90 mmol) wasadded. The reaction mixture was cooled to room temperature and dilutedwith one volume of ether. The resulting solids were filtered to giveN—[N-(3,3-dimethyl)-N-(6-bromohexyl)aminopropyl)phthalimide quaternaryammonium salt as a white solid. MS 395.2 (M-Br)+.

Example 4 Synthesis of N-(2-methylaminoethyl)phthalimido

Step 1

N-Methylethylenediamine (3.38 g, 45.6 mmol) was dissolved in chloroform(60 mL) and a solution of N-carbethoxyphthalimide (10 g, 45.6 mmol) inchloroform (30 mL) was added rapidly. After 6 h, the clear solution wasconcentrated in vacuo to give an oil which was dissolved in methanol,acidified with 4 M hydrochloric acid in dioxane (15 mL). Diethyl etherwas added to crystallize N-(2-methylaminoethyl)-phthalimido as thechloride salt (9.25 g, 84%). MS 205 (M-Cl)+.

Example 5 Synthesis of O-(2-methoxybenzyl)-6-dimethylaminohexanol

6-(Dimethylamino)hexanol (8.80 g, 60.6 mmol) was dissolved in ananhydrous 2:1 mixture of tetrahydrofuran and dimethylformamide (150 mL)and the solution was cooled in an ice bath. Sodium hydride (60% in oil,3.23 g, 80.8 mmol) was added in portions and after 5 min. the water bathwas removed. After 45 min., 2-methoxybenzyl chloride (6.28 g, 40.4 mmol)was added. After 4 h, the reaction mixture was quenched with 1 M sodiumthiosulfate and tetrahydrofuran was removed in vacuo. The reactionmixture was washed with ethyl acetate and the aqueous phase was basifiedwith 3 M sodium hydroxide, followed by extraction with ether. The etherlayer was dried over potassium carbonate, filtered and acidified with 4M hydrochloric acid in dioxane. The reaction mixture was concentrated invacuo and the residue was crystallized form ethanol/ether to give O-(2-methoxybenzyl)-6-dimethylaminohexanol as the hydrochloride salt(10.4 g, 85%). MS (M-Cl)+266.3.

Example 6 Synthesis of1-{[N-(3-phthalimidopropyl)-N,N-dimethylamino]-6-[4-(N-2-biphenylyl)carbamate)piperidin-1-yl]}hexanehydrobromide salt

To N—[N-(3,3-dimethyl)-N-(6-bromohexyl)aminopropyl)phthalimidequaternary ammonium salt (16 mg, 0.03 mmol), prepared as above, inacetonitrile (1 mL) was added 4-piperidyl N-(2-biphenylyl)carbamate (10mg, 0.03 mmol), prepared as above, and the reaction mixture was heatedat reflux for 3 h. The reaction mixture was cooled to room temperature,and the product was precipitated as the hydrobromide salt. The solidswere isolated by filtration to give 20 mg (77%) of the desired productas white solids. The product was characterized by NMR (MeOH) and MS(calculated, (M-HBr₂)⁺=611.3600; found, 611.5).

Example 7 Synthesis of Compounds of Formula (I) Via CombinatorialChemistry

An aliquot (0.22 mL) of a solution prepared fromN-[2-dimethylamino)-ethyl]phthalimido 14 (1.25 g, 3.2 mmol) and EtNiPr₂(0.79 mL) dissolved in enough anhydrous acetonitrile to bring the totalvolume up 6.4 mL was added to a 1 dram vial charged with2,6-bis(bromomethyl)pyridine (26.5 mg, 0.10 mmol) in acetonitrile (0.22mL). The vial was closed with a Teflon cap and then placed in a 72° C.heating block for 24 h to give a mixture of compounds 15, 16, and 17.After cooling to room temperature, 4-piperidyl-N-(2-biphenyl)-carbamate18 (0.33 mL) (prepared by dissolving 2.96 g of 18 in anhydrous DMF toproduce a total volume of 33 mL) was added and the vial was resealed andheated overnight at 72° C. in a heating block. The mixture was cooled,quenched with 5% TFA/water (0.30 mL), diluted with acetonitrile andwater, filtered, and purified using preperative LC/MS [Zeng, L; Kassel,D. B. Anal. Chem. 1998, 70, 4380-4388 and references therein] to providethe individual components. Quality and

identity of the collected fractions was verified using analytical HPLCand electrospray MS.

Example 8 Synthesis of Compounds of Formula (I) Via CombinatorialChemistry

N-(2-Methylaminethyl)phthalimido 23 (0.20 mL, of a 0.5 M solution, 0.10mmol) (prepared by dissolving 168 mg of N-(2-methylaminethyl)phthalimidoin DIPEA (0.18 mL) and enough anhydrous acetonitrile to bring thesolution to a total volume of 1.4 mL), and a solution of compound 22(0.167 mL) (prepared by dissolving 673 mg of 22 in enough anhydrousacetonitrile to bring the total volume to 4 mL), and NaI (0.20 mL of a 1M solution in anhydrous acetonitrile) were combined in a 1 dram vialcharged with 1,11-dibromoundecane (0.10 mmol). The vial was closed witha Teflon sealed cap and the placed in a 72° C. heating block for a 21 h.The mixture was cooled, quenched with 5% TFA/water (0.30 mL), dilutedwith acetonitrile and water, filtered, and purified using preperativeLC/MS [Zeng, L; Kassel, D. B. Anal. Chem. 1998, 70, 4380-4388 andreferences therein] to provide the individual components 26-21. Qualityand identity of the collected fractions was verified using analyticalHPLC and electrospray MS.

Example 9 Synthesis of1-{[N,N-dimethyl-N-ethylaminomethyl]-4-[4-(N-2-biphenylyl)carbamate)piperidin-1-ylmethyl]}benzenehydrobromide salt

Step 1

In a sealed tube, a mixture of 2-biphenyl isocyanate (4.80 g, 24.6 mmol)and 1-benzyl-4-hydroxypiperidine (5.88 g, 30.7 mmol) in acetonitrile (25mL) was heated at 90° C. overnight. The reaction mixture was cooled toroom temperature and concentrated under reduced pressure. The resultingyellow oil was dissolved in ethyl acetate and hexane was added to give asolid which was filtered and washed with cold hexanes to yieldN-benzylpiperidin-4-yl benzhydrylcarbamate as white solid.

Step 2

A mixture of N-benzylpiperidin-4-yl benzhydrylcarbamate (46.3 g, 119mmol) and formic acid (100 mL) in methanol (600 mL) was stirred at roomtemperature and nitrogen was bubbled through the reaction mixture forabout 20 min. The reaction mixture was then transferred to a slurry of10% palladium on carbon in water (75 mL.) via a thick needle andstirring was continued overnight. The reaction mixture was filtered,concentrated under reduced pressure, and dried under high vacuumovernight. The residue was then diluted with ethyl acetate and washedwith satd. NaHCO₃ (aq.). The organic layer was separated, concentratedunder reduced pressure, diluted with 0.1N HCl (pH3) and ether. The etherlayer was separated and the aqueous layer was basified with 1N NaOH (aq)to pH 13-14. to give a solid which was filtered to yield piperidin-4-ylbenzhydrylcarbamate.

Step 3

A mixture of piperidin-4-yl benzhydrylcarbamate (2.68 g, 9.05 mmol) anddibromo p-xylene (2.39 g, 9.05 mmol) in acetonitrile (45 mL.) was heatedto 80° C. After 1 h, N,N-dimethyl-N-ethylamine (0.98 mL., 9.05 mmol) wasadded to the reaction mixture. After 4 h, the reaction mixture wascooled and concentrated under reduced pressure and purified by HPLC toyield the desired product, MS: 474(M+H⁺).

Example 10 Synthesis of1-{[N,N-dimethyl-N-ethylaminomethyl]-3-[4-(N-2-biphenylyl)carbamate)piperidin-1-ylmethyl]}benzenehydrobromide salt

A mixture of piperidin-4-ylbenzhydrylcarbamate (2.68 g., 9.05 mmol),prepared as described in Example 9 above, and dibromo m-xylene (2.39 g.,9.05 mmol) in acetonitrile (45 mL.) was heated to 80° C. After 1 h,N,N-dimethyl-N-ethylamine (0.98 mL, 9.05 mmol) was added to the reactionmixture. After 4 h, the reaction mixture was cooled and concentratedunder reduced pressure and purified by HPLC, 10%-50% CH₃CN in H₂O, toyield the desired product. MS: 474(M+H⁺).

Example 11 Synthesis of1-{[N-(2-pyridin-2-yl)ethyl-N-methylamino]-7-[4-(N-2-biphenylyl)carbamate)piperidin-1-yl]}nonane

A mixture of piperidin-4-yl benzhydrylcarbamate (1.95 g, 6.60 mmol),prepared as described in Example 9 above, and 1,9-dibromononane (1.34mL., 6.60 mmol) in acetonitrile (45 mL.) was heated to 80° C. After 1 h,2-(2-methylaminoethyl)pyridine (0.94 mL, 6.60 mmol) was added to thereaction mixture and heating was continued. After 4 h, the reactionmixture was cooled and concentrated under reduced pressure and purifiedby HPLC, 10%-50% CH₃CN in H₂O, to yield the desired product. MS:557(M+H⁺).

Example 12 Synthesis of1-{[N-methyl-N-ethylaminomethyl]-4-[4-(N-2-biphenylyl)-carbamate)piperidin-1-ylmethyl]}benzene

A mixture of piperidin-4-yl benzhydrylcarbamate (1.96 g., 6.60 mmol) anddibromo p-xylene (1.75 g., 6.60 mmol) in acetonitrile (45 mL.) washeated to 80° C. After 1 h, N-methyl-N-ethylamine (0.569 mL, 6.60 mmol)was heating was continued. After 4 h, the reaction mixture was cooledand concentrated under reduced pressure and purified by HPLC, 10%-50%CH₃CN in H₂O, to yield the desired product. MS: 459(M+H⁺).

Example 13 Synthesis of1-{[N-methyl-N-ethylaminomethyl]3-[4-(N-2-biphenylyl)carbamate)piperidin-1-ylmethyl]}benzene

A mixture of piperidin-4-yl benzhydrylcarbamate (1.96 g, 6.60 mmol) anddibromo m-xylene (1.75 g, 6.60 mmol) in acetonitrile (45 mL.) was heatedto 80° C. After 1 h, N-methyl-N-ethylamine (0.569 mL, 6.60 mmol) wasadded to the reaction mixture and heating was continued. After 4 h, thereaction mixture was cooled and concentrated under reduced pressure andpurified by HPLC, 10%-50% CH₃CN in H₂O, to yield the desired product.MS: 459(M+H⁺).

Example 14 Synthesis of1-[(32,2-diphenyl-2-acetamido)pyrrolidin-1-yl]-7-{[N,N-dimethyl-N-6-(2-methoxybenzyloxy)hexyl]amino}hexane

Step 1

6-Dimethylamino-1-hexanol (8.80 g, 60.6 mmol) was dissolved in 2/1mixture of THF/DMF (150 mL) and the solution was cooled in an ice/waterbath. Sodium hydride (3.25 g, 80.8 mmol, 60% in oil) was added. After 40min., 2-methoxybenzyl chloride (6.28 g, 40.4 mmol) was added and thesolution was allowed to warm to room temperature over 1 h. After 3 h,the reaction was quenched by the addition of 1M NaHSO₄. Tetrahydrofuranwas removed in vacuo, and the solution was washed with EtOAc. Theaqueous phase was basified with 3M NaOH and extracted with ether. Thecombined ether phases were dried over K₂CO₃, filtered, and the productwas crystallized by the addition of 4M HCl/dioxane to giveO-(2-methoxybenzyl)-6-dimethylaminohexanol (10.4 g) as a white solid.

Step 2

Compound O-(2-methoxybenzyl)-6-dimethylaminohexanol (602 mg, 2.0 mmol)was partitioned between EtOAc and 50% saturated NaHCO₃. The organicphase was separated and the aqueous layer was extracted once with EtOAc.The combined EtOAc phases were washed with water, brine, dried overK₂CO₃, filtered, and concentrated to the free base as an oil. The freebase was dissolved in dry acetonitrile (10 mL) and 1,7-dibromoheptane(1.03 g, 4.0 mmol) was added. The solution was heated at reflux for 20h. The solution was concentrated to ¼th volume and the product wasprecipitated by adding ether. The ether was decanted off, and theresidue was washed once more with ether. The residue was dissolved inacetonitrile (10 mL) and 2,2-diphenyl-2-[2-(R)-pyrrolidin-3-yl]acetamide(491 mg, 1.75 mmol) and diisopropylethylamine (0.22 g, 1.72 mmol) wereadded. The solution was heated at reflux for 14 h and then concentratedin vacuo. The residue was purified by reversed-phase HPLC to give1-[(32,2-diphenyl-2-acetamido)-pyrrolidin-1-yl]-7-{[N,N-dimethyl-N-6-(2-methoxybenzyloxy)hexyl]amino}hexane(119 mg) as the bis-trifluoroacetate salt.

Analytical data are as follows: ¹H NMR (300 MHz, MeOH-d₄) 7.41-7.23 (m,10H), 6.92 (m, 2H), 4.85 (s, 6H), 4.51 (s, 2H), 3.93 (m, 2H), 3.82 (s,2H), 3.75 (m, 1H), 3.53 (m, 3H), 3.41 (m, 1H), 3.25 (m, 4H), 3.15 (m,2H), 2.97 (m, 1H), 2.86 (m, 1H), 2.61 (m, 1H), 2.39 (m, 1H), 2.02 (m,1H), 1.79-1.28 (m, 16H); MS (M+) 642.4; IR (thin film) 2937, 1674, 1200cm⁻¹; reversed-phase analytical HPLC (H.-P. Zorbax column, 2.1 i.d., 5cm length, 5 micron) using a 10-70% aqueous ACN (0.1% TFA) gradient overfive minutes starting at 0.5 minutes during a six minute run time, gavea single peak with retention time=3.13 minutes.

Following the procedures described above but substituting appropriatestarting materials, compounds of Formula (I) listed in Table III belowwere prepared.

Orthosteric to Allosteric Dimers

Formulation Examples Example 1

Hard gelatin capsules containing the following ingredients are prepared:

Quantity Ingredient (mg/capsule) Active Ingredient 30.0 Starch 305.0Magnesium stearate 5.0

The above ingredients are mixed and filled into hard gelatin capsules in340 mg quantities.

Example 2

A tablet Formula is prepared using the ingredients below:

Quantity Ingredient (mg/tablet) Active Ingredient 25.0 Cellulose,microcrystalline 200.0 Colloidal silicon dioxide 10.0 Stearic acid 5.0

The components are blended and compressed to form tablets, each weighing240 mg.

Example 3

A dry powder inhaler formulation is prepared containing the followingcomponents:

Ingredient Weight % Active Ingredient 5 Lactose 95

The active ingredient is mixed with the lactose and the mixture is addedto a dry powder inhaling appliance.

Example 4

Tablets, each containing 30 mg of active ingredient, are prepared asfollows:

Quantity Ingredient (mg/tablet) Active Ingredient 30.0 mg Starch 45.0 mgMicrocrystalline cellulose 35.0 mg Polyvinylpyrrolidone 4.0 mg (as 10%solution in sterile water) Sodium carboxymethyl starch 4.5 mg Magnesiumstearate 0.5 mg Talc 1.0 mg Total 120 mg

The active ingredient, starch and cellulose are passed through a No. 20mesh U.S. sieve and mixed thoroughly. The solution ofpolyvinylpyrrolidone is mixed with the resultant powders, which are thenpassed through a 16 mesh U.S. sieve. The granules so produced are driedat 50° to 60° C. and passed through a 16 mesh U.S. sieve. The sodiumcarboxymethyl starch, magnesium stearate, and talc, previously passedthrough a No. 30 mesh U.S. sieve, are then added to the granules which,after mixing, are compressed on a tablet machine to yield tablets eachweighing 120 mg.

Example 5

Capsules, each containing 40 mg of medicament are made as follows:

Quantity Ingredient (mg/capsule) Active Ingredient 40.0 mg Starch 109.0mg Magnesium stearate 1.0 mg Total 150.0 mg

The active ingredient, starch, and magnesium stearate are blended,passed through a No. 20 mesh U.S. sieve, and filled into hard gelatincapsules in 150 mg quantities.

Example 6

Suppositories, each containing 25 mg of active ingredient are made asfollows:

Ingredient Amount Active Ingredient 25 mg Saturated fatty acidglycerides to 2,000 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve andsuspended in the saturated fatty acid glycerides previously melted usingthe minimum heat necessary. The mixture is then poured into asuppository mold of nominal 2.0 g capacity and allowed to cool.

Example 7

Suspensions, each containing 50 mg of medicament per 5.0 mL dose aremade as follows:

Ingredient Amount Active Ingredient 50.0 mg Xanthan gum 4.0 mg Sodiumcarboxymethyl cellulose (11%) Microcrystalline cellulose (89%) 50.0 mgSucrose 1.75 g Sodium benzoate 10.0 mg Flavor and Color q.v. Purifiedwater to 5.0 mL

The active ingredient, sucrose and xanthan gum are blended, passedthrough a No. 10 mesh U.S. sieve, and then mixed with a previously madesolution of the microcrystalline cellulose and sodium carboxymethylcellulose in water. The sodium benzoate, flavor, and color are dilutedwith some of the water and added with stirring. Sufficient water is thenadded to produce the required volume.

Example 8

A formulation may be prepared as follows:

Quantity Ingredient (mg/capsule) Active Ingredient 15.0 mg Starch 407.0mg Magnesium stearate 3.0 mg Total 425.0 mg

The active ingredient, starch, and magnesium stearate are blended,passed through a No. 20 mesh U.S. sieve, and filled into hard gelatincapsules in 425.0 mg quantities.

Example 9

A formulation may be prepared as follows:

Ingredient Quantity Active Ingredient 5.0 mg Corn Oil 1.0 mL

Example 10

A topical formulation may be prepared as follows:

Ingredient Quantity Active Ingredient 1-10 g Emulsifying Wax 30 g LiquidParaffin 20 g White Soft Paraffin to 100 g

The white soft paraffin is heated until molten. The liquid paraffin andemulsifying wax are incorporated and stirred until dissolved. The activeingredient is added and stirring is continued until dispersed. Themixture is then cooled until solid.

Another preferred formulation employed in the methods of the presentinvention employs transdermal delivery devices (“patches”). Suchtransdermal patches may be used to provide continuous or discontinuousinfusion of the compounds of the present invention in controlledamounts. The construction and use of transdermal patches for thedelivery of pharmaceutical agents is well known in the art. See, e.g.,U.S. Pat. No. 5,023,252, issued Jun. 11, 1991, herein incorporated byreference in its entirety. Such patches may be constructed forcontinuous, pulsatile, or on demand delivery of pharmaceutical agents.

Other suitable formulations for use in the present invention can befound in Remington's Pharmaceutical Sciences, edited by E. W. Martin(Mack Publishing Company, 18th ed., 1990).

Biological Examples Example 1 M₃ Muscarinic Receptor In Vitro BindingAssay

The M₃ muscarinic receptor binding activity of compounds of theinvention was tested as follows:

SF9 cell membranes containing human M₃ muscarinic receptor was obtainedfrom NEN (Boston, Mass.). In 96-well microtiter plates, eight serialfive-fold dilutions were prepared with the compound to be assayed; thehighest concentration was typically 4 μM (4× the final concentration).To 100 μl of compound dilution was added 150 μL M₃ receptor membranepreparation in PBS/1.0 mM MgCl₂/pH 7.4. 50 μl of 3.2 mM3H—N-methylscopolamine radioligand was added. The total volume in eachwell was then 300 μl. The filter plate was pre-blocked using 0.3% PEIfor at least 15 minutes, and then washed twice with 200 μl PBS. Theassay plate was incubated for 1 hour at room temperature with gentleshaking. The contents of the assay plate were then transferred to thefilter plate, and washed three times using 200 μl PBS. About 40 μl ofscint was added to each well and then the plate was allowed to sit atroom temperature for 2 h, and then counted using a Packard Topcount NXT.Counting was typically performed for 1 minute per well using a standardprotocol on a Packard top counter. The raw data was fit to a standard4-parameter equation given below and a value of IC₅₀ obtained.

Y=(a−d)/(1+(x/c)^(b))+d where

Y=cpm a=total binding b=slopec=IC₅₀ x=[compound] d=nonspecific binding

A similar protocol was used to measure M1, M2, M4 and M5 humanmuscarinic receptor activity.

Example 2 Rat Heart Muscarinic Receptor In Vitro Binding Assay

Tissue (rat heart) muscarinic receptor binding activity of compounds ofthe invention was tested as follows:

First, muscarinic receptor enriched membranes were isolated from wholehearts (Pelfreeze Laboratories). Rat heart tissue was typically preparedas follows. 25 μl of ice cold buffer (20 mM HEPES, 100 mM NaCl/10 mMMgCl₂ at pH 7.5 with “Complete” protease inhibitor cocktail purchasedfrom Boehringer Mannheim was added into an oakridge tube. To the tubewas then added 2 g of rat heart (purchased from Harlan). The contents ofthe tube were then transferred to a wheaton glass cylinder andhomogenized using a Polytron homogenizer (setting 22, 15 seconds×2), andthen transferred back to the oakridge tube, and centrifuged for 10minutes at 1500 g. The supernatant was removed and then centrifuged for20 minutes at 45000 g. The supernatant was removed and the pelletresuspended in 5 mL buffer and transferred to a wheaton glass cylinder.This material was then homogenized using a Potter type glass teflonhomogenizer with 7-8 passes. The material was then transferred to anoakridge tube and the total volume was brought up to 25 mL. Thismaterial was then centrifuged for 20 minutes at 45000 g, and the pelletresuspended in 2 mL buffer using 2 passes of a teflon homogenizer, andstored at −80° C. until used.

Second, a protocol similar to that used for cloned receptor binding wasused: Eight serial five-fold dilutions were prepared with the compoundto be assayed; the highest concentration was typically 4 μM (4× thefinal concentration). To 50 μl of compound dilution in a 96-well assayplate was added an appropriate amount of rat heart membrane (usually12.5 μl of membrane prep in 87.5 μl of 20 mM HEPES, 100 mM NaCl/10 mMMgCl₂ at pH 7.5). The amount of membrane added depends in general on theresults of signal optimization, and ranges from 6.25-12.5 μl. Last, 50μl of 2.12 nM 3H—N-methylscopolamine radioligand was added. The totalvolume in each well was 200 μl. The filter plate was pre-blocked using0.3% PEI for at least 15 min., and then washed twice with 200 μl PBS.The assay plate was incubated for 1 h at room temperature with gentleshaking. The contents of the assay plate were then transferred to thefilter plate, and washed three times using 200 μl PBS. About 40 μl ofscint was added to each well and then the plate was allowed to sit atroom temperature for 18 h, and then counted using a Packard TopcountNXT. Counting was typically performed for 1 min., per well using astandard protocol on the Packard counter. The data was fit to the fourparameter fit described above in Example 19.

A similar procedure was used to measure muscarinic receptor binding atrat submaxillary gland, rat bladder, guinea pig heart, guinea pigsubmaxillary gland, and guinea pig bladder.

Example 3 Rat Bladder M₃ In Vitro Binding Assay

Bladder was comprised of both M₂ and M₃ muscarinic receptors. The ratiowas typically 4:1 M₂:M₃. In order to measure binding of test compoundsto one of M₂ or M₃, the other was blocked with a reversible ligand thatbinds selectively to that receptor. The following example illustratesthe procedure for M₃ bladder binding.

Membranes from rat bladder were prepared in a similar fashion to thatused to isolate heart membrane above. Eight serial five-fold dilutionswere prepared with the compound to be assayed in compound dilutionbuffer (20 mM HEPES/100 mM NaCl/10 mM MgCl₂/4 μM Methoctramine); thehighest concentration was typically 4 μM (4× the final concentration).The concentration of methoctramine was sufficient to block >99% of theM2 receptor in bladder, but less than 40% of the M₃ receptor in bladder.To 50 μl of compound dilution in a 96-well assay plate was added anappropriate amount of rat heart membrane (usually 25 μl of membrane prepin 75 μl of 20 mM HEPES, 100 mM NaCl/10 mM MgCl₂ at pH 7.5). The amountof membrane added depended in general on the results of signaloptimization, and ranged from 12.5-25. Last, 50 μl of 2.12 nM3H—N-methylscopolamine radioligand in compound dilution buffer wasadded. The total volume in each well was 200 μl. The final concentrationof methoctramine was 2 μM. The filter plate was pre-blocked using 0.3%PEI for at least 15 mins., and then washed twice with 200 μl PBS. Theassay plate was incubated for 1 hour at room temperature with gentleshaking. The contents of the assay plate was then transferred to thefilter plate, and washed three times using 200 μl PBS. About 40 μl ofscint was added to each well, the plate was allowed to sit at roomtemperature for 18 h, and then counted using a Packard Topcount NXT.Counting was typically performed for 1 minute per well using a standardprotocol on the Packard counter, and the data was fit to the fourparameter equation described in Example 19.

A similar procedure was used to measure binding at bladder M₂, but inthis case, 2 μM Darifenacin was used to block >99% of the M₂ receptor,but minimal M₃ receptor.

Example 4 Ex Vivo Rat Bladder Contraction Assay

The ability of the test compound to inhibit cholinergically stimulatedbladder contraction was tested as follows:

Male Sprague-Dawley rats weighing 250-300 g are killed by CO₂ overdose.The bladder was removed and placed in a petri dish containingKrebs-Henseleit solution at room temperature. The apex and dome areas ofthe bladder were discarded and the remaining tissue cut intolongitudinal strips (4 from each rat). The strips were mounted in anorgan bath containing Krebs-Henseleit solution at 37° C., under aresting tension of 0.5 g. The tissues were allowed to equilibrate for 60min., (washes at 0, 30 and 60 min.). Tension was readjusted to 1 g asnecessary. A cumulative concentration response curve to carbachol (10-8M to 10-5 M (e.g.) in 3-fold increments) was constructed in each tissue.Tissues were then washed every 5 min., for 30 min., and tensionreadjusted to 1 g. After additional 30 min., muscarinic antagonist(typically 1×10-7 M) or vehicle was added. Thirty minutes afterantagonist or vehicle addition, a cumulative concentration responsecurve to carbachol (10-8M to 10-3M (e.g.)) was constructed. Data fromeach concentration response curve was expressed as a percentage of themaximum contraction to carbachol. The EC₅₀ values were calculated. Theconcentration-ratios were calculated taking into account any spontaneousshift in the control tissue. For competitive antagonists, the pKb valuewas calculated using the following equation:

${pKb} = {{- \log}\frac{\lbrack {{antagonist}\mspace{14mu} {concentration}} \rbrack}{{CR} - 1}}$

Example 5 In Vivo Rat Salivation Assay

Male Sprague-Dawley rats weighing 250-300 g were anesthetized withpentobarbital (60 mg/kg i.p.). Rats were placed on a heated blanketunder a 20 degree incline. A swab was placed in the rat's mouth.Muscarinic antagonist or vehicle was administered i.v. via the tailvein. After 5 min., oxotremorine (0.3 mg/kg) was administered s.c. Theswab was discarded and replaced by a pre-weighed swab. Saliva was thencollected for 15 min. After 15 min., the swab was weighed and thedifference in its weight was used to calculate the antisecretory potencyof the antagonists. The ID₅₀ value for each antagonist is calculatedusing the four parameter fit equation given above.

Example 6 In Vivo Bladder Assay

Male Sprague-Dawley rats weighing 250-300 g were anesthetized withurethane (1.3 g/kg, i.p.), inactin (25 mg/kg, i.p.), and xylazine (4 mg,i.p.). The jugular (or femoral) vein was isolated and ligated and asmall incision was made in the vein distal to the ligation. A catheter(micro-Renathane tubing (0.014 mm ID×0.033 mm OD) filled with saline wasinserted into the vein and secured into place with suture thread. Thetrachea was isolated and placed in a small hole between two of therings. Tubing (1.57 mm ID×2.08 mm OD) was inserted into the trachea andtied into place with suture thread. The incision was closed leaving thetubing exposed. The tracheotomy was to prevent the animal fromasphyxiating on his own saliva following oxotremorine administration.The stomach was shaved and then cleaned with ethanol. A midline sagitalincision was made in the skin and muscle layers of the lower stomach.The bladder was exposed and the saline filled cannula (22-gauge needleattached to a pressure transducer with PE 90 tubing) was inserted intothe apex of the bladder to the most distal part of the bladder. Thebladder was placed back into the peritoneal cavity. The bladder wasemptied manually by disconnecting the cannula and allowing the contentsto flow out until the bladder was approximately 1 cm in diameter. Theincision was closed with suture thread, first the muscle layer, then theskin in order to keep the bladder moist and warn. The exposed portion ofthe cannula to the skin surface was sutured to hold it in place. After15 min. oxotremorine (0.3 mg/kg, SC, baseweight) was injected. After 10min., (or until baseline stabilized) a test compound or a referencestandard was injected with a dose equivalent to 0.005-0.01 mg/kg, IV,baseweight of atropine that produced a 30-70% decrease in intraluminalpressure. After 5 min., a high dose of atropine 0.1 mg/kg was injected,i.v., to establish the true 100% inhibition point.

For data analysis, the oxotremorine response (zero inhibition) wasdetermined by measuring the mean pressure 1 minute prior to theantagonist injection. Then, to assess antagonist inhibition, meanpressure was measured beginning at 1 minute and ending 2 minutes afterantagonist administration. If the pressure had not leveled off after 1minute, a wait was initiated until it was stable and then a 1-minutesample of the mean was taken. Lastly, to determine the true 100%inhibition point, the mean pressure was measured beginning 1 minutes andending 2 minutes after the high dose atropine challenge. The percentinhibition by the antagonist can be determined by the ratio of thedecrease from the zero to 100% values.

The formula is: oxotremorine mean−treatment mean*100oxotremorinemean−atropine mean.

The foregoing invention has been described in some detail by way ofillustration and example, for purposes of clarity and understanding. Itwill be obvious to one of skill in the art that changes andmodifications may be practiced within the scope of the appended claims.Therefore, it is to be understood that the above description is intendedto be illustrative and not restrictive. The scope of the inventionshould, therefore, be determined not with reference to the abovedescription, but should instead be determined with reference to thefollowing appended claims, along with the full scope of equivalents towhich such claims are entitled.

All patents, patent applications and publications cited in thisapplication are hereby incorporated by reference in their entirety forall purposes to the same extent as if each individual patent, patentapplication or publication were so individually denoted.

1-50. (canceled)
 51. A compound of the formula:

wherein: L^(b) is a group of formula (h):

n₁₁ is an integer from 1 to 7; n₁₂ is 0 or an integer from 1 to 7; F isselected from —NR⁴⁰—, —O—, —S—, and —CHR⁴¹—; and R⁴⁰ and R⁴¹ areindependently selected from hydrogen, alkyl, and substituted alkyl; F″is selected from a covalent bond, —OR⁴³, —NR⁴²R⁴³, and —N⁺R⁴³R⁴⁴R⁴⁵; R⁴²is hydrogen or alkyl; R⁴⁴ and R⁴⁵ are independently alkyl; and R⁴³ is acovalent bond attaching the group of formula (h) to X; R³⁶ is selectedfrom hydrogen, alkyl, halo, nitro, cyano, hydroxy, alkoxy, carboxy,alkoxycarbonyl, acyl, thio, alkylthio, alkylsulfonyl, alkylsulfinyl,sulfonamido, alkylsulfonamido, carbamoyl, thiocarbamoyl, mono- ordialkylcarbamoyl, amino, mono- or dialkylamino, aryl, aryloxy, arylthio,heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl,heterocyclyloxy, aralkyl, heteroaralkyl, and alkyl optionallysubstituted with one, two or three substituents selected from halo,hydroxy, carboxy, alkoxycarbonyl, alkylthio, alkylsulfonyl, amino, andsubstituted amino; R³⁷ is selected from hydrogen, alkyl, halo, nitro,cyano, hydroxy, alkoxy, alkoxycarbonyl, acyl, thio, alkylthio, amino,mono- or dialkylamino, aryl, aryloxy, arylthio, heteroaryl,heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, aralkyl,heteroaralkyl, and alkyl optionally substituted with one, two or threesubstituents selected from halo, hydroxy, carboxy, alkoxycarbonyl,alkylthio, alkylsulfonyl, amino, and substituted amino; R³⁸ is selectedfrom hydrogen, alkyl, halo, hydroxy, alkoxy, and a covalent bondattaching the group of formula (h) to X, provided that at least one ofR³⁸ and R⁴³ attaches the group of formula (h) to X; R³⁹ is selected fromhydrogen, alkyl, halo, hydroxy, alkoxy, and substituted alkyl; X is agroup of the formula:—X^(a)-Z-(Y^(a)-Z)_(n)-Y^(b)-Z-X^(a)— m is an integer from 0 to 20;X^(a) at each separate occurrence is selected from a covalent bond, —O—,—S—, —NR—, —C(O)—, —C(O)O—, —C(O)NR—, —C(S)—, —C(S)O—, and —C(S)NR—; Zat each separate occurrence is selected from a covalent bond, alkylene,substituted alkylene, cycloalkylene, substituted cycloalkylene,alkenylene, substituted alkenylene, alkynylene, substituted alkynylene,cycloalkenylene, substituted cycloalkenylene, arylene, heteroarylene,and heterocyclene; Y^(a) and Y^(b) at each separate occurrence areselected from a covalent bond, —O—, —C(O)—, —OC(O)—, —C(O)O—, —NR—,—S(O)_(n)—, —C(O)NR′—, —NR′C(O)—, —NR′C(O)NR′—, —NR′C(S)NR′—,—C(═NR′)NR′—, —NR′C(═NR′)—, —OC(O)NR′—, —NR′C(O)O—, —P(O)(OR′)O—,—OP(O)(OR′)—, —S(O)_(n)CR′R″—, —S(O)_(n)NR′—, —NR′S(O)_(n)—, and —S—S—;n is 0, 1 or 2; and R, R′ and R″ at each separate occurrence areselected from hydrogen, alkyl, substituted alkyl, cycloalkyl,substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl,substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl,heteroaryl, and heterocyclic; or a pharmaceutically-acceptable saltthereof.
 52. The compound of claim 51, wherein n₁₁ is 1 or
 2. 53. Thecompound of claim 51, wherein n₁₂ is 0 or
 6. 54. The compound of claim51, wherein F is —NR⁴⁰—, —O— or —CHR⁴¹—; and R⁴⁰ and R⁴¹ areindependently selected from hydrogen and alkyl.
 55. The compound ofclaim 51, wherein F″ is a covalent bond, —NR⁴²R⁴³, or —N⁺R⁴³R⁴⁴R⁴⁵. 56.The compound of claim 51, wherein R³⁶ is hydrogen, halo, nitro, hydroxy,or alkoxy.
 57. The compound of claim 51, wherein R³⁷ is hydrogen, halo,hydroxy, or alkoxy.
 58. The compound of claim 51, wherein R³⁸ ishydrogen or hydroxy.
 59. The compound of claim 51, wherein R³⁹ ishydrogen.
 60. A pharmaceutical composition comprising apharmaceutically-acceptable carrier and the compound of claim 51.